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ABSTRACT
RYAN C. GESSNER: Acoustic angiography: a new imaging platform for
high resolution mapping of microvasculature and tumor assessment.
(Under the direction of Paul A. Dayton, Ph.D.)
Statistically, one in four Americans will die from cancer. Many new tumor detection
and therapeutic approaches have improved patient outcomes, but cancer continues to
run rampant in our country; it claimed the lives of 1.6 million Americans in 2012.
To put this number of annual deaths in perspective, it is over 500 times the number
of people who died in the horrific attacks on September 11, 2001. This dissertation
does not offer either an antidote to the disease, nor a detection mechanism appropriate
for all tumor types. It does, however, present the description and characterization of
a novel dual-frequency ultrasound imaging transducer, capable of operating in a new
imaging mode we call ‘acoustic angiography.’ These images offer high resolution and
high contrast 3D depictions of the microvasculature; herein we demonstrate its cancer
assessment utility by way of multiple imaging studies.
Throughout this dissertation, image data from both healthy and diseased tissues are
presented. Additionally, acoustic assessments of vasculature within an ex vivo bioma-
trix scaffold model (a platform for creating of artificial organs) are presented. A vessel
mapping algorithm, originally developed for human magnetic resonance angiography
images, has been implemented in both in vivo and ex vivo tissue volumes. A novel mi-
crovessel phantom generation technique is presented, which allows ground-truth coor-
dinates for vascular networks to be defined and imaged. Finally, the ultrasound pulsing
technique, radiation force, was used as a method to improve the diagnostic sensitivity
of ultrasound to malignant tumors. Together, the results of these studies suggest that
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the imaging approach, acoustic angiography, enabled by our new dual-frequency ultra-
sound transducer, could eventually be used to detect and monitor tumors in a clinical
imaging context.
This dissertation supports the following three hypotheses:
1. A prototype dual-frequency ultrasound transducer can be used to de-
pict in vivo microvasculature,
2. These microvascular images can be quantitatively assessed as a means
to characterize the presence of a tumor, and evaluate tumor response
to therapy, and
3. Radiation force can be used as a method to improve ultrasonic diag-
nostic sensitivity to the presence of a tumor.
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CHAPTER 1
INTRODUCTION
1.1 Cancer imaging with ultrasound
This dissertation is devoted to presenting and discussing work surrounding the devel-
opment of ultrasound imaging tools to improve cancer research and diagnostics. It is
well established that a tumor’s growth is highly dependent on its blood supply, which
is under constant and chaotic remodeling as a neoplasm evolves. [1] Thus, there exists
a widespread demand within the clinical and preclinical cancer research communities
for methods to noninvasively and quantitatively assess tumor vascularization and blood
supply. These research communities constantly seek to improve their imaging meth-
ods to thereby increase their understanding of tumor progression, and the quality of
their diagnostic and therapeutic decision making. Ultrasound offers several advantages
over other imaging modalities for the preclinical and clincial assessment of tumors and
tumor blood flow.
Widespread accessability
Ultrasound systems are easily portable, which enables bedside-imaging within a clinical
environment (examples of two common systems, one clinical and the other preclinical,
can be seen in Figure 1.1). In fact, some ultrasound systems are now so miniaturized
that they are capable of being carried in physicians’ pockets. In addition to being
significantly smaller than other imaging systems, ultrasound devices are also relatively
inexpensive, costing only a fraction of what other modalities’ systems cost (magnetic
resonance (MR) and x-ray computed tomography(CT)). This makes ultrasound much
more accessible to rural or less aﬄuent communities, and much more financially viable
for longitudinal studies with many timepoints, or drug efficacy studies with many sub-
jects. Using other imaging approaches, these large-cohort or multiple-timepoint studies
could be prohibitively expensive.
Noninvasive and real time
Ultrasound images do not require ionizing radiation to create images, as is the case with
x-ray CT. Whereas longitudinal studies with CT imaging necessitate careful dose con-
siderations, longitudinal ultrasound acquisitions are not problematic, enabling physi-
cians or preclinical researchers to assess changes in tumor size and blood perfusion at
many timepoints before, and throughout treatment. Images are also real-time, enabling
rapid feedback for imaging transducer position to optimize image quality.
Figure 1.1: The ultrasound systems used to collect image data for this dissertation.
A: The system used for acoustic angiography, B: Transducers for each system, C: The
system used for CPS molecular imaging.
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1.2 Contrast ultrasound
Because the cost of drug development is so high - many estimates put drug develop-
ment, from initial compound screening through clinical trials at over 1 billion USD
[2] - preclinical drug researchers continually seek to drive down costs of their studies.
Some of these preclinical drug researchers have started using high resolution ultrasound
to evaluate their candidate therapeutics.[3; 4; 5; 6]. Lipid-encapsulated microbubbles
are often implemented as contrast agents during these ultrasound studies to improve
detection of blood flow [7]. Microbubbles typically consist of a high molecular weight
gas core stabilized with a lipid. High molecular weight gasses are preferred due to
their low solubility in blood and poor diffusivity through their encapsulating shell.
This extends microbubble circulation time in vivo. The acoustic impedance mismatch
between the gas cores of microbubbles and the surrounding blood and tissue is ap-
proximately four orders of magnitude [8], causing them to scatter significantly more
ultrasound energy than blood components, and thus enabling improved sensitivity of
ultrasound to blood flow (Figure 1.2). Their use requires an intravascular injection of
a solution of microbubbles immediately before an imaging exam. After their injection,
the microbubble contrast agents traverse the circulatory system with similar rheology
to erythrocytes [9].
Figure 1.2: Far left: Vials of lipid and gas before and after mixing.The white froth is
the suspension of microbubbles. If we zoom in a single contrast agent (cartoon) it is
possible to see the orientations of the lipid monolayer, gas core, and PEG spacers.
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The most basic method of contrast enhanced ultrasound relies on receiving the
acoustic signal scattered from microbubbles at the fundamental imaging frequency.
One limitation to this detection method is that echoes from both tissue and microbub-
bles are in the same frequency band. This necessitates a large quantity of injected
microbubbles to compete with the inherent and unwanted tissue backscatter. However,
owing to the broadband and nonlinear acoustic responses of these gas-filled spheres
it is possible to overcome this limitation with other detection strategies. The most
powerful microbubble imaging methods are derived from the nonlinear responses of mi-
crobubbles to ultrasound, providing distinct differences in microbubble echo signatures
when compared with the linear responses of tissue and blood. Imaging modes such as
harmonic imaging [10], subharmonic imaging [11; 12], phase inversion [13; 14], contrast
pulse sequence (CPS) imaging [15; 16], and harmonic contrast imaging [17] exploit mi-
crobubbles’ nonlinear response; all of these methods provide improved contrast-to-tissue
ratios compared with the previously described fundamental mode imaging. Figure 1.3
provides a cartoon overview behind the pulsing schemes used to create images from
the nonlinear oscillations of contrast agents in response to ultrasound pulses. Although
these nonlinear imaging methods are now widely utilized in commercial ultrasound sys-
tems operating in the 1 to 15 MHz range, they are more challenging to implement in
high-frequency ultrasound systems. One reason for this is that optimal microbubble
response requires excitation near the resonant frequency [18], which is approximately
14 to 1.5 MHz for lipid-encapsulated bubbles that are 0.8 to 4 µm in diameter, respec-
tively. Most commonly available commercially produced microbubbles fall within this
diameter range.
There is thus a well established tradeoff between imaging sensitivity to microbub-
bles, and imaging resolution, as lower frequencies correspond to lower spatial resolu-
tions. This presents a problem for preclinical imaging studies, as imaging a preclinical
4
Figure 1.3: A cartoon illustration of how CPS and acoustic angiography are distinct
from fundamental mode imaging. The ‘Resulting echoes’ column illustrates the non-
linear responses of microbubbles to different polarities and frequencies of pulses. HPF:
‘high pass filter.’
model (mouse or rat) requires higher resolution than most clinical systems will al-
low. This mismatch between microbubble resonance frequency and preclinical system
imaging frequency provided the motivation behind the creation of a novel ultrasound
imaging transducer capable of circumventing this tradeoff. This transducer is addressed
in Chapter 3.1.
There are several contrast ultrasound techniques to evaluate a tumor’s blood supply
or interior vascularization. Some of these strategies seek to quantify the amount of
vascularization within the tissue by using Doppler techniques [19; 20; 21; 22], or contrast
image-subtraction approaches [23; 24]. Other strategies attempt to extract information
about the perfusion rates at which blood flows through the tissue using contrast-based
destruction reperfusion (or “flash replenishment”) techniques [25; 26; 27; 28; 29; 30;
31]. Additionally, others have attempted to extract quantifiable metrics for vessel and
5
vessel network structure as a means to understand disease progression [32; 33; 29;
34]. Of particular interest is vessel tortuosity, or bendiness which is a morphological
abnormality exhibited by cancerous vasculature in both humans and rodents [35; 36],
and has been used as a marker for disease state and therapeutic response in clinical
studies based on image-derived data [37; 38]. This effect will be described in more
detail in Chapter 2.
Because the US Food and Drug Administration (FDA) has practiced excessive cau-
tion with respect to microbubble contrast agents, there is currently only one approved
clinical application which implements a contrast ultrasound imaging protocol. Their
use in other applications such as liver, kidney, thyroid, prostate, and breast tumor as-
sessment, is becoming increasingly widespread, however, in several European and Asian
countries. Additionally, as described above, there are a host of exciting new applica-
tions being developed in the preclinical realm with potential for clinical translation.
Over the next decade, it is likely that the US clinical community will begin catching
up with their European and Asian colleagues with respect to the frequency with which
they implement these powerful contrast ultrasound imaging approaches. This thesis is
primarily devoted to the research and results surrounding one of these new contrast
imaging approaches, acoustic angiography. This imaging technique, while maybe years
away from actual clinical use, is an exciting advance in the field.
1.3 Dissertation scope and objectives
The overarching theme of this dissertation is the development and assessment of a new
ultrasound imaging approach, acoustic angiography, enabled by a novel dual-frequency
transducer prototype. The diagnostic context for using this imaging approach is pre-
sented in Chapter 2, followed by a physical description of the transducer and preliminary
pilot studies in several different contexts (in vitro, ex vivo, and in vivo) presented in
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Chapter 3. Following these pilot studies we present a description of the limitations
in our ability to assess vascular morphological features, evaluated in a controlled in
vitro context (Chapter 4) by way of a novel microvessel phantom generation approach.
The final two chapters focus on the in vivo application of this imaging approach to
cancer assessment and response to therapy, with Chapter 5 focusing on vessel network
architectural features (vessel tortuosity and tumor vascularization) while Chapter 6 fo-
cuses on the application of molecular imaging approaches with both our dual-frequency
transducer and a clinical ultrasound system.
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CHAPTER 2
DETECTING CANCER’S VASCULAR FOOTPRINT
The first section of this chapter introduces the effect of cancer-associated vasculature
having abnormal morphologies, and how these distinct features are detectable by a
quantitative algorithm (Chapter 2.1). The second section describes another method of
detecting cancer with ultrasound contrast agents, called ‘molecular imaging.’ (Chapter
2.2)
2.1 Detecting cancer’s footprint
Tumor growth beyond 2 mm3 has been shown to depend on angiogenesis, which is
defined as the formation and recruitment of new microvessels from existing vessels.
[39; 40; 41]. There are many differences between vessels associated with angiogenic
tumors and healthy vessels which can be used as diagnostic indicators of tumor pres-
ence and malignacy. For this dissertation, the scope of tumor assessment by way of
aniogenisis detection is confined to two facets of vascular composition: (1) vascular
Note: This chapter has two sections, both of which draw from previous published material. Pre-
viously published material was reprinted with permission from the publishers.
Chapter 2.1: Ryan C. Gessner, Stephen Aylward, Paul A. Dayton, Imaging tortuosity: the po-
tential utility of acoustic angiography in cancer detection and tumor assessment. Imaging in Medicine,
4(6):581-583, 2012. editorial
Chapter 2.2: Ryan Gessner, Paul A. Dayton. Advances in molecular imaging with ultrasound.
Mol Imaging, 9(3):117-27, 2010. review .
architecture (both at the individual vessel level, and at the network level) and (2) an-
giogenic molecular markers expressed on the vascular endothelium. The following two
sections describe these vascular features in greater detail, and provide some background
information on detection strategies.
2.1.1 Pathologic tissue’s aberrant vessel morphologies
The morphology and structure of the vasculature associated with malignant tumors has
long been observed to be chaotic and unusual compared with that of healthy tissues.
In tumors, vessel diameters and branching patterns appear random, and the actual
trajectories charted through the 3D tumor volume are often tortuous [36; 42]. These
morphological abnormalities are hypothesized to be a result of a number of compli-
cated physiological effects occurring in parallel, such as tumor cells’ high metabolic
demand and their unusual microenvironment (hypoxic, acidic and so on). These fac-
tors contribute to a heightened level of angiogenic activity in and around the tumor,
which becomes a self-amplifying cycle when the newly formed vessels fail to supply
the tumor cells’ insatiable appetite for nutrients [43]. The heightened angiogenic activ-
ity also causes the basement membrane and support structure of the vessels to break
down. Additionally, the poor organization of the vessel network results in an increase
in pressure within the vessels, which is further exacerbated by the absence of lymphatic
drainage from the tumor stroma.
As described above, the morphology and makeup of tumor vasculature diverge from
healthy vasculature in several ways and these differences can be elucidated by either
direct or indirect observations. For direct observations (i.e., quantification of 3D vessel
morphologies) there are three critical components. First, the imaging modality must
have a high enough spatial resolution to enable individual vessels to be resolved, and it
must have sufficient signal-to-noise to enable differentiation of vessels from surrounding
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tissue. Second, a segmentation approach must be able to extract vessels from the image
volumes in a repeatable and reliable way. This stage usually requires some user input
and feedback, although automated approaches allow for higher throughput and thus
would be more amenable to clinical implementation. Finally, a classification algorithm
based on the segmented vessel data that indicates the presence or degree of pathology
is needed. Morphological features can be examined at either the vessel level (e.g., the
tortuosity of a single vessel) or at the network level (e.g., the fractal dimension of the
vessel tree). Indirect observations of cancer-associated vascular abnormalities are far
more prevalent in the clinic today. Examples include measures of overall tissue per-
fusion and vessel permeability. These types of measurements are powerful indications
of tumor presence and malignancy, but they are limited to more global estimations of
vessel morphology within a tissue volume, and thus are insensitive to subtle changes oc-
curring therein. These two types of observations (direct and indirect) have been shown
to provide independently useful diagnostic information [44]. It is, therefore, unlikely
that direct assessments of vascular structure will ever replace existing cancer imaging
approaches; however, rather they will compliment them with additional diagnostically
powerful information. This could result in a hybrid cancer-assessment approach that
is more sensitive than either component alone.
Diagnostic information gleaned from vascular architecture
Of interest from a cancer screening perspective, tumor-associated vascular irregulari-
ties can extend beyond the margins of a lesion, as angiogenic growth factors promoted
by tumor cells can influence the morphologies of even major vessels in the vicinity of
tumors [38]. Additionally, cancer-associated tortuous vessel morphologies have been
observed in animal models much sooner than the arrival of a palpable mass. For ex-
ample, within one day of the introduction of only a few tens of cancer cells, initially
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Figure 2.1: Comparison of cancerous vasculature viewed at different scales by differ-
ent imaging modalities. Top: Intravital microscopy images from the Dewhirst lab at
Duke University of tumor cells growing within a window chamber model in a rat (scale
bar = 200 µm). The images illustrate vascular morphological abnormalities occurring
within days of implantation of cancer cells. (Figure portions, from [35], reprinted with
permission). Bottom: a maximum intensity projection through an acoustic angiogra-
phy dataset illustrating the same type of morphological abnormalities both within and
surrounding the tumor margins (dashed yellow line).
healthy vasculature in the tumor vicinity develop tortuosity abnormalities, [35] an ef-
fect observed across many cancer types.[45] Tortuosity abnormalities can spread to
even major vessels over time, and have been observed with MRI in humans 1 cm away
from any visible lesions.[38] Segmenting and quantifying the morphology of these abnor-
mally shaped vessels has been shown to predict tumor therapeutic response between 2-6
months sooner in humans than traditional methods of estimating tumor volume.[38; 36]
Additionally, successful tumor treatment has been shown to lead to rapid regression
in tortuosity abnormalities, with changes occurring between hours to days after treat-
ment. [38; 36; 46; 47] Finally, this vessel-morphology analysis has been performed in
conjunction with a traditional blood perfusion analysis in an MRI therapeutic response
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study of patients with intracranial neoplasms,[44] and the two methods were shown
to provide independently useful diagnostic information. The renormalization of tumor
vasculature is also of great interest to researchers and clinicians alike, as anticancer
therapies, when effectively quelling a tumor’s progression, have been shown to have a
rapid effect on the local vascular morphology. This normalization of vessels has served
as an indication of eventual tumor volume reduction and the lack of normalization has
correspondingly been associated with poor therapeutic response [48].
Thus the motivation for applying a quantitative vessel-morphological analysis to
preclinical models of cancer is apparent, as most anti-cancer drug studies are performed
in small rodents. To date, most recent progress in ultrasound assessment of therapeutic
response has been in molecular and perfusion imaging, and there are some groups who
have used 3D high frequency Doppler techniques to image vascular networks. Analyses
of vessel network and vessel morphologies based on segmentations from ultrasound data,
however, are scarce, though they have been achieved at lower imaging frequencies (and
thus lower spatial resolution) in human thyroid and breast tumors imaging studies.
[32; 33; 29; 34; 49] Analyzing the morphology of a vascular network within a diseased
tissue volume provides a very sensitive method to assess the effects of therapy, which is
particularly necessary when clinicians are seeking to tune their personalized therapeutic
approaches [50].
2.1.2 How are vessels extracted from images?
The following is an overview of how the segmentation algorithm used throughout this
project functions. The mechanics of the algorithm are discussed at length in [51].
Finding the vessel’s centerline:
The extraction process is initialized after a user provides seed point near an intensity
ridge (assuming vessels are bright on a dark background), and a scale of the blood
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vessel selected. The gradient of the image is followed at the location the user specified
until a local intensity maximum is reached (assumed to be the true center of the vessel).
Following the vessel’s centerline:
Once an intensity ridge has been found, the extractor looks for what direction the
vessel is traveling. This information is gleaned from the Hessian matrix, which allows
the extractor to find the direction of least curvature, important in this case as this
direction will be the one along an intensity ridge (i.e. normal to the plane bisecting the
vessel, and in the direction of the vessel’s trajectory). The next point along the vessel’s
centerline is then determined by stepping the normal plane at the intensity ridge a very
small distance in the previously described direction of least curvature. The assumption
here is that if the centerline is representing an anatomically relevant tube (vessel),
its smooth trajectory will necessitate it passing through that shifted plane. The next
intensity ridge is then found at the location of the shifted normal plane, and a new vessel
trajectory and normal plane determined at this new intensity ridge. This process is
repeated iteratively in both positive and negative directions from its initial starting
point.
Determining vessel radius
The radius of the vessel is determined every ten steps along the ridge traversal. This
is achieved by convolving a customized kernel with the image data in the previously
described normal plane defined by the trajectory of the vessel at the location of inter-
est. This “medialness” kernel is a circularly symmetric arrangement of spheres, and is
maximized when the radius of the kernel equals that of the vessel. A physical analog
to this operation is considering a ring of magnets of variable radius r oriented so that
all North sides of the magnets are facing away from the center of the ring. If this
ring of magnets is placed over another ring of fixed radius R oriented in the opposite
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direction, the r that will result in the most stable configuration is when r = R. The ex-
tractor tests scales for vessel radius which are within 10% of the previous measurement
of vessel radius, which assumes that the radius of anatomically relevant tubes will not
rapidly fluctuate (an often accurate assumption, especially since the step size between
centerline points is less than one voxel, so if the radius is increasing by more than 10%
within that small distance, it’s probable that the tube being extracted is not actually
a vessel).
When does the extractor know to stop?
There are several criteria which result in the termination of a vessel extraction. These
are tested at each point along the extraction. If a ridge does not exist in the shifted
normal plane, the extraction will terminate (this could occur if the intensity drops below
the noise level, as would be the case when large vessels feed sub-resolution capillary
beds). Additionally, if a T-junction is encountered, the extraction will terminate. A T-
junction would result in the vessel trajectory at the next test point along the centerline
not falling within a specified “cone of acceptability.”
Finally, there are several conditions that must be satisfied for a test location to be
deemed a ‘ridge point,’ or valid location for a vessel centerline coordinate. These are
listed as follows:
1. It must be on a convex intensity ridge. Mathematically this can be verified by
ensuring the eigenvalues of the Hessian matrix at this location are negative.
2. It must be a local intensity maximum. Mathematically this can be demonstrated
if the projections of the gradient at this location are equal to zero.
3. It must be located near a tube of a roughly circular cross section. This is de-
termined by calculating the ratio of eigenvalues of the Hessian matrix in the
direction normal to the ridge in question. This ratio changes as tubes become
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more elliptical in cross-section.
2.1.3 How are vessel structures quantified?
After an ensemble of microvessel centerlines had been extracted, their morphologies
were quantified via previously established metrics for tortuosity [52]. These metrics,
which provide a means to assess two distinct types of centerline tortuosity, were the
distance metric (DM) and sum of angles metric (SOAM). The DM is a measure of how
far a curve meanders between its end points and is computed as the ratio of the length
of the extracted vessel path and the length of the secant line between the vessel’s start
and end. The SOAM is an index of vessel tortuosity that is computed by integrating
the angular changes occurring between successive pairs of points along the vessel’s
centerline, normalized by the total vessel path length. (Figure 2.2)
Relationship between imaging system resolution and tortuosity metrics
Assuming the same vessel is imaged by two distinct imaging systems, its digitized rep-
resentation also will be different and thus the reported tortuosity values for that vessel’s
two image-derived segmentations could be reported as different. What follows is a short
overview on the relationship between the imaging system’s acquisition characteristics,
and the reported tortuosity for a vessel imaged by that system.
A blood vessel can be considered a continuous curve through 3D space. Its repre-
sentation by an ultrasound imaging system can be modeled in the most simple case as
the original continuous curve first becoming blurred by the point spread function of the
transducer, and then discretized by the pixels of the imaging system. By way of these
processes, information can be lost and the true morphology of the vessel misrepresented.
The following analysis will be restricted to 2D for convenience of illustration, though
the concepts could be extended to 3D for volumetric data. Assume the continuous
vessel curve, parameterized by C(x,y), has a sinusoidal shape with a spatial period, T,
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Figure 2.2: A cartoon illustration of how the DM and SOAM are computed from the
vessel centerlines.
and is imaged by a system with isotropic resolution in the x and y axes of distance R.
The data is discretized by pixels of width p for display. There are multiple scenarios in
which the imaging system parameters (R and p) could bias tortuosity measurements
computed from the segmentation S(x,y) for continuous curve C(x,y).
If p is larger than R, then vessels smaller than a pixel’s width will be displayed by
the imaging system as rectangular in cross-section (a form of quantization error). This
will artificially inflate the intervoxel angles of S(x,y). This is sometimes referred to the
‘ping ponging’ effect - imagine a ball bouncing erratically through a smooth pipe. This
can also occur as a result of the extractor not being appropriately tuned to the point
spread function of the imaging system. The ping-ponging effect will correspondingly
16
inflate the tortuosity values reported for a vessel. In the presence of this type of p>R
quantization error, the SOAM values will be significantly more affected, since part of
its computation involves the integral of these angular deviations between successive
points. (Figure 2.2) The DM will also be impacted by this type of error, since the
ping-ponging centerline of S(x,y) has a longer path length than the smooth centerline
C(x,y), with the same secant cord between the end points, though to less of a degree,
since the path length errors away from the true centerline to not contribute appreciably
to the overall path length, especially for anatomically relevant curves.
Another way the imaging system can bias the results of the tortuosity computation
is if the resolution, R, is too close in size to the spatial period of the vessel being
imaged (assume p<R and quantization errors are no longer significant). One should
think of this in terms of the Nyquist-Shannon sampling theorem. The Nyquist-Shannon
criterion states that for a continuous periodic curve to be accurately defined by a
discretized representation, a sampling frequency of at least twice the frequency of the
periodic signal must be implemented. Equivalently, in spatial units this means that
the resolution of the imaging system must be at most half of the period of the curve
C(x,y). If the condition (R ≤ T
2
) does not hold, then the curve will be aliased (Figure
2.3). Practically speaking, this means for an imaging system with R = 150 µm, the
smallest periodic deviation which could be reliably imaged has a period of 300 µm.
This relationship is more quantitatively established in Chapter 4.
2.2 Detecting molecular signatures of disease
One of the hallmarks of tumor cells is their upregulation of angiogenic growth factors,
which when released into their surroundings promote endothelial cells in their vicinity
to release proteases that degrade the basement membrane. This is beginning of sprout-
ing angiogenesis (the formation of new blood vessels from existing blood vessels). The
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Figure 2.3: A simulation of a continuous vessel curve, C(x,y), being sampled by an
imaging system at three different resolutions: T/4, T/2, and T, where T is the spatial
period of the main spatial frequency in C(x,y). Simulated segmentations, S(x,y) are
overlaid in yellow.
adhesion molecules used by endothelial cells to migrate along these new ‘sprouts’ are
called integrins, enabling them to populate the voids in the matrix created by the pro-
teases. These integrins are one potential site to which molecularly targeted contrast
agents can be designed to bind. [53] There are several imaging modalities capable of
molecular imaging of tumors - such as with SPECT, PET, and optical imaging modal-
ities - and ultrasonic molecular imaging is still in its infancy. However, in preclinical
studies, ultrasonic molecular imaging has shown promise in assessing angiogenesis and
the functional status of tumors. This section describes the background behind ultra-
sonic molecular imaging, as well as an acoustic pulsing technique, known as “radiation
force,” which can substantially improve the capabilities and utility of ultrasonic molec-
ular imaging in vitro by circumventing one of the largest challenges to the approach
(low numbers of retained contrast agents). In Chapter 6, this is tested for the first time
18
in vivo in which the radiation force pushing and the imaging are achieved on the same
clinical ultrasound system.
2.2.1 Ultrasonic molecular imaging
Traditional non-contrast enhanced ultrasound imaging utilizes a transducer to produce
pulses of sound that propagate into tissue. These sound pulses are scattered from in-
terfaces between tissue components of different density and compressibility. Scattered
ultrasound reflections are detected and processed to form an image based on the inten-
sity of scattered echoes and the time delay, which corresponds to the depth from which
echoes have returned. As such, standard ultrasound imaging is well suited for assess-
ment of anatomical features and measurement of blood flow in large vessels, however,
there is no mechanism by which non-contrast enhanced ultrasound can detect changes
in physiology on a molecular level.
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Molecular imaging with ultrasound is typically performed as follows: an ultrasound
transducer is fixed in position over the region of interest with a mechanical arm to avoid
motion artifacts from operator movement. A targeted contrast agent is administered
into the peripheral vasculature, often through a tail vein during serial imaging studies in
rodents. Prior to imaging, a waiting period of approximately 4-30 minutes is required,
depending on contrast agent circulation characteristics.[54] During this period, there
is a first phase when the targeted contrast agents accumulate in the microvasculature,
followed by a second phase when freely circulating agents are cleared from the ani-
mal’s system (Figure 2.5). After free agent clearance, imaging is performed to detect
molecularly targeted contrast agents retained in regions of pathologic tissue. When
possible, a first acquisition of several imaging frames is followed by a destruction pulse,
which clears all contrast within the field of view. A second set of imaging frames can
then be gathered as a no-contrast baseline to quantify image intensity increase due to
molecularly targeted agents.
Figure 2.5: A cartoon graph illustrating how freely circulating and targeted mi-
crobubbles contribute to the overall concentration of contrast within an in vivo
environment.[55] MCA = microbubble contrast agent.
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2.2.2 Challenges in molecular imaging with ultrasound
Although ultrasonic molecular imaging has made significant progress over the last
decade, this technology still faces several challenges before it can rise to its full di-
agnostic potential. It is the ideal goal of this technology to determine if a molecular
target is present, and if so, to what degree. This requires that the contrast agents
specifically adhere to their molecular target, and bind in quantities great enough to
overwhelm the signal contributions from non-specific retention. Additionally, the ul-
trasound system should have sufficient sensitivity to detect the targeted agents present
at the site of pathology, and be able to assess the pathology in its entirety. In this re-
view, we hypothesize that several limitations have slowed the progression of ultrasonic
molecular imaging - however, recent advances in contrast agent development, ultra-
sound technology, and detection strategies demonstrate the potential to substantially
improve the capabilities and utility of ultrasonic molecular imaging. Two of these chal-
lenges are addressed in this dissertation: (1) low numbers of retained contrast agents
and (2) ultrasound’s limited field of view.
Low numbers of retained contrast agents
Since the magnitude of the detected ultrasound signal is a function of the quantity of
contrast agents retained at the site of target endothelium it is intuitive that the retention
of targeted contrast agents at a site of diseased tissue should be maximized, while non-
specific contrast retention should also be minimized. For molecular imaging studies in
small animals, the injected concentration of microbubbles is typically on the order of
107-108 bubbles/kg. Prior studies assessing the adhesion of targeted microbubbles have
observed only small amounts of targeted contrast retained in vivo, on the order of several
bubbles per cubic millimeter.[56; 57] Correspondingly, video intensity due to targeted
agents in vivo is typically only several fold higher than background.[58; 16; 59; 60]
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It has also been proposed that radiation force might play a role in pulse sequences
designed to enhance the detection of targeted contrast agents in molecular imaging. A
transducer directing energy perpendicular to flow in a vessel can displace moving mi-
crobubbles to the wall of the vessel opposite of the sound source, and greatly enhance
microbubble-endothelial interactions. It has been hypothesized that the ability to in-
crease ligand-receptor proximity and reduce the velocity of flowing microbubbles would
greatly increase the amount of targeted microbubble adhesion in molecular imaging
studies [61; 62] (Figure 2.6).
Figure 2.6: A cartoon illustration of radiation force enhanced microbubble targeting.
A: no radiation force is administered, resulting in some passive targeting, but most
microbubbles passing through unbound. B: radiation force is administered, greatly
increasing the number of retained contrast agents.
Limited field of view
One limitation of ultrasound imaging, in general, compared with modalities such as
CT, MRI, PET, and SPECT is a smaller field of view. Until fairly recently, ultrasound
imaging was largely a two-dimensional modality, depicting only a single image slice
through tissue. In diagnostic imaging, the real-time imaging capability compensates
for this, as it allows a sonographer to scan through the tissue of interest to view or mea-
sure target features. In ultrasonic molecular imaging, however, most current protocols
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involve maintaining the transducer fixed in a clamp to observe the same slice of tis-
sue. This is usually required because quantifiable measurement of signal from contrast
involves a background subtraction after a destructive pulse, which creates artifacts in
the presence of tissue or transducer motion. Recent advances in transducer technol-
ogy have led to the implementation of matrix array transducers allowing real-time 3D
ultrasound imaging (also called 4D, considering the time dimension). 3D ultrasound
is still relatively new to the clinic, and is used primarily in obstetrics and cardiology.
However, due to the complicated pulse sequences required to differentiate microbubble
contrast agents from surrounding tissue, 3D contrast imaging has been challenging to
implement on matrix array probes. Although some ultrasound system manufacturers
currently have real-time 3D contrast imaging capability, the performance of contrast
imaging modes on matrix array transducers still falls short of the resolution and con-
trast detection capability available on transducers for 2D imaging. Hence, to date
ultrasonic molecular imaging has been largely limited to a single slice of tissue.
By acquiring multiple 2D images via a motorized stage and reconstructing the data
oﬄine, it has been hypothesized that heterogeneities within pathologic tissue volumes
are observed that would be impossible to assess with traditional single-slice molecular
imaging. 3D contrast imaging capabilities have been in development[63; 64] and contin-
ued improvements in low mechanical index, high resolution 3D imaging will eventually
allow for the full volumetric characterization of tissue pathologies ensure consistent
data collection in longitudinal studies.
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CHAPTER 3
ACOUSTIC ANGIOGRAPHY - A NEW CONTRAST IMAGING
APPROACH
The first section describes the characterization of the ultrasound transducers used
throughout this dissertation (Chapter 3.1). The second section illustrates the imple-
mentation of the acoustic angiography imaging approach in ex vivo liver samples as a
method to assess vascular architecture within these biomatrix scaffolds (Chapter 3.2).
The final section presents several 3D datasets acquired of in vivo tissues and compares
them to two other modalities for imaging preclinical vasculature: photoacoustics and
CT (Chapter 3.3).
This chapter has three sections, some of which draw from previous published material. All previ-
ously published material was reprinted with permission from the publishers.
Chapter 3.1: Ryan Gessner, Marc Lukacs, Mike Lee, Emmanuel Cherin, F Stuart Foster, Paul
A Dayton, High-resolution contrast-enhanced imaging of the microvasculature using a dual-frequency
transducer, IEEE Trans Ultrason Ferroelectr Freq Control, 57(8):1772-81, 2010.
Chapter 3.2: Ryan C. Gessner, Steven Feingold, Avery Cashion, Ariel Hanson, Bryant Wu,
Christopher Mullins, Stephen R. Aylward, Lola Reid, Paul A. Dayton. New Ultrasound Perfu-
sion Imaging Techniques Enable Functional Assessment of Biomatrix Organoid Scaffolds. 2013.
Submitted for publication.
Chapter 3.3: unpublished pilot studies.
3.1 Evaluating a prototype dual-frequency transducer
Recently, dual-frequency excitation-detection been demonstrated by using either two
confocal transducers, or alternating elements in a linear array [65; 66]. Bouakaz demon-
strated that a contrast-to-tissue ratio of 40 dB over conventional b-mode imaging could
be attained using a dual-frequency imaging technique with excitation at 0.8 MHz and
detection at 2.8 MHz [65]. Kruse demonstrated that when the bubbles were excited
with several hundred kilopascals at 2.25 MHz, broadband frequency content could be
detected from the contrast agents as high as 45 MHz [66]. These initial studies by Kruse
provided the proof-of-concept for implementing the dual-frequency imaging method
with higher frequencies suitable for implementation in small animal imaging studies. A
dual-frequency approach enables the use of low frequencies to excite microbubble con-
trast agents, with simultaneous detection of the broadband backscatter produced by
oscillating or fragmenting bubbles, preserving high spatial resolution while suppressing
background from tissue. It became clear throughout this study that high resolution
high contrast images resulted from this dual-frequency excitation-detection approach,
and thus we hereafter refer to our specific pulsing and receiving scheme as ‘acoustic
angiography.’
For in vivo acoustic angiography imaging, we have designed a prototype dual-
frequency imaging transducer which has been integrated with a Vevo770 small ani-
mal imaging system (VisualSonics, Toronto, ON, Canada). In this section, we present
Note: This section was written in 2009 when only one dual-frequency prototype probe - hereafter
referred to as the ‘generation 1’ probe - was built. Later, improvements were made and a second
transducer - the ‘generation 2’ probe - was manufactured. Thus most of the data herein was acquired
for the generation 1 probe, though the beamfields were later acquired when the generation 2 probe was
tested and retroactively added to Figures 3.2 and 3.3. These will illustrate that the second generation
probe’s beam alignment was superior, and all subsequent studies were performed with the generation
2 probe.
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results from initial studies on the performance of the dual-frequency probe from sev-
eral studies performed in rats. Our studies assess contrast-to-tissue ratios compared
with traditional high-frequency b-mode imaging, and sensitivity to tissue motion com-
pared with image subtraction and power Doppler, common methods utilized to detect
contrast agents at high frequencies. Our acoustic angiography imaging strategy pro-
vides improved contrast over traditional high-frequency b-mode imaging as well as a
reduction in sensitivity to animal motion compared with both image subtraction and
power Doppler methods. Additionally, we examine the capacity of the probe to produce
acoustic radiation force, which is maximized on microbubbles when excited near their
resonant frequency [62]. Radiation force has been demonstrated to enhance the delivery
of acoustically-active drug delivery vehicles [67; 68], and hypothesized to enhance the
retention of targeted contrast agents [69; 70].
3.1.1 Materials and methods
The dual-frequency probe
The confocal imaging probe designed by our group is an adaptation of a VisualSonics
RMV707 ultrasound probe and is used with a VisualSonics Vevo 770 micro-imaging
system, a commonly implemented preclinical ultrasound imaging system. Tradition-
ally, the high-frequency piston transducer element within the RMV probe mechanically
sweeps to obtain images. An additional 2.5 MHz transducer was added confocally
outside the inner 30 MHz element in the adapted setup (Figure 3.1b). This outer low-
frequency transducer enabled us to transmit at a frequency near microbubble resonance,
while receiving the emitted high-frequency signal content with the inner transducer. A
schematic displaying how the waveforms were delivered and received by the setup can
be seen in Figure 3.1a.
After the low-frequency pulses are delivered into the animal, the 30 MHz inner
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Figure 3.1: (A) Schematic for the operation of the prototype dual-frequency transducer.
The arbitrary waveform generator (AWG) (Sony Tektronix) was triggered to send 512
low-frequency pulses through the RF amplifier (RFA) within each frame of image data
by the Vevo770 line trigger. (B) A diagram displaying how the two confocal elements
were constructed within the RMV probe scanhead.
element receives the reflected ultrasound signal. The unwanted backscatter of tissue
is suppressed by sending each line of raw RF data through a seventh-order 10 MHz
high-pass filter (HP-F, in the Figure 3.1) (TTE Inc., Los Angeles, CA) before being
displayed and saved by the ultrasound imaging system.
Characterizing the probe
Using a 40-µm needle hydrophone (Precision Acoustic, Dorchester, UK) and a 3D mo-
tion stage, the beam-fields of the dual-frequency probe’s two individual elements were
measured at their foci. The pressure outputs of the two elements were also measured
relative to the center of the high-frequency element. To determine the resolution achiev-
able with our acoustic angiography imaging approach, two studies were performed. One
of these studies was based on the collected RF data from single microbubble contrast
agents, which enabled us to make estimations about the theoretical limits, or best
case for axial resolution using our imaging parameters. The second study was based
on video data collected from single bubbles, which allowed us to determine the point
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spread function of our imaging system and thus determine the practical lateral and axial
resolutions achievable in actual ultrasound studies implementing our parameters. Axial
and lateral are defined as the parallel and orthogonal directions of wave propagation
respectively. Within an image, axial represents the depth axis.
For the first resolution study, a dilute concentration of microbubble contrast agents
was pumped through a 27-gauge needle tip coupled to a 380 µm polyethylene tube
(Becton Dickinson, Sparks, MD), which was then coupled to a 200 µm capillary tube
(Spectrum Labs, Rancho Dominguez, CA) The transducer was set to acquire data with
a frame rate of approximately 1 Hz and bubbles were pumped through the capillary
tube at 1 mL/h, which corresponded to a linear flow velocity of 9 mm/s. RF data
was collected with the 30 MHz element of individual bubble responses for single cycle
excitations at 2.5 MHz and at peak negative pressure of 617 kPa. After more than 100
bubble responses were acquired, the time-domain signals were Fourier transformed and
averaged together in the frequency domain. Once all pulses had been averaged, the
mean frequency-domain signal was then inverse-Fourier transformed to yield a mean
time-domain signal. The envelope of this mean signal was determined using Matlab
(The MathWorks, Natick, MA), via the absolute value of the Hilbert transform, and the
full-width at half-maximum (FWHM) of the envelope used to yield the theoretical limit
of the axial resolution for acoustic angiography imaging at our pulsing and receiving
parameters.
For the second resolution study, a dilute concentration of bubbles was pumped
through a setup similar to the one described for the first resolution study. The tube
was oriented horizontally and imaged at 2.5 MHz at a 1 Hz rate. The video data were
exported as uncompressed AVI files and analyzed oﬄine in Matlab. Because the con-
centration of bubbles was dilute, not all frames contained images of bubbles, though in
each video frame containing a bubble, its center was manually defined. The vertical and
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horizontal cross-sections through this point were extracted from the image data (rep-
resenting the axial and lateral components of the point spread function, respectively),
interpolated, and the FWHM in each dimension was determined. Thirty samples were
collected and averaged. The mean FWHMs in each direction-lateral and axial-were
taken as their respective directional resolutions.
Animal and contrast agent preparation
A total of eight Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN) were im-
aged in the course of this study: three during the contrast-to-tissue comparison study
and five during the sensitivity to motion study. Before all imaging studies, animals were
prepared in the same way. Each animal was first anesthetized in an induction chamber
by introducing a 5% aerosolized isoflurane-oxygen mixture. Once sedated, the animal
was removed from the induction chamber, the isoflurane concentration reduced from
5% to 2% and maintained via mask delivery. Its abdomen was shaved and a depilating
cream was applied to the animal’s skin to dissolve any remaining hair. A 24-gauge
catheter was inserted into the animal’s tail vein for the administration of microbub-
bles. The animal was then placed in dorsal recumbancy on a heating pad. Finally,
ultrasound coupling gel was placed between the imaging transducer and the animal’s
skin to ensure the quality of signal transmission. Animals were handled according to
National Institutes of Health guidelines and our study protocol was approved by the
UNC Institutional Animal Care and Use Committee.
The microbubbles used in this study were the perfusion agent formulation made
with a lipid shell and perfluorocarbon core (Appendix A). Contrast agents were diluted
in sterile saline to result in a final concentration of 2.2x109 bubbles/mL (unless oth-
erwise stated) and a mean diameter of 0.9±0.45 µm, determined with a particle-sizer
(Accusizer 780A, Particle Sizing Systems, Santa Barbara, CA).
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Determining contrast-to-tissue ratios
Two studies were performed to examine how imaging pressure affected the probe’s
sensitivity to contrast. This sensitivity was quantified with the measure of contrast-
to-tissue ratio (CTR). The first study was performed in vitro, and was designed to
determine the acoustic responses of both tissue and contrast agents when subjected to
the imaging parameters utilized by our probe. The second study was an in vivo study,
which compared the CTRs achieved by the probe operating in both high-frequency and
acoustic angiography imaging modes within an actual tissue environment.
1) In Vitro CTR Study
For the in vitro CTR study, individual microbubbles in a flow phantom were imaged
in acoustic angiography mode at four different mechanical indices (MIs) between 0.33
and 0.57. Bovine muscle tissue was also imaged at the same parameters to simulate the
acoustic response of non-perfused tissue. The lines of RF data from these scans were
Fourier transformed and divided by the frequency bandwidth of the receiving element.
This allowed us to appropriately weight the frequencies in the measured signal which
were higher and lower than the probe’s 30 MHz fundamental frequency. By doing this,
we were able to compare the spectral power of the true bubble and tissue signals and
thus, to compute a theoretical CTR versus frequency plot for multiple imaging pres-
sures (regardless of our specific receiving element’s sensitivity).
2) In Vivo CTR Study
Three animals were imaged for the CTR study. Their kidneys were selected as the imag-
ing region of choice because of the organ’s high degree of vascularization, thus providing
an opportune target to image large numbers of injected microbubbles. Each animal had
both kidneys imaged in both acoustic angiography and high-frequency modes, resulting
in six independent trials. Contrast agents were delivered at a continuous infusion rate
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AA HF
PNP (kPa) MI PNP (kPa) MI
292 0.18 978 0.18
391 0.25 1318 0.24
492 0.31 1935 0.35
617 0.39 2347 0.43
716 0.45 2792 0.51
814 0.51 3295 0.60
900 0.57 3514 0.64
1030 0.65 3881 0.71
Table 3.1: A Summary of the Imaging Pressures and Mechanical Indices Used in the In
Vivo Contrast-to-Tissue Study for Acoustic Angiography and High-Frequency Imaging
Modes.
AA: ‘Acoustic Angiography’ (transmit 2.5 MHz)
HF: ‘High Frequency’ (transmit 30 MHz)
of 3 mL/h using a syringe pump (Harvard Apparatus, Holliston, MA). The microbub-
ble solution was allowed one minute to reach equilibrium before any image data was
collected. Approximately 20 video frames were acquired at 2 Hz in both high-frequency
and acoustic angiography modes at each of the six imaging locations. The acoustic an-
giography mode was operated with a 2.5-MHz pulsing frequency and a 30-MHz receiver
element. The high-frequency imaging mode was operated with pulse-echo only from the
30-MHz element. Both imaging modes used one-cycle sinusoidal driving pulses. Differ-
ent image pulsing pressures were evaluated in both imaging modes, as summarized in
Table 3.1.
For analysis of CTR at each tested parameter, the onboard software of our ultra-
sound system was utilized after all data had been collected. Regions of interest (ROIs)
were defined for both contrast and tissue regions for each kidney imaged. The centers
of all ROIs were defined within 1 mm of the transducers’ foci to ensure that we were
consistently sampling from imaged regions of tissue that had received a similar amount
of acoustic energy. Although different ROIs for both tissue and contrast regions were
defined for the six different kidneys imaged, the same ROIs were applied to the data
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sets collected in each of the kidneys at the different imaging parameters. B-mode im-
ages were acquired before and after each administration of contrast agents to ensure
consistency of the contrast and tissue ROIs used for each kidney over time (i.e. to
ensure they were not corrupted by global shifts in tissue). The mean pixel intensity in
the ROIs were calculated at each imaging parameter and compared between animals.
Determining sensitivity to motion
To test the robustness of the acoustic angiography method in the presence of respi-
ratory motion, five animals were imaged with power Doppler, image-subtraction, and
acoustic angiography imaging modes. The imaging protocol consisted of administer-
ing 150 µL bolus injections of microbubble contrast agents, and observing the kidney
without respiratory gating as the contrast washed out of the system. The goal was
to examine the different imaging modes’ abilities to detect the sharp increase in video
intensity following the introduction of microbubbles into the renal volume, as well as
their consistency in monitoring the steady decrease in intensity as the contrast agents
were cleared from the different animals’ systems. To record the entire contrast washout
curve, the left kidney of each animal was imaged for at least 6 min following each
injection. All three imaging modes were tested within the same anatomical region of
each animal (meaning neither the animal nor the transducer was moved between data
acquisitions with different imaging modes). Following the collection of data, videos
were exported and examined oﬄine in Matlab for analysis of these curves.
Production of radiation force
The ability of the dual-frequency probe to produce radiation force was tested in vitro
in a water bath. microbubbles were prepared and pumped through a 200 µm cellulose
tube using a syringe pump (Harvard Apparatus, Holliston, MA) at several different
constant volumetric flow rates. These flow rates are summarized in Table 3.2 along
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with the corresponding linear flow velocities.
V-FR (mL/h) L-FR (mm/s) Analogous environment
9.05 200 Large artery
1.81 40 Small artery
1.81 40 Large vein
0.90 20 Arteriole
0.45 10 Small vein
0.14 3 Venule
0.01 0.3 Capillary
Table 3.2: A summary of the range of blood velocities in different vasculature types.
Modified from [71]. These velocities formed the basis for the tested range of flow
velocities of contrast agents undergoing radiation force.
V-FR: ‘Volumetric flow rate’
L-FR: ‘Linear flow velocity’
The tube was oriented horizontally, and was located at the focus of both the dual-
frequency probe and a high-speed camera (APX-RS, Photron, San Diego, CA) equipped
with a 60x water immersion lens (LUMPlanFI/w, Olympus, Melville, NY). The axes of
the camera and the transducer were perpendicularly aligned with the tube at the same
location. This dual-focus setup was achieved by positioning a needle hydrophone in the
optical focus, and aligning the pulsing transducer such that the measured signal from
the hydrophone was maximized. The microbubble solution was then pumped through
a 200 µm tube at the different flow rates and exposed to 200-cycle low amplitude pulses
[peak negative pressure (PNP) ∼13 kPa] at 4 MHz and a pulse repetition frequency of
15 kHz. This frequency was out of the optimal bandwidth of the low-frequency element,
but was chosen to reduce bubble destruction. The effects of these pulses were observed
in real time as well as recorded to later confirm the efficiency of the radiation force
pulses oﬄine.
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3.1.2 Results
Characterizing the probe
The -6 dB beamwidth in the focal planes of the 30-MHz and 2.5-MHz transducers were
determined to be 0.21 mm and 0.51 mm, respectively. The results of the beamfield
maps acquired for each element can be seen in Figure 3.2. The axial -6 dB focal regions
(depths of field) were determined to be 2.7 mm and 10.3 mm for the two respective
elements. The experimentally determined limit of axial resolution, measured using the
FWHM of the RF data for averaged microbubble bubble responses, was 95±3.47 µm.
The uncertainty in this measurement is the standard deviation of the FWHMs collected
at the different mechanical indices tested (N = 8, between MI of 0.28 and 0.57). There
was not a significant trend observed in this value with increasing low-frequency MI.
The experimentally determined lateral resolution of the probe operating in acoustic
anigraphy mode, as estimated from the average FWHM of a horizontal profile taken
through a bubble response in multiple frames of video data, was 296±67 µm. Likewise,
the experimentally determined axial resolution was determined to be 161±31 µm via
the mean FWHM in the vertical profiles acquired in the same method. The uncertainty
in these measurements is the standard deviation of the FWHM values (N = 32 for both).
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Figure 3.3: Axial dimension pressure maps for both (A) first generation and (B) second
generation dual-frequency transducers.
Contrast-to-tissue ratios: in vitro
The acoustic responses of both bubbles and tissue were used to create a measure of CTR
versus receive frequency at several different mechanical indices for the imaging pulses.
To illustrate the difference between the types of signals received from microbubbles and
from tissue, time domain plots are provided (Figure 3.4). These data were acquired
using the maximum transmit mechanical index for the study (MI = 0.65).
Figure 3.4: These data illustrate the difference between the nonlinear and nearly delta-
function response from microbubbles (left) and more linear response from tissue (right).
Speed of sound assumed to be 1540 m/s for converstion to distance.
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To illustrate the frequency domain characteristics of these data, the Fourier trans-
formed data are provided (Figure 3.5) with the receive transducer’s bandwidth super-
imposed for reference.
Figure 3.5: Frequency responses of the single lines of microbubble (blue) and tissue
(red) RF data seen in Figure 3.4. The transducer’s receive bandwidth is approximated
as a Gaussian with 100 percent bandwidth centered at 30 MHz.
CTR data was computed as the ratio of the averages of the frequency domain
data seen in Figure 3.5 (i.e. Figure 3.5 shows the Fourier transform of single RF
lines, whereas these frequency domain data were averaged over many acquisitions for
the CTR plots). The CTR data can be seen in Figure 3.6a. The signals from both
the microbubbles and tissue were corrected for the receiving element’s bandwidth to
measure the ratios of their spectral content irrespective of the imaging system used to
detect the signals. The data shows improved CTR with increasing mechanical index.
The CTR versus frequency plots also demonstrate this improved contrast sensitivity
relative to tissue with increasing mechanical index. Between the mechanical indexes
tested, a similarly decreasing slope of 1 dB/MHz is observed throughout the bandwidth
of the probe. The decibel values in Figure 3.6a are relative to the tissue responses at
each frequency and MI.
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Figure 3.6: (A) Contrast-to-tissue ratios measured in vitro as a function of frequency
at several different mechanical indices of incident pulses. Decibel values are relative to
the tissue response at each frequency and MI. (B) Contrast-to-tissue ratios measured in
vivo in six different kidneys which were imaged in both high-frequency b-mode (dashed
line) and acoustic angiography mode (solid line).
Contrast-to-tissue ratios: in vivo
The video data collected from contrast enhanced ultrasound studies on both kidneys
of three different animals in both traditional high-frequency b-mode and acoustic an-
giography imaging modes were analyzed to determine CTR in an in vivo environment.
Both a 2D slice and a 3D maximum intensity projection of a kidney imaged in acoustic
angiography mode can be seen in Figure 3.7, providing a representative view of the
extent of tissue suppression provided by this imaging method. In a 2D image slice
of each kidney, ROIs were selected around regions of tissue and contrast for both the
acoustic angiography and high-frequency imaging studies, and these values were used
to determine the CTR at each imaging pressure. These values are plotted in Figure
3.6b.
The CTR in the high-frequency in vivo imaging studies was nearly constant as a
function of pressure, with an average value of 1.18±0.01. Across the pressures studied
(1000 to 4000 kPa), the mean pixel intensity within regions of contrast flow were only
18% greater than those of tissue. The mean in vivo CTR values obtained in the
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Figure 3.7: (A) A 2D transverse slice through a rat kidney with contrast agents seen
entering the volume through the large renal vasculature. (B) A 3D maximum intensity
projection through a rendered volume of sequential image slices as seen in (A). The
multiple 2D slices were acquired using a translational motor stage with step sizes of
200 µm. The images analyzed in the CTR portion of this study were identical to the
cross-sectional slice seen in (A).
acoustic angiography mode ranged between 1 and 5 for the pressures tested, with a
linear increase between MI = 0.19 and 0.51 (290 and 813 kPa) with a slope of 0.0074
kPa−1 (R2 = 0.97). At acoustic angiography imaging pressures higher than 813 kPa, the
CTR data leveled off and approached an average value of 4.8. Thus, at pressures greater
than approximately 800 kPa, the acoustic angiography imaging method resulted in an
average 12.3 dB improvement in CTR, compared with high-frequency b-mode imaging,
for this range of mechanical indices. The maximum improvement in CTR between two
images acquired from the same anatomical location with acoustic angiography imaging
mode compared with high-frequency b-mode was 17.2 dB at a low-frequency MI of
0.51.
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Sensitivity to motion
Within the seven sets of image data collected in five different animals with power
Doppler, image subtraction, and acoustic angiography imaging modes without respira-
tory gating, acoustic angiography imaging was significantly more robust at monitoring
the presence of microbubbles. Because of the artifacts in the video data resulting from
respiratory motion, the image-subtraction method was unreliable without respiratory
gating. In this mode, the changes in video intensity caused by tissue motion were
approximately the same amplitude as the signal from the circulating contrast, and we
were only able to observe a decay slope of the contrast washout in the kidney ROI in
one of the animals.
Similarly, 5 of 7 imaging studies using power Doppler were corrupted to the point
that a washout curve could not be acquired. Examples of how these imaging modes
were corrupted by breathing motion can be seen in Figure 3.8. In contrast, the acous-
tic angiography imaging experiments (N = 7) produced a defined contrast washout
curve in each case despite substantial respiratory motion. Figure 3.9 illustrates the
relative success rates for the different imaging strategies, with acoustic angiography
mode demonstrating a 3.5- and 7-fold improvement over power Doppler and image-
subtraction, respectively.
Production of radiation force
Using a dual optical-acoustic focus and contrast agents flowing in a 200-µm cellulose
tube, we have verified that the probe is capable of applying radiation force in vitro.
The transducer was aligned above the tube and the incident radiation force pulses were
capable of pushing a polydisperse distribution of flowing microbubbles perpendicular
to their direction of motion against buoyancy. The proficiency of these sequences of
radiation force pulses, administered with a single 3-second sweep, was tested at several
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Figure 3.8: Example image data collected from the same animal without respiratory
gating enabled. (A) B-mode imaging before the introduction of contrast agents. (B)
Acoustic angiography data while contrast is circulating. (C) Image-subtraction frame
while contrast is circulating. Note the strong artifacts near the tissue borders (indicated
by white arrows). (D) Power Doppler with contrast circulating. Small regions of
enhanced contrast can be seen near the bottom of the image, although most of ROI is
washed out by motion artifact.
different linear flow velocities between 0.3 and 200 mm/s, as summarized in Table
3.2. The radiation force pulses from the probe were able to divert the flow of contrast
agents a distance of 200 µm-the diameter of the tube-at all linear flow velocities less
than 50 mm/s. At flow rates faster than this, the direction of the microbubble stream
was perturbed, though did not significantly divert within the viewing window of 500
µm. At 200 mm/s, the stream was only estimated to divert approximately 50 µm at
our push parameters. The ability to divert the stream is well visualized with time-
axis projections, an example of which is seen in Figure 3.10. In this image, the mean
intensities of movie pixels throughout the time of data collection are mapped to pixels
in a single 2D image.
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Figure 3.9: A plot comparing the abilities of the three different imaging modes to
monitor contrast flow in the presence of respiratory motion. Values are expressed as a
percentage of the seven attempted trials. Note: ‘Dual-frequency’ = acoustic angiogra-
phy
Potential for bioeffects
The interactions between ultrasound pulses and microbubble contrast agents have been
shown in the past to potentiate bioeffects, both in in vitro assays as well as in vivo
imaging studies. The following (Figure 3.11) is an overview of some recent studies
performed using various commercially available contrast agents (Optison, Levovist,
Definity, among others), insonified at a range of mechanical indexes. These studies
(references in Figure 3.11 caption) represent data from a wide range of subjects (rat,
human, mouse), anatomical locations (muscle, lung, tumor, kidney), and acoustic puls-
ing schemes (continuous wave Doppler, b-mode, harmonic imaging mode) and peak
rarefactional pressure amplitudes. The specific pressures and frequencies used by our
lab’s prototype dual-frequency transducers are also displayed on this plot, in addition to
the pressure thresholds above which bioeffects have been observed. This data suggests
that the two probes are unlikely to be causing adverse in vivo effects from microbubble
contrast agent cavitation, though this has not be explictly tested with these specific
probes.
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Figure 3.10: A time-axis projection image produced from bright-field optical video
data, which demonstrates the proficiency of the dual-frequency probe at diverting a
moving stream of microbubbles. The linear flow velocity in this image was 40 mm/s, a
comparable speed to a human small artery or large vein.
3.1.3 Discussion
Based upon the work of Kruse et al. [66], we hypothesize that the high-frequency energy
that we are detecting from the microbubbles is generated during the rapid collapse of
the gas core during the low-frequency driving pulse. In the frequency domain, these
emitted acoustic transients were confirmed to be very broadband, as seen in Figure
3.6a, allowing them to be detected at frequencies far away from the fundamental.
The 3D hydrophone scans performed to map the beam-fields of our dual-frequency
probe’s two elements revealed that the inner and outer elements were misaligned. Nei-
ther transducers’ focus perfectly overlapped the center of the z-axis of the mechanically
scanning arm, with the low-frequency element having an off-axis misalignment of 255
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Figure 3.11: An overview of bioeffect-inducing acoustic parameters. These studies are
referenced as follows. A:[72], B:[73], C:[74], D:[75], E:[76], F:[77], G:[78], H:[79], I:[80],
J:[81], K:[82], L:[83], M:[84], N:[85], O:[86], P:[87], Q:[85].
µm compared with the high-frequency element’s 16 µm. There were several conse-
quences of this misalignment. One issue with this was that the focus of the 30-MHz
element overlapped the 2.5-MHz element approximately -6 dB from the focus, and
hence the signal intensity from the microbubbles detected during acoustic angiography
mode was substantially less than optimal. One other consequence was that the mi-
crobubbles were rapidly destroyed outside of the imaging region because of a higher
pressure at the focus of the misaligned 2.5-MHz transducer. This resulted in differences
in the contrast intensity depending on whether the transducer was scanning with the
focus of the 2.5-MHz element preceding or following the imaging element.
Another limitation of the prototype probe compared with the standard mechanically
scanned probes made by VisualSonics was the reduced maximum frame rate. The
maximum sweep speeds of for RMV probes vary between 25 and 75 Hz, depending
on the model of the probe and the imaging depth of field, however, the speed of the
prototype probe was limited as a result of the increased mass incurred by the outer
confocal element to 20 Hz.
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For all imaging pressures tested, the CTR versus frequency curve peaked at approx-
imately 15 MHz, and decreased from there with increasing frequency (Figure 3.6). This
decline in CTR was caused by the decrease in spectral power of the acoustical tran-
sients at the higher frequencies, because the spectral power of the tissue signal quickly
approached the noise floor above the fundamental imaging frequency of 2.5 MHz. The
CTR increased uniformly across all frequencies in the bandwidth of the receiving ele-
ment with increasing imaging MI, which can be attributed to more violent collapses of
the microbubble gas cores at increasing pressures.
The results obtained during the in vivo CTR portion of the study showed that
the acoustic angiography imaging method could be used in animal studies to improve
contrast sensitivity over conventional high-frequency imaging methods. High-frequency
b-mode imaging showed little improved contrast signal over tissue signal regardless of
imaging pulse pressure. The average CTR in high-frequency b-mode was 1.18. Acoustic
angiography imaging of the same animals and the same imaging locations showed a
linearly increasing trend in average CTR ranging from 1.3 to 4.8, increasing as a function
of increasing imaging pressure. After approximately 800 kPa, the rate of increase in the
contrast signal was similar to that of the tissue signal and the CTR did not noticeably
improve at higher imaging pressures.
There was an approximately 10-fold difference between the in vitro and in vivo
CTR studies when implementing acoustic angiography imaging at the pressures listed
in Table 3.1. It is important to note that thein vitro analysis of CTR was performed
without consideration for several realities present in the in vivostudy, and in all ultra-
sound imaging exams. The simplifying factors of the in vitro setup which artificially
enhanced the measured CTR were, namely, the absence of signal attenuation expected
to occur in a tissue medium, and the analysis of RF data mitigated the loss of signal
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information inherent in any imaging system’s compression and video-data display al-
gorithms. Instead, this data served to provide a basic understanding of the acoustic
responses of microbubbles and tissue at frequencies higher than previously examined.
In Figures 3.7 and 3.8b, it is clear that the larger vasculature within the kidney is
brighter and better delineated from the surrounding tissue than smaller blood vessels.
Thus the contrast provided by our acoustic angiography imaging method appears to be,
predictably, a function the quantity of contrast agents present within the imaging ROI.
If the probe is to be operated within a destructive pressure regime for microbubbles
(a range which provided the best contrast within our in vivo CTR study [88]), one
potential limitation of our imaging strategy would be the need to delay imaging pulses
to allow contrast refresh within the micro-vasculature. This decreased frame rate would
be beneficial for imaging tissues with slow perfusion times.
The acoustic angiography method was compared with power Doppler and image-
subtraction, two common methods to monitor the presence and flow of contrast with
ultrasound on high-frequency imaging systems. Power Doppler is very effective at de-
tection of contrast agents because of the high-amplitude post wall-filtered power pro-
duced by moving or breaking bubbles. However, as a result of this detection strategy,
power Doppler also proved very sensitive to tissue motion. Image-subtraction, another
method to monitor contrast presence, compares a pre-contrast baseline image to con-
trast enhanced images on a pixel-by-pixel basis, and likewise proved very sensitive to
tissue movement. This tissue motion resulted in many pixels differing from their origi-
nal baseline values, yielding substantial artifacts, especially along boundaries between
tissue types, as indicated by the white arrows in Figure 3.8(c). Our results suggest
that both of these methods require respiratory gating to produce consistent results in
a high-tissue-motion environment. Even when respiratory gating was enabled, imple-
menting these two imaging methods could be a challenge if tissue motion is excessive,
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because global tissue migration will invalidate the original pre-contrast baseline images.
Acoustic angiography imaging, on the other hand, exploits the nonlinear response of
microbubbles to enhance contrast signal intensity and thus proved significantly more
robust in the presence of respiration-induced tissue motion than either power Doppler
or image-subtraction methods.
Although not shown here, we were able to generate overlays of contrast data over the
b-mode tissue by utilizing a relay circuit to toggle excitation of the low-frequency and
high-frequency elements with successive imaging frames, and then displaying successive
tissue and contrast frames together by color coding the contrast data.
Based on the results of the in vitro radiation force experiments, the dual-frequency
probe could be utilized to direct microbubbles to the endothelial wall in targeted imag-
ing studies over a range of physiologically relevant flow velocities. Additionally this
ability could be implemented in acoustically-mediated drug delivery studies, because
the probe is also capable of delivering acoustic energy above the bubble destruction
threshold, which would facilitate site-specific release of therapeutic agents.
Although the studies within this section were performed in rats, its resolution as
well as its sensitivity makes its implementation in mice studies also highly attractive.
However, the high-frequency components come at the cost of a loss in penetration
depth (less than ∼2 cm), and thus our specific parameters are less suitable for clinical
application and more appropriate for translational research with small animal models.
The combination of high contrast-to-tissue ratios and high spatial resolution achievable
with our prototype probe make novel approaches to understanding and quantifying
specific morphologies of pathologic vasculature an exciting possibility. For an additional
perspective on our imaging strategy’s ability to visualize microvessels in vivo, the reader
is referred to a supplemental video in which a volumetric rendering of the vasculature
within a subcutaneous rat fibrosarcoma tumor model is displayed.
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3.1.4 Conclusion
We have demonstrated that acoustic angiography imaging can be utilized in vivo at
higher frequencies than previously demonstrated to produce high-resolution images
with high contrast-to-tissue ratios. Because of the substantial tissue suppression, this
technique is robust in the presence of tissue motion. Additionally, the probe effectively
produced radiation force in vitro on microbubbles with flow-rate parameters analogous
to most types of environments found within a wide range of vasculature types.
3.2 High resolution assessment of vessel architecture - ex vivo tissue sam-
ples
Liver transplantation is the gold standard for end-stage liver disease. Currently, more
than 16,000 adults and children are in need of liver transplants, but unfortunately
the amount of livers available for transplantation is in short supply [89]. Therefore,
alternatives, such as bioartificial organs, are being explored. Clinically relevant bioar-
tificial livers typically use hepatocytes from xenografts, seeded in a semi-permeable
membrane and based on hemodialysis of the patient’s blood [90]. Unfortunately, these
bioartificial livers only provide temporary relief until a transplantable organ is avail-
able. In order to provide a true replacement for live donor transplantations, a more
sophisticated artificial organ is needed. The desire to produce an artificial liver to
replace the dependency on living donors has led to a push to develop decellularized
liver organs that, after recellularization, would house patient-specific human hepatic
cells. The method of decellularization converts an ex vivo or cadaveric liver organ
to an acellular, three-dimensional structure of naturally occurring scaffold materials.
These scaffolds would then be reseeded with a patient’s own cells and, in theory, would
act as a functional liver. The new organoid would provide the same, albeit improved,
metabolic operations as their original liver, theoretically without the need for the heavy
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immunosuppressant treatments associated with liver transplants. Thus, it is these ex-
tracellular matrix scaffolds prepared from decellularized tissues that are the hope for
stable organoids. Ongoing efforts are focused on establishing human liver organoids by
seeding liver biomatrix scaffolds with stem cells, hHpSCs10 or biliary tree stem cells11,
and with their mesenchymal cell partners (angioblasts and precursors to endothelia and
hepatic stellate cells)[91].
Protocols to decellularize organs vary among labs, and thus the resulting scaffolds
contain varying amounts of matrix molecules. The matrix molecules that are retained
after decellularization are important for cell engraftment, mitosis and differentiation
[92]. Some labs have been able to achieve cellular engraftment in the decellularized
scaffolds, though the reported functional data - such as albumin and urea secretion -
from reseeded cells has been lower relative to healthy hepatic output. For reseeded scaf-
folds to provide either an adequate organ transplantation alternative, or in vivo model
for drug discovery, cell function must meet that of normal human livers. It is thus one
of the common objectives in tissue engineering to optimize scaffold reseeding protocols,
thereby maximizing the structural integrity and functionality of the organoids. Since
cell seeding and organoid functionality are directly related to the patency and struc-
ture of the microvascular scaffold, there is a crucial need to non-destructively assess the
structural characteristics of the scaffold vascular matrix. Without adequate perfusion,
the reseeding process of biomatrix scaffolds with new cells cannot be accomplished, as
this process relies on fluid transport through the matrix remnants of the vascular bed
for the delivery of the cells. Also, after cells have been engrafted throughout the 3D
volume of tissue, their continued function depends on a long-term delivery of nutrients
and oxygen. In the past, perfusion in biomatrix scaffolds have been assessed in dif-
ferent ways, but it generally was achieved by qualitatively examining the color of the
tissue sample, with regions of discoloration in the sample indicating a lack of adequate
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internal flow. This approach can be useful for identifying insufficient flow within large
regions in the sample, such as throughout an entire lobe, but it is insensitive in detect-
ing subtle variations in volumetric perfusion over time. Thus a method to image both
the anatomy and flow within the sample is highly desirable. Hence, in these studies, we
have developed a protocol to enable rapid yet detailed assessment of vascular structural
and functional characteristics within liver biomatrix tissue scaffolds.
Imaging methods for assessing tissue engineering scaffolds
There are many methods used to image tissue scaffolds, including scanning and trans-
mission electron microscopy (SEM and TEM) and optical microscopy[93], magnetic
resonance (MR) imaging and microscopy [94], computed tomography (CT) [95], opti-
cal coherence tomography (OCT) [96], and Doppler ultrasound[97]. The selection of
any one modality will always yield inherent tradeoffs, such as cost, invasiveness to the
sample, field of view, resolution, acquisition time, and type of information gleaned. For
an extensive assessment of the tradeoffs, the reader is referred to a review by Mather
[98]. The only imaging modalities in the above list which can holistically (i.e. image
a sample in its entirety) and non-invasively image a rodent tissue biomatrix scaffold
sample in its entirety are MR, CT, and ultrasound. MR and CT are widely available
in both clinical and research contexts, though require expensive hardware, are not real
time, require long image acquisition times (MR), can cause radiation damage to cells
(CT), and suffer from poor soft tissue contrast (CT). Ultrasound, on the other hand
is real-time, relatively inexpensive, non-invasive, does not use ionizing radiation, and
has excellent soft-tissue contrast. In addition to these, ultrasound is able to assess
multiple different facets of a tissue volume (applicable to both in vivo volumes and
in vitro biomatrix scaffolds), including tissue structure with standard b-mode[99], me-
chanical stiffness[100], microvascular perfusion architecture[101], parametric perfusion
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speed[31]. One possible challenge hindering ultrasound’s utility for scaffold perfusion
assessment has likely been the modality’s limited field of view, allowing for freehand
visualization of different 2D slices, or small 3D sub-volumes, but never holistic visual-
ization or quantitation. Our objective in this study was to design a tissue preparation,
restraint, and imaging protocol to enable the 3D visualization and quantification of
perfusion throughout a biomatrix scaffold.
Contrast ultrasound imaging
In addition to traditional grayscale ultrasound to provide reference images of the scaf-
fold physical structure, two different contrast enhanced ultrasound techniques were uti-
lized in this work to provide functional information about biomatrix scaffold microvas-
culature. The first technique, referred to as “flash replenishment” (sometimes called
“destruction reperfusion”), allows relative blood flow rates to be spatially mapped by
assessing the speed at which contrast agents refill a sample volume after clearance[25].
While this technique is not new, it has not previously been performed in this type
of ex vivo scaffold imaging application. The other contrast imaging approach imple-
mented in this study is new technique we refer to as acoustic angiography. Acoustic
angiography is a newly developed imaging method differing from traditional ultrasound
imaging in that it is designed only to visualize vascular and microvascular structure,
rather than tissue anatomy [66; 102]. Unlike, flash replenishment, acoustic angiogra-
phy does not yet have the ability to parametrically map perfusion rates, however, it
can provide detailed visualization of vessel architecture, and provided a high resolu-
tion dataset from which vessels can be segmented and quantitatively mapped (vessel
network volume, length, etc.). Thus, our protocol involves three imaging scans, first
defining the biomatrix scaffold physical structure (anatomy), mapping vessel architec-
ture with high resolution acoustic angiography for vascular network visualization and
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quantitation, and then mapping perfusion rates with flash replenishment. Note that
all three studies could be performed sequentially with appropriate system hardware.
3.2.1 Materials and methods:
The scaffold preparation procedure is provided in Appendix C.
Sample imaging chamber
The sample imaging chamber was designed to allow a tissue sample to be imaged
while submerged under a fluid. This allows for non-contact image acquisition - as
opposed to gel-based coupling, which is typical for ultrasound imaging exams - and
thus no tissue warping was caused during imaging, resulting in better registrations of
multiple sub-volumes of image data. The imaging chamber designed for this purpose
was composed of two concentric 0.25 inch thick acrylic cylinders (Figure 3.12, A+B)
each 3 inches tall. The outer diameters of the outer and inner cylinders were 6 and 5
inches, respectively. This outer cylinder was mounted to the 6x6x0.3 inch acrylic base
of the imaging chamber via acrylic glue. The inner cylinder was fit to the imaging
chamber’s base over a Vaseline-lubricated silicone O-ring allowing for quick coupling
with a tight seal. Though not implemented in this study, this O-ring design also enabled
bidirectional imaging orientations (i.e. it was possible to rotate the inner chamber and
image the contralateral side of the tissue sample). The interior cylinder served several
purposes. It provided a frame for the tissue sample support webbing, made of 5-0
silk suture (Ethicon - Somerville, New Jersey). This support webbing held the sample
suspended in the interior of chamber. Additional suture was loosely tethered over the
top of the tissue to prevent flotation or shifting during the imaging study. The interior
cylinder of the sample imaging chamber also acted as a buffer for the circulating bubble
clearance fluid circuit (described later in this section), as the larger holes in it allowed
for efficient fluid transfer but also limited turbulence near the sample.
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Figure 3.12: Schematics for the sample imaging chamber. A) Assembled sample imag-
ing chamber and B) exploded view of the sample imaging chamber. C) A top-down
cartoon schematic illustrating the two flow circuits in the setup. Flow Circuit 1 pro-
vided perfusion and microbubbles to the liver scaffold, while Flow Circuit 2 provided
continuous circulation through the microbubble sequestration and destruction chamber
(MSDC) to remove contrast excreted from the sample.
Preliminary studies showed that the peristaltic pump, which powered flow circuit
#1 (Figure 3.12C), caused a slight periodicity in the flow rate through the scaffold
samples as a result of the pump’s rotary wheel design. The frequency of this period-
icity would scale with the speed of the peristaltic pump. This would result in beat
frequencies between this pump frequency and the frame rate of our imaging systems,
which manifested as large cyclic variations in contrast intensity between adjacent imag-
ing planes. To prevent this artifact, a pulse dampener (Model 07596-20 - Cole Parmer,
Vernon Hills, IL) was placed between the output from the peristaltic pump and in the
input to the sample. Preliminary studies also showed that microbubbles exiting the
sample into the surrounding fluid after perfusing through the portal circuit resulted in
a decrease in image quality over time. These freely flowing microbubbles in the fluid
surrounding the biomatrix scaffold caused excessive attenuation of imaging signal. To
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prevent this, a bubble clearance fluid circuit was implemented (Flow circuit 2 in Figure
3.12C). This circulated the fluid surrounding the scaffold sample though a microbub-
ble sequestration and destruction chamber (MSDC) before reinjection back into the
imaging chamber. The MSDC was a 2 L Erlenmeyer flask in which was suspended a 1
MHz unfocused piston transducer (Valpey-Fisher - Hopkinton, MA) designed to facil-
itate contrast destruction. The 1 MHz piston transducer was pulsed at 10 Hz with a
pressure of 460 kPa via a pulser (Model 801A, Ritec - Warwick RI). Media surrounding
the biomatrix scaffold was continually pumped through this chamber at 1 mL/min via
a centrifugal pump (model PQ-12, Greylor - Cape Coral, FL) powered by an external
DC power supply (model DIGI360, Electro Industries - Westbury, NY). Four nylon luer
fittings were attached to the outer cylinder for coupling the sample imaging chamber
to the two flow circuits. All fluid circuits used 0.125 inch inner diameter Tygon tubing,
except between the catheter entering the scaffold sample and the outer cylinder of the
imaging chamber: this was 0.062 inch diameter tubing.
Contrast imaging
Flash replenishment imaging was performed using an Acuson Sequoia 512 equipped
with a 15L8 transducer (Siemens Medical Solutions USA Inc, Moutain View, CA). The
“CPS Capture” software algorithm was used to measure perfusion time. 3D images of
the liver scaffold were acquired by scanning the transducer in the elevational direction
using a linear stage and motion controller (UTS150PP and ESP300, Newport, Irvine,
CA) interfaced through LabVIEW (National Instruments, Austin, TX) as described in
[31]. Perfusion images were parametrically mapped to contrast arrival times between 1
and 10 seconds. These images were stored in DICOM format with JPEG compression
and analyzed oﬄine in Matlab (Mathworks - Natick, MA). Perfusion times within the
regions of interest were assessed.
55
Acoustic angiography was performed on the second generation dual-frequency probe
described in Chapter 3.1 with imaging parameters previously described [101]. Briefly,
the imaging system was a VisualSonics Vevo770 (Toronto, ON, Canada) pulses were
emitted at 4 MHz at 1.23 MPa, and echoes were received on a 30 MHz transducer
with 100% bandwidth after being passed through a 15 MHz high pass filter to remove
non-contrast signal. 3D images were acquired with the VisualSonics 1D motion stage
with inter-frame distance of 100 µm to yield nearly isotropic voxels. Images were
acquired with a frame rate of 2 Hz, with 5 frames averaged at each location. High
resolution b-mode images were also acquired on the Vevo770 system with the same
imaging parameters, except the transmit frequency changed to 30 MHz. After imaging,
data was exported from the ultrasound system as 8 bit uncompressed AVIs.
The microbubbles used in this study were prepared with the Perfusion Agent formu-
lation as described in Appendix A. Microbubbles were introduced to the perfusion fluid
circuit through a T-valve injection port located between the pulse dampener and the
biomatrix. A 24 gauge needle was used to pierce the septum, and microbubbles could
then be injected into the fluid circuit via a computer controlled syringe pump (Harvard
Apparatus - Holliston, MA). Microbubbles were administered into the fluid circuit at
a rate of 20 µL min−1 and concentration of 1.5x109 mL−1 out of a 1 cc syringe.
Three different livers scaffolds were imaged for this study, hereafter referred to as
samples numbered 1 through 3. The left lateral lobe (LLL) of each liver scaffold was
selected as the lobe of interest for this study because it is easily accessed for imaging.
Another advantage of this lobe was its narrow morphology - the Vevo770 has a fixed
acoustic focus, and thus has a narrow depth of field (< 1 cm). Our goal was to provide a
holistic assessment of perfusion throughout a volume of tissue, and thus the left lateral
lobe was most amenable to this objective. That said, the techniques presented herein
could be extended to the entire volume of tissue if one had a transducer with a larger
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axial field of view. Each liver biomatrix scaffold was imaged with two imaging modes:
flash replenishment, and acoustic angiography.
Validating imaging consistency
Microbubble buoyancy and floatation within syringes is known to cause a reduced
concentration output from a syringe over time [103]. It was hypothesized that the
change in microbubble concentration input to the tissue sample would cause different
perfusion values reported for the same location in tissue, as this has been observed
for in vivo kidney studies [31]. To mitigate this effect the syringe was gently agitated
throughout the imaging procedure as described previously [103]. To characterize the
degree to which this affected the consistency in the reported perfusion data extracted
from the image data, a study was performed in which the transducer was fixed at a
single location and flash replenishment images acquired approximately every minute
for 30 minutes. The data was exported to Matlab for analysis. A region of interest
(ROI) was defined around the perimeter of the lobe being imaged. Two quantities
were assessed at each timepoint within the ROI: the total number of perfused pixels,
and the average perfusion value. If the output microbubble concentration into the
scaffold perfusion circuit was dynamically changing, it would be expected that both
of these quantities would also change. If a perfectly stable concentration of bubbles
was maintained, then neither quantity would change. Two scaffolds were used for this
study; the first was imaged with the non-agitating protocol susceptible to microbubble
floatation. After data was analyzed oﬄine, a second liver scaffold was imaged to observe
the effects of syringe agitation on perfusion assessment consistency.
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Registration of sub-volumes
Because the lateral field of view of the ultrasound transducers used for these imag-
ing studies was insufficient to capture the entirety of the liver lobe of interest, multi-
ple “sub-volumes” were acquired on each system and later registered together oﬄine.
Throughout this manuscript, sub-volume is used to describe a 3D volumetric image that
does not holistically capture a tissue of interest. Registration of these sub-volumes was
performed within the open source 3D Slicer environment (ver 4.2.1, National Alliance
for Medical Image Computing - www.slicer.org) using the Merge module, part of the
TubeTK extension. This module is designed to register together two images that have
a small degree of overlap along one of the axes. When the sub-volumes were registered
together using the Merge module, they would form a single cohesive volume for the
liver lobe of interest for each image type (b-mode, flash replenishment, and acoustic
angiography). The transforms module was used to then register the three types of
ultrasound image data to each other, creating a single composite 3D image for each of
the livers imaged.
Assessing liver biomatrix perfusion
The two perfusion imaging modes implemented in this study (acoustic angiography and
flash replenishment) were acquired on different ultrasound systems, thus an initial reg-
istration step was necessary prior to the merged volumetric datasets being in the same
coordinate system. This registration step was performed via a rigid transform within
the Slicer Transforms module. The lobe of interest could then be manually segmented
and the same ROI used for all three datasets. The manual segmentation of the LLL
was performed in Matlab using the function roipoly.m. Because the segmentation and
registration process was performed entirely oﬄine, it was impossible to re-collect the
ultrasound data of a scaffold if it became clear that small portions of the tissue were
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not imaged. In these cases, ROIs were defined to the edge of the available image data,
or across regions of tissue if it was obvious to the viewer what path the tissue boundary
was taking.
Each voxel within the flash replenishment images represented a spatially localized
estimate of perfusion speed. To assess perfusion throughout the volume of tissue, all
values were vectorized and histograms were created for each sample. These perfusion
histograms were binned by perfusion time, and area normalized by total perfused voxels
(i.e. the integral of the histogram was set to unity). To segment the vessels out of the
acoustic angiography datasets, a previously described segmentation algorithm was used
[51]. These segmentations were used to compute total length and volume of the vessel
network, vascularity ratio (volume of vessel network/volume of liver lobe). The volume
of each discretized location in the segmented vessel network was computed and summed
to yield total vessel network volume and length. The proportion of the vessel network
occupied by vessel segments of a range of radii between 50 µm (minimum voxel size)
and 500 µm was computed.
3.2.2 Results
Validation of imaging consistency
An improvement in imaging consistency was observed as a result of the rotation of
syringe during the infusion of microbubble contrast. The percent deviation (%σ = σ/µ)
in the normalized perfused area (NPA) within the 2D region of interest was reduced from
13.3% to 6.3%, and the percent deviation in the normalized perfusion speed (NPS) was
reduced from 15.1% to 6.6%. The NPA and NPS values are normalized to the starting
value at the beginning of the 30 minute acquisition. Additionally, there was a 10-fold
reduction in slope magnitude for the linear fit in the NPS measurements after changing
the protocol (Figure 3.14 B and D), changing from -0.0081 to 0.0008, indicating a
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more consistent measurement for perfusion speed over time. The change in slope for
the NPA was less dramatic, changing from 0.0006 to -0.0035 (Figure 3.14 A and C),
corresponding to a 0.2 fold change, suggesting that the same number of pixels were, in
general, perfusing throughout the data acquisition period for both the syringe rotation
and non-syringe rotation protocols.
Liver biomatrix lobe imaging, segmentation, and perfusion assessment
All three scaffold samples imaged required the registration of multiple sub-volumes
for holistic visualization. Perfusion rate information required two sub-volumes for all
samples, while the anatomical information and acoustic angiography data required
three sub-volumes for sample #1 and two for samples #2 and #3. Once completed,
the acoustic angiography data was displayed via maximum intensity projections (MIPs)
(Figure 3.15). Anatomical b-mode data cannot be displayed in this fashion, so XZ slices
through the merged volumes were displayed. The reperfusion rate data were displayed
both as 2D slices through the volume.
Sample #1 was noticeably different than samples #2 and #3, from a qualitative
standpoint in both the acoustic angiography and perfusion images. There were fewer
smaller vessels visible within perfusion data. This was due to an experimental error
during setup of the sample the biomatrix scaffold’s surface was pierced during its
placement in the sample imaging chamber. The result was several low resistance outlets
for contrast exiting the system. One large perforated outlet was clearly visible within
the acoustic angiography image set (Figure 3.15, Sample #1, yellow arrow).
Another insight gleaned from the visualization of the scaffold samples (Figure 3.15)
was the ability to delineate vessels as part of either the hepatic or portal circulatory
networks within the tissue volume (white vs. black arrows, respectively). Because
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contrast was infused though the portal vein, the hepatic circuit did not contain mi-
crobubble contrast and thus was not visualized under acoustic angiography. When the
b-mode volumes were registered to the acoustic angiography volumes, flow voids in the
b-mode, which were not perfused within the acoustic angiography dataset, could be
classified as components of the hepatic circuit.
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Figure 3.13: A: The orientation of the biomatrix scaffold sample as viewed from above
with the following visible lobes labeled: left lateral lobe (LLL), inferior right lobe (IRL),
anterior caudate lobe (ACL), posterior caudate lobe (PCL), superior right lobe (SRL),
and median lobe (ML). The LLL was the lobe we imaged in this study. Lobes were
identified in this figure via an available surgical guide [104]. B: Orientation of the
imaging sub-volumes relative to the tissue sample. XY dimensions were lateral and
axial axes within the ultrasound coordinate space, with the Z axis being the elevational
scan direction. C: Schematic explaining the registration of multiple 3D volumes from
three distinct ultrasound imaging approaches into the final composite volume, and what
quantities could be extracted
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Figure 3.14: Data illustrating the stability of the normalized perfusion area (NPA) and
normalized perfusion speed (NPS) before and after modifying the contrast injection
protocol. A+B represent data before syringe mixing, while C+D show after syringe
mixing. Note the improvement in consistency (i.e. the reduction in percent standard
deviation) for both parameters after implementing syringe mixing.
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Figure 3.15: A compilation of all image data acquired of the three biomatrix scaffold
samples. Yellow arrow indicates location of sample #1 which were perferated, and
thus leaking microbubbles. Each row was acquired with the following imaging modes
(from top to bottom): Acoustic angiography, vascular segmentations, b-mode, manually
defined regions of interest, and flash replenishment. White and black arrows on the
b-mode images indicate vessels identified as part of either the portal or hepatic circuits,
respectively. In the flash replenishment images, the top images are 2D XY slices, and
the bottom are Z-projection renderings. The flow rate colorbar indicates pixels mapped
to between 10 and 1 second reperfusion times for slow to fast flow, respectively.
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Vessel network architecture was assessed via over 1,700 vessel segmentations (Fig-
ure 3.15) extracted from the acoustic angiography image data (image data from which
these were extracted in Figure 3.17). These data were rendered in 3D and color coded
by whether vessels are inside or outside the manually defined tissue boundary. Different
numbers of vessels were extracted from each sample: for sample #1 (N = 415 vessel
segmentations), sample #2 (N = 702 vessel segmentations), and sample #3 (N = 671
vessel segmentations). The volumes and total length of these vessel network segmen-
tations were computed to be 142.6, 226.6, and 241.3 µL and 1.0245, 16177, and 1.4646
m for samples #1, #2, and #3 respectively. The vascularity ratios were 1.97%, 3.82%,
and 3.10% for samples #1, #2, and #3 respectively (Figure 3.17D). While these met-
rics each reveal sample #1 to be contain fewer perfused vessels (both in total volume
of the vessel network, and as a proportion of total volume of the biomatrix tissue) the
distribution of vessel sizes were similar between all three of the samples (Figure 3.16,
bottom).
3.2.3 Discussion and concluding remarks
Biomatrix scaffolds are complex, 3D tissue extracts of extracellular matrix that can be
used as substrata for establishment of organoids. They are chemically and functionally
tissue-specific but not species-specific. Thus scaffolds prepared from rat and murine
tissues can be used to establish human organoids. Their potential for tissue engineer-
ing is implicated by the findings that they can be isolated rapidly (in a few hours),
contain essentially all of the collagens (>98%) and all known collagen-bound matrix
and matrix-bound growth factors/cytokines and with localization of the components
to relevant histological sites. Prior reports demonstrated that frozen sections or pul-
verized forms of biomatrix scaffolds can be used as substrata for cells; they enable cell
attachment within seconds to minutes; maintain adult rodent and human cells in a fully
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Figure 3.17: 3D renderings of the biomatrix acoustic angiography data (A-C). Color is
defined as either inside (green) or outside (blue) of the manually defined tissue border.
D: quantitative assessments of vascular network volume, length, and vascularity ratio.
Data are normalized to sample #1.
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differentiated state for more than 8 weeks; and induce lineage restriction of stem cells
to mature cells in approximately a week after which they remain stably differentiated
for months[105]. The ultrasound images provide novel insights into the complexity
of the matrix remnants of the liver architecture and of the vascular channels. The
dimensions of the channels can be quantified precisely using these ultrasound technolo-
gies and corresponding segmentation algorithms, allowing one to identify categories of
blood vessels for which such dimensions are known. Important experimental logistics.
During the development of this acoustic imaging protocol for assessing liver biomatrix
scaffold perfusion, several experimental techniques were discovered to be of significant
importance for effective experimental outcomes. The first was the importance of main-
taining a consistent microbubble concentration input to the scaffold, suggested by [31],
and evaluated via the longitudinal consistency analysis (Figure 3.14). Agitating the
microbubble-containing syringe during infusion doubled the reported perfusion consis-
tency values, and reduced the variability in the reported perfusion speeds to below
10%. The minimization of contrast administration-induced variability in perfusion as-
sessments is critical for accurate inter-sample comparisons.The second experimental
technique found to result in significant variability in reported perfusion was the care
with which the samples were handled prior to imaging. While it may seem self evident
that biomatrix scaffolds ought to be handled with care, we would not have known we
had compromised sample #1 without examining the image data.
The plume of contrast visibly exiting the scaffold boundary, and the vast differ-
ences in reported perfusion between sample #1 (perforated surface) and samples #2
and #3 (both undamaged) (Figures 3.15, 3.16, and 3.17) highlight the importance of
being mindful of biomatrix scaffold fragility during decellularization and imaging setup
procedures. The observation that dramatic differences in image quality and reported
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perfusion rate distributions result from damaged samples also suggest that these imag-
ing methods could be used as screening methods to assess the integrity of a biomatrix
scaffold, and thus reducing waste. An imaging study after decellularizing sample #1,
for example, would have revealed that efforts to reseed cells within the scaffold would
surely have failed, thereby saving time and reagents.Oﬄine data analysis. During the
oﬄine registration and segmentation processing steps, it was discovered that some por-
tions of the LLL were excluded from analysis. This was due to the transducers form
factors being too large to image the portions of the scaffold tissue close to the sample
imaging chamber’s wall (b-mode images for samples #1 and #2 in Figure 3.15 illus-
trate this). We estimate this lack of image data to result in relatively minor errors in
ROI definition, and thus relatively small errors in the estimates for perfusion (since the
periphery of the LLL would be most affected by this). Thus, since the periphery of the
liver’s lobes are predominantly occupied by slowly perfusing vasculature[104], the mean
perfusion values reported via these manual segmentations will not be affected by the
exclusion or inclusion of a small proportion of this region of tissue. Nonetheless, these
errors are preventable, and can be avoided by placing the sample with the lobe of inter-
est as close to the center of the sample imaging chamber as possible, thereby preventing
contact between the transducer face and inner cylinder wall. Alternatively, a sample
imaging chamber with a larger interior diameter could be selected as a way to circum-
vent this, but care must be taken when increasing the size of the chamber; volume of
a cylinder increases proportionally to the radius cubed. A sample imaging chamber
with a significantly larger volume would require a much faster flow rate through the
microbubble sequestration and destruction chamber (MSDC in Figure 3.12) to prevent
contrast accumulation.Though not explicitly implemented in this study, it was discov-
ered during the registration and display of the merged volumetric b-mode and acoustic
angiography data (Figure 3.15) that the hepatic and portal circuits could be delineated
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by comparing speckle voids in the b-mode data to acoustic angiography data contrast
enhancement regions of overlap are the portal circuit (since this was the circuit perfused
by microbubbles) and those without mutual overlap are the hepatic circuit. Alterna-
tively, we could have infused contrast into the hepatic circuit to elucidate that vascular
network instead.
Significance of these novel ultrasound imaging methods
Evaluation of biomatrix scaffolds (or any form of decellularized tissue scaffold) prior
to use for recellularization and during the recellularization process can be achieved
with the protocol contained herein for perfusion assessment of scaffolds via multiple
ultrasound imaging modes. The method necessitates a sample imaging chamber to hold
and restrain the ex vivo sample, a systematic method for acquiring overlapping sub-
volumes, a registration method for merging the sub-volumes into cohesive 3D images
of the entire volume. The form factor of the sample imaging chamber designed for
these studies allows for contact-free imaging, mitigating the tissue warping effects of
imaging studies implementing coupling gel, and therefore registrations between the
sub-volumes were straight forward. All the image visualization and most of the image
analysis can be performed in freely available open source software. The ultrasound
approaches described herein offer a real time and inexpensive technique (relative to
CT, and MR) for visualization of biomatrix scaffold perfusion, with anatomical images
acquired with the same probes as vascular perfusion data acquisition. Additionally,
these approaches offer a better depth of penetration into the scaffold than optical
imaging approaches, allowing for the visualization of the entirety of the LLL (at the
expense of both axial and lateral resolution, which is worse than systems imaging at
optical wavelengths). Finally, the method was non-destructive to the sample, unlike
microscopy-based methods of scaffold assessment.
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While advantages to the protocol presented in this manuscript are numerous, there
are also several drawbacks worth mentioning. Currently, there are no ultrasound trans-
ducers capable of acquiring both types of contrast imaging approaches implemented in
this study: high resolution acoustic angiography and dynamic perfusion speed mapping.
In addition to multiple image acquisitions requiring more time to collect the data, this
also necessitates the experimentally cumbersome maneuver of transferring the sample
imaging chamber between systems. Also, while several groups have made strides to-
ward calibrating flash replenishment imaging against absolute values for perfusion rate
calibrated against gold standards[25; 106] the technique currently only provides rela-
tively quantitative measures for perfusion. This is adequate for assessing differences
in regions within a given sample, such as would be necessary for identifying pockets
of occlusion, it does not yet allow one to determine absolute flow rates (mL s−1cm−3)
within the biomatrix scaffold.
Nondestructive 3D perfusion imaging of decellularized organs and tissues could have
significant value in the field of tissue engineering. To date, recellularization of entire
liver biomatrix scaffolds after imaging the vasculature has not been demonstrated but
is currently the focus on ongoing studies. Future studies could include the correlation
of structural information, such as vessel diameters, perfusion rates, and patency with
the gold standard of histological data after reseeding and recellularization procedures
are complete. Additionally, these structural details could later be correlated to regions
of cell attachment and cell differentiation to help identify and tune optimal cell seeding
perfusion rates and incubation times. Finally, ligand-bearing microbubbles could be
implemented in a 3D ultrasonic molecular imaging study to spatially map specific
regions and types of adherent cells within the scaffold.
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3.3 Acoustic angiography for assessing microvasculature structure: pilot
in vivo studies
In this section the technique of high-resolution microvascular imaging using a prototype
dual-frequency transducer is examined in greater detail. This transducer enables vascu-
lar imaging with both extremely high contrast sensitivity and imaging resolution. With
this technology, the traditional resolution vs. contrast-sensitivity tradeoff can be par-
tially circumvented by detecting of the high-frequency components from the wideband
acoustic energy produced by microbubbles excited at low frequencies near their reso-
nance, as reported initially by [66]. A more detailed discussion of the transducer design,
resolution, and contrast-to-noise performance has been presented earlier in this chapter
(Chapter 3.1). The resulting ultrasound images illustrate high-resolution depictions of
the microvasculature, without background from surrounding tissue, not unlike x-ray
angiography images. Furthermore, through use of traditional single-frequency pulse-
echo, a tissue b-mode image can be acquired for anatomical reference. Thus, we refer
to images acquired with this technology as “acoustic angiography.” In this collection of
pilot studies, we present examples of high resolution in vivo 3D images acquired with
our prototype transducer which display both healthy and diseased vascular networks.
For qualitative comparison, we also provide contrast enhanced CT and photoacoustic
images, and we compare and contrast acoustic angiography with these other imaging
techniques.
3.3.1 Animal imaging
All animal studies were approved by the UNC Chapel Hill Institutional Animal Care
and Use Committee. All imaging studies were performed in rats. Seven animals were
imaged for this study: three healthy controls were imaged in their flank region, three
animals with a tumor model contained within the same type of tissue were imaged, and
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one animal was imaged for a healthy kidney for comparison to contrast enhanced CT
imaging. The tumor model (fibrosarcoma) was initiated by propagating tumor tissue
through subcutaneous implant in the rodent flank. Initial tumor samples were provided
by the Dewhirst lab at Duke University. The nonlinear ultra-broadband ultrasound
imaging strategy necessitates the use of contrast agents to provide signal from the
vasculature. In these studies, microbubble contrast agent with a polydisperse diameter
distribution centered at 0.9 µm with a standard deviation of 0.45 µm were prepared with
the perfusion formulation. Microbubble contrast was diluted in saline and administered
via a tail vein catheter with a syringe pump at 70 µL/min at a concentration of 3.3x109
bubbles/mL. Imaging pulses were 4 MHz single cycle sinusoids with a peak negative
pressure of 1.23 MPa (MI = 0.62). 3D ultrasound images were acquired with interplane
step sizes of 150-200 µm, and required fewer than 3 minutes to acquire. Since the
tissues of interest were in the lower abdomen and flank, respiratory motion artifacts
were limited. All ultrasound images were acquired coplanar with the axial anatomical
plane with animals in dorsal recumbency.
The CT images were acquired of the rat kidney 45 minutes after the injection
of contrast. The contrast agent implemented was Fenestra VC (Advanced Research
Technologies, Montreal, QC), an iodinated lipid blood pool CT contrast agent injected
at a concentration of 3 mL/450 g tissue. CT images were acquired using the GE
eXplore SpeCZT CT 120 SPECT/CT (GE Healthcare - London, ON) at 90 kVp using
900 views over 360 degrees with total output 576 mAs. The total dose delivered was
300 mGy. Reconstruction was performed on 100 µm isotropic grid with a standard
FDK algorithm.
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3.3.2 Results
Tumor imaging
One likely application of acoustic angiography will be the visualization of tumor mi-
crovascular structure. Figure 3.18A illustrates the ability of the probe to acquire both
vascular images and tissue images of the same in vivo sample volume. Vessels im-
aged in acoustic angiography mode are overlaid on a traditional high-frequency b-mode
image, thereby enabling the visualization and spatial characterization of vessel-tissue
integration.
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Figure 3.19 depicts both b-mode and acoustic angiography images of the microvas-
culature surrounding two different tumors versus microvasculature from two normal
tissue volumes. Differences in the vascular architecture within these two types of tis-
sue volumes are immediately observable. Highly tortuous vessel structure is typical
of angiogenic tumor vasculature [48; 35] and is not observed with as much frequency
in the data for the healthy flank as it is in the tumor-bearing tissue volumes (Figure
3.19). Moreover, the angiogenic nature of tumors can be visualized by the many vessels
gravitating toward the tumor lesion. Further analysis of microvasculature morphology
is outside of the scope of this section, though appears later in this dissertation (Chap-
ter 5.1). These images provide compelling evidence of the possibility of applying this
imaging technique toward quantitative approaches to assessing vessel architecture.
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Acoustic angiography compared to photoacoustic imaging and micro-CT
To compare acoustic angiography images against images acquired with a photoacoustic
imaging system, we present data of subcutaneous microvasculature in rodents with both
imaging methods. Figure 3.20A illustrates vasculature in the lower abdomen of a rat
acquired with contrast ultrasound at transmit 4 MHz and receive 30 MHz. Figure 3.20B
illustrates vasculature around the abdomen of a mouse obtained by photoacoustics using
an excitation wavelength of 590 nm as acquired by [107]. The ultrasound transducer
in the photoacoustic apparatus was a 38 µm thick FPI polymer spacer, with a -3 dB
acoustic bandwidth of 22 MHz. Its frequency response is characterized by a smooth roll-
off, with a its zero response occurring at 58 MHz [107]. In this image, the photoacoustic
resolution was approximately 90 µm (depth) by 130 µm (lateral), and the imaging
depth of field was 2 mm. The acoustic angiography images are of lower resolution
(approximately 150 µm (depth) by 200 µm (lateral)), however illustrate a greater depth
of penetration in this particular data set (5 mm in this case). Although not presented
here, newer photoacoustics techniques have illustrated sub-100 µm spatial resolution at
depths of almost 10 mm. [108] Similarly, we estimate that acoustic angiography could
be achieved at depths up to several centimeters by reducing the receiving frequency,
albeit at the expense of a reduced spatial resolution and with more background noise
from tissue.
We also qualitatively compared acoustic angiography to contrast enhanced micro-
CT. Coronal maximum intensity projections (MIP) through the ultrasound and CT
acquisitions of the same kidney were performed (Figure 3.21). The CT dataset was
reconstructed with a 100 µm voxel grid, which resulted in an improved SNR, compared
to the ultrasound image’s 50 µm voxel grid. Despite the slightly lower resolution of the
ultrasound, previously measured to be approximately 150 µm [102], the two imaging
techniques illustrate similar anatomical microvascular features within the rat kidney.
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Figure 3.20: Comparison of acoustic angiography (A) to a photoacoustic imaging ap-
proach (B). The orientations of the acoustic angiography images have been purposefully
arranged to mimic the photoacoustic images (adapted, with permission, from [107]) to
allow a quick comparison between the two modalities. The imaging location in (A) is
similar to the ones indicated in Figures 3.18 and 3.19
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3.3.3 Discussion and summary
The contrast ultrasound technology demonstrated herein has the capability to obtain
high-resolution angiographic images of the microvasculature in rodents. This type
of noninvasive and high throughput imaging technique could provide researchers and
clinicians a new tool in the assessment of disease and response to therapy, while avoiding
drawbacks associated with CT and MR, such as high cost, long acquisition times, and
ionizing radiation dose (for CT). Although photoacoustics has advantages in improved
resolution, optical techniques remain fundamentally limited with penetration depth.
The tradeoff between resolution and depth of penetration is the primary limitation
of the acoustic angiography imaging approach. Due to the increased absorption of
sound at high frequencies, penetration depth is limited to a few centimeters. For
our prototype probe, this limitation is further exacerbated by the fixed focus of the
transducer’s current form factor, as not only does it suffer from a limited depth of
penetration but also a fairly narrow depth of field (approximately 1 cm). However, this
depth and depth of field are sufficient for nearly all mouse and most rat imaging. A
transmit low-receive high array with dynamic focusing would alleviate this problem,
though such an array has yet to be constructed in the frequency range optimal for
small animal imaging. Another limitation of the acoustic angiography technique is the
need for an imaging path unobstructed by strong acoustic reflectors; bowel gas and
skull bone would hinder imaging, for example. Finally, because this is a contrast-based
technique, the method does require an intravascular injection of microbubbles.
While the studies presented in this section are by no means comprehensive, the
tissue signal suppression and microvascular imaging ability they have demonstrated
motivation for the development of additional transducer designs to implement acoustic
angiography. The approach could enable numerous applications for both preclinical and
clinical interrogation of disease presence and response to therapy. Preclinical arrays
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could be designed for larger animal models, such as for rabbit or dog imaging. It is
possible that in each of these clinical and preclinical applications the presence of disease-
associated vascular abnormalities could be detected by acoustic angiography, as could
the modifications to these vascular networks (such as the elimination or normalization
of tumor vasculature) by effective therapeutic regimens.
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CHAPTER 4
TOWARD THE DETECTION OF ABERRANT VESSEL
MORPHOLOGIES WITH ACOUSTIC ANGIOGRAPHY
The first section in this chapter describes a method to create microvessel phantoms
to test the segmentation algorithm (Chapter 4.1) and the second section describes its
implementation to test the limits of the microvessel segmentation algorithm’s accuracy
and repeatability (Chapter 4.2).
4.1 3D microvessel-mimicking ultrasound phantoms produced with a scan-
ning motion system
The development and implementation of ultrasonic vascular imaging techniques, along
with their corresponding image analysis strategies, necessitates an understanding of
their resolution and detection sensitivity as well as their sensitivity to corruption by
the unfortunate realities of in vivo imaging studies, such as respiratory motion and
signal attenuation. In vitro phantoms are utilized as a means to simulate anatomically
relevant structures in a controlled environment to test sensitivity as well as the effects of
Note: This chapter has two sections, both of which draw from previous published material. Pre-
viously published material was reprinted with permission from the publishers.
Chapter 4.1: Ryan C. Gessner, Roshni Kothadia, Steven Feingold, Paul A. Day-
ton. 3-d microvessel-mimicking ultrasound phantoms produced with a scanning motion system,
Ultrasound Med Biol, 37(5):827-33, 2011.
Chapter 4.2: Ryan C. Gessner, Roshni Kothadia, Steven Feingold, Stephen Aylward, Elizabeth
Bullitt, Paul A. Dayton, Blood vessel structural morphology derived from 3D dual-frequency ultrasound
images, IEEE International Ultrasonics Symposium Proceedings. 2010
these variables. Blood vessel mimicking flow phantoms are often constructed of either
acoustically transparent cellulose tubes set in gelatin for support, or wall-less gelatin
bores through which contrast agents can be flowed and imaged. While these techniques
are sufficient to test an imaging strategy’s sensitivity or signal to noise ratio, they are
suboptimal in creating environments for simulating blood vessel networks which have
nontrivial structural details. Furthermore, attempts to simulate structural features in
the hundred-micron range can be prohibitively difficult simply due to the challenge of
working with materials on a sub-millimeter scale. This is a problem which most affects
those seeking to characterize the structural morphologies of individual vessels or vessel
networks as markers for disease.
Presented in this section is a novel method of generating individual 3D vessel phan-
toms with predefined coordinates of nearly any morphology. Our microvessel phantoms
can be constructed with <10 µm precision. The technique is extended to the gener-
ation of entire vasculature networks via basic image addition of the independently
constructed vessels. The principle behind our strategy is that an object is continuously
imaged while also being translated in a controlled manner by a computer-controlled
motion stage. If this motion occurs between imaging frames, it will appear smooth and
continuous in the final 3D image. The strategy could be beneficial for determining the
accuracy and sensitivity of imaging and image-analysis techniques seeking to quantify
the structural morphology of vessels or vessel networks, as well techniques quantifying
blood flow speed. It can also assist in determining imaging resolution, sensitivity to ar-
tifacts, and detection sensitivity for any of the ultrasound imaging strategies commonly
implemented for vascularity assessment.
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4.1.1 Materials and methods
Microcapillary and contrast agents
The complex microvessel flow phantoms generated in this manuscript were created
by spatially manipulating a contrast-filled microcapillary during imaging. The mi-
crocapillary was a single thin-walled 200 µm cellulose microtube (Spectrum Labs -
Rancho Dominguez, CA) coupled with hot-melt glue to 380 µm polyethylene tubes
(Becton Dickinson, Sparks, MD). The cellulose tube region was imaged, while the
larger polyethylene tubes were implemented to facilitate coupling with the syringe for
contrast injection. A polydisperse distribution of perfusion microbubble contrast agents
(mean diameter 0.9 µm, standard deviation 0.45 µm) (Appendix A) were prepared and
pumped through the tubes via coupling with a 27-gauge blunt needle. The tube was
suspended in a water bath from one of the arms of a precision three-axis motion stage
(Newport model XPS - Irvine, CA). A contrast-specific high resolution imaging method
was implemented on a Vevo 770 ultrasound system (VisualSonics, Toronto CA), as pre-
viously described (Chapter 3.1).
Motion system
A custom LabView (National Instruments - Austin, TX) program was written on a
personal computer (PC) to control the motion stage, as seen in Figure 4.1A. The
transducer was positioned above the tube, with the tube’s axis oriented normal to the
imaging plane, and parallel to the direction of the transducer’s translational motor
stage as seen in Figure 4.1B. The frame trigger from the ultrasound system was used
to trigger the PC, which then activated the motion stage to move the cellulose tube
to the next X-Y coordinate in its centerline. The imaging system was set to acquire
images at a fixed rate of 2 Hz, and the motion stage would increment the position of the
microtube once between each image frame acquisition. 3D images were acquired via
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the ultrasound system’s stepwise translational motor stage, with an inter-frame step
size of 0.05 mm. This yielded isotropic voxels in the resulting 3D images.
Figure 4.1: (A) Schematic block-diagram of the phantom generation system. Motion
stages 1 and 2 correspond to the Newport and VisualSonics stages, respectively. (B)
Drawing schematic of the spatial relationships between the physically moving compo-
nents of the setup.
Image acquisition
Prior to phantom imaging, X-Y-Z coordinates of the desired vessel’s centerline were
generated in Matlab (The Mathworks - Natick, MA) and exported as tab-delimited
text files. For the remainder of this manuscript, the X, Y, and Z axes correspond to
the transducer’s lateral, axial, and elevational directions respectively. Any arbitrarily-
shaped vessel curve could be generated, provided the resulting centerline did not fail
the “vertical line test” in the X-Y plane. This caveat was due to the method by which
we were acquiring our 3D images: the transducer only would acquire a single image
at every Z location, thus it was impossible for a vessel to loop back on itself in the Z
direction, although this could be done with future modification to the system.
Single vessel phantoms were generated and imaged with different morphologies,
including helical-shaped and meandering vessels with random tortuosity added. Ad-
ditionally, by summing up images of single vessel phantoms, we were able to create a
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multiple vessel composite phantom to simulate a vessel network. Our methodology for
3D single vessel phantom generation is illustrated by the cartoon diagram in Figure
4.2. The transducer’s Z position is in red, and is controlled by the ultrasound system.
In these examples, as the probe is scanned the Newport motion stage moves the tube
A) up and down, or B) in a circle within the 2D ultrasound imaging plane. The result
is a sinusoid or a helix in the resulting 3D ultrasound image.
Figure 4.2: Two cartoons illustrating the methodology of simulating complex 3D vessel
structures by independently controlling the X and Y locations of the vessel’s centerline.
Blue curves are controlled by the Newport motion stage. Red curves are controlled
by the VisualSonics motion stage. (A) Sinusoid is generated. (B) Two out-of-phase
sinusoids result in the generation of a helix
In order to use this system to assess contrast intensity as a function of axial depth
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and pulsing pressure, coordinates were generated for a simple linear and diagonal phan-
tom originating deep in the field of view and concluding very close to the transducer.
The gradual slope of this phantom enabled a precise characterization of contrast sensi-
tivity as a function of depth, in 100 µm intervals (this distance is two pixels on screen).
Moreover, by modulating the pressure output of the transducer, we characterized con-
trast sensitivity for depth of field over multiple pulsing pressures between 300 and 650
kPa.
4.1.2 Results
3D tortuosity vessel phantom generation
We discuss specifically the generation of two types of vessel phantoms of potential
interest to those studying vessel structure and morphology. The first, seen in Figure 4.3,
is a single vessel which develops tortuosity abnormalities along its path. In this study, a
single gently meandering vessel, representing “healthy” vasculature has noise randomly
added to the X and Y coordinate of each point along its centerline. The amplitude of
the noise is modulated to create a more tortuous vessel. The most tortuous vessel has
a mean deviation of 445 µm from the healthy vessel’s centerline. This type of phantom
could be utilized to simulate morphological abnormalities relevant to tumor response
to treatment, as described by [37].
Bifurcating vessel phantom generation
Another type of phantom generated was a composite-vessel structure composed of mul-
tiple independent vessel phantoms. First, X-Y-Z coordinates were independently gen-
erated for each of the four vessels in Matlab, and the resulting four 3D images of each
vessel added together to simulate a single continuous vessel network (Figures 4.4A-C).
The 3D ultrasound image in Figure 4.4D was rendered in ImageJ (National Institutes
of Health - Bethesda, MD). This vessel network was designed to have three different
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Figure 4.3: 3D maximum intensity projections of ultrasound data collected of various
vessel phantoms. These phantoms represent simulations of a healthy vessel developing
high spatial-frequency tortuosity abnormalities that are typical of cancerous vascula-
ture. Mean deviations (Mean Dev.) from the healthy vessel’s centerline range between
35 µm and 445 µm.
bifurcations. At each bifurcation, the two daughter vessels diverge in opposite direc-
tions. Prior to a bifurcation, the daughter vessels resulting from that bifurcation trace
equivalent paths to ensure smoothness at these junctions. By varying the angles at
which daughter vessels diverge, one could simulate vascular changes due to the onset
of disease. The angles at which vessels diverge have been linked to the presence of
liver disease [32], with the fibrous tissue in diseased livers causing wider divergence
angles between hepatic vessels. Thus, this type of phantom could be used to measure
an imaging system’s sensitivity to these types of morphological changes occurring in in
vivo vasculature.
Measuring contrast sensitivity
By simulating a diagonal phantom oriented in the Y-Z plane, we were able to measure
our contrast detection sensitivity as a function of imaging pressure and location within
the field of view. The tube was raised in 100 µm increments between images, and
was imaged at points ±6 mm from the acoustic focus. Images were acquired at eight
different pulsing pressures between 300 and 650 kPa. The data is summarized in Figure
4.5A, with a corresponding cartoon demonstrating the orientation of the transducer
89
Figure 4.4: (A,B) Lateral and axial projections of 3D vessel network coordinate data,
respectively. The network was designed so that all bifurcations result in daughter
vessels diverging in opposite axial directions, as seen in (A). (C,D) 3D projections of
vessel network coordinate data and ultrasound (US) data, respectively.
and tube in Figure 4.5B. The detection sensitivity in Figure 4.5A was quantified by
averaging the pixels with image intensities above the noise floor in each 2D image in the
3D dataset. The phantom tube’s mean intensities in each 2D image could be directly
mapped to the distance from the tube to the transducer’s focus since this relationship
was governed by the coordinates used by the motion stage to create the phantom.
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Figure 4.5: (A) An image displaying the sensitivity of our ultrasound probe to contrast
as a function of pulsing pressure. The rows in this image correspond to the distance
from the transducers focus to the tube. The columns in the image represent the discrete
pulsing pressures tested between 300 and 650 kPa. (B) A drawing illustrating how the
tube was moved to simulate a diagonal-sloped ramp phantom through 3D space.
4.1.3 Discussion and conclusions
Advantages of the phantom generation technique
The most enabling component of the technique described in this chapter for 3D flow
phantom generation is the ability to create precise structures in the ultrasound data that
would otherwise be prohibitively difficult or impossible to construct using conventional
flow phantom materials. We have demonstrated the capability to generate phantoms
with shapes such as helices, sinusoids, vessels with varying degress of tortuosity, and
bifurcating vessels; all with effective diameters on the order of 200 µm. Additionally, the
micron-level accuracy of today’s computer controlled motion stages offers fine control
over phantom precision.
There exist other applications of this phantom generation technique which were not
tested in these studies. For example, the motion stage-tube apparatus could be used to
determine the sensitivity to slowly flowing blood by modulating the speed of the motion
stage and measuring the reported flow speed against the known speed of the tube. One
could also use the setup to simulate respiration artifacts of different magnitudes in order
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to determine an imaging strategy’s sensitivity to this reality of in vivo imaging studies.
Finally, the approach could be used to measure an imaging strategy’s resolution. If
two tubes are simulated which pass through each other at a shallow angle of attack,
the actual separation distance between the tubes’ centerlines is known, so one could
extract the last point at which they appear distinct and know the analogous physical
separation between them (i.e. the imaging system’s spatial resolution).
Limitations of the phantom generation technique
While the phantom generation technique presented herein is a novel means to more
accurately construct micro-flow phantoms for ultrasound imaging studies, there are
several limitations of the technique worth noting. First and foremost, it must be
implemented in a water bath, as the tube needs a smooth acoustically transparent
medium through which to move. This then makes it necessary to add speckle noise
as a post-processing step if one is interested in analyzing vessels in a more realistic
imaging context. Since the process of building up vessel networks presented in this
manuscript is via simple voxel addition, the signal to noise ratio between the vessels
and the background noise in the final composite vessel images is spatially variant as
a function of how many vessel signals are added together at a given location. The
noise power increases uniformly throughout the image volume of the composite vessel
phantom as each individual vessel phantom is added to the composite image; the signal
power within the vessels does not always increase at all locations, however. In some
locations of a composite image multiple vessels can be present, such as in the region
before a bifurcation, and thus when they are added the final “vessel signal” increases N
times (where N is the number of vessels present at a location). After vessels bifurcate
and trace unique trajectories through the image space, their signals do not add any
longer and thus are reduced relative to the increased noise power. While this was not
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accounted for in these preliminary proof-of-concept imaging studies, one could compen-
sate for this by characterizing the noise of the imaging system and normalizing the noise
to the vessel signals in a post-processing step after the composite vessel networks had
been constructed, as the centerlines of each vessel within the network are known. An
additional limitation of the phantom generation technique is the amount of translation
which can be used while still maintaining the illusion of a smooth and continuous tube
through 3D space. Because the tube was oriented normal to the imaging plane, every
2D image has a nearly circular cut through the tube. If phantoms with steep angles
relative to the plane of the image are created, the circular tube will need to translate
many pixels between imaging frames and thus have a stratified appearance in the final
3D image. This effect can be partially accounted for by choosing small elevational step
sizes. Although it was not necessary to consider the orientation of the tube relative
to the imaging plane with our contrast detection strategy, those implementing Doppler
techniques for contrast detection would need to take this into consideration to avoid
the detection sensitivity issues associated with 90 degree Doppler angles. Additionally,
if one is interested in achieving non-trivial velocity streamlines within a vessel phantom
generated by the method presented herein, additional degrees of freedom must be added
to their experimental apparatus. For instance, if one wanted to simulate a change in
flow direction at a bifurcation they would need to rotate the transducer relative to the
tube at the appropriate location along the vessel’s centerline (or equivalently: rotate the
tube beneath the transducer). This would become increasingly difficult in situations
where a vessel’s trajectory varied in both the X and Y dimensions, such as those in
Figure 4.4, as the transducer would need to undergo two independent rotations. While
not impossible, it is likely that this type of imaging procedure would be prohibitively
difficult. Thus, we propose this phantom generation method as primarily of interest for
those interested in assessing complex vessel morphology.
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4.2 Quantifying vessel structure in controlled in vitro context
The work presented in this section demonstrates the use of a segmentation algorithm
previously written for clinical MR images. It has been used to quantify total vessel
number, vessel radii histograms, blood vessel density, number of vessel trees, number
of branches within each tree, and several 3D quantitative measures of vessel tortuosity
(distance metric, sum of angles metric, inflection count metric). To date, this type of
vascular analysis has been challenging on preclinical ultrasound data. This was due to
the difficulty of obtaining images of the microvasculature in 3D, with minimal tissue
background. Our recent implementation of ultra-broadband contrast imaging with a
prototype dual-frequency ultrasound probe (Chapter 3) has enabled the acquisition of
3D maps of rodent microvasculature with high resolution and a high contrast-to-tissue
ratio. The objective of this study was to examine the feasibility of implementing our
segmentation algorithm on this data. We estimate the limit of our imaging system’s
sensitivity to these quantitative metrics of morphology, and demonstrate the repeata-
bility of our segmentation algorithm in this new imaging context.
4.2.1 Methods
Image acquisition
Images were acquired with a prototype dual-frequency transducer and a preclinical
ultrasound system (Chapter 3). Our pulsing sequence was a single-cycle 2 MHz sinusoid
and our receiving transducer had a 30 MHz center frequency with 100% bandwidth. A
10 MHz 7th order high pass filter was placed in-line with all received RF data, thus
eliminating nearly all signal contributions from non-contrast agents. Perfusion contrast
agents used in this study were implemented and had a mean diameter of 0.9±0.45 µm
(Appendix A).
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Vessel phantom creation
Vessel-mimicking flow phantoms were created from 200 µm acoustically transparent
cellulose tubes. Both the tendency of these tubes to crimp upon rapid changes in
orientation, and their small size encouraged alternative means to simulate vessels with
various morphologies in our in vitro setup. A novel method of simulating custom-
shaped vessels in 3D with <10 µm resolution was implemented with a precision motion
stage (Newport model XPS - Irvine, CA). A LabView (National Instruments - Austin,
TX) program was written to control the position of the tube in each 2D ultrasound
imaging frame, and was mastered by the frame trigger of the imaging system. Using
predefined X-Y coordinates, the program would move the tube between imaging frames
to different locations in the 2D image, and thereby effectively re-create a curved flow-
phantom through 3D space. This approach is outlined in Chapter 4.1.
Figure 4.6: 3D maximum intensity projections of ultrasound data acquired of the vari-
ous types of phantoms implemented in this study. The helical phantom is an extension
of the sinusoidal phantom, with both x and y axes varied out of phase with one another.
Multiple vessel morphologies were simulated for this study: sinusoidal curves, straight
lines smoothly perturbed by Gaussians, and meandering curves to which high frequency
noise was added. These types are heretofore abbreviated SP (sinusoidal phantom), GP
(Gaussian phantom) and TP (tortuous phantom) respectively. All phantom types were
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used for the segmentation consistency analysis, and SPs were used for the segmentation
sensitivity analysis. Examples of each type of phantoms can be seen in Figure 4.6.
Vessel segmentations
Our vessel segmentation algorithm, originally developed in 1996 [109] has since been
implemented extensively in human MRI images. [38; 37; 44; 110; 48] The algorithm is
semi-automated, and it is initialized by a user-defined seed point in the center of a vessel.
The user also provides an approximate radius for the vessel at the seed point location.
The algorithm then iteratively tracks the vessel’s centerline along both directions away
from the seed point. The algorithm is guided by eigen values of the Hessian matrix
calculated for the 3D image. The segmentation ends when any one of several criteria
fail to be satisfied, such as vessel termination, encountering a T-junction with another
vessel, or losing a circular cross section.[51]
Figure 4.7: Example centerline segmentations corresponding to the ultrasound data in
Figure 4.6
1) Testing segmentation consistency
Two tests were implemented to estimate the consistency of our image-segmentation
pipeline. The first tested intra-image repeatability (the same image segmented multiple
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times), and the second tested inter-image consistency (the same phantom parameters
imaged multiple times, and each image independently segmented). The three phantom
types were imaged for this portion of the study: a GP with an amplitude of 1 mm and
a FWHM of 2 mm, an SP with a period of 3 mm and an amplitude of 0.2 mm, and a
TP with an average deviation from normal of 310 µm. The 3D curves were generated
in both the axial-elevational and the lateral-elevational planes, and are referred to as
the “axial” and “lateral” phantoms, respectively. For the inter-image repeatability test,
both lateral and axial phantoms were imaged five times and the vessel segmented from
the images. For the intra-image repeatability test, one of the five images was randomly
selected for both axial and lateral phantoms and the vessel within it segmented five
different times with a random seed point location. Consistency was quantified by
comparing both the tortuosity metrics output by the segmentation algorithm, and by
comparing the maximum deviations and standard deviation of each point along the
centerlines of the segmented vessel centerlines. “Deviations” in this case meant as the
distance from the nth point of the segmentation to the mean X-Y-Z values of same nth
point in all other segmentations for that vessel. In other words: if all five segmentations
pass through the same voxel of the 3D image, then the deviation at that location of
the centerlines would be reported as zero.
2) Measuring sensitivity to morphology abnormalities
To estimate our sensitivity to subtle changes in vessel morphology, SPs were generated
with various amplitudes between 0.05 mm and 0.4 mm. The lower end of this range
was approximately the voxel size in our images. The quality of the resulting sinusoidal
outputs were analyzed by comparing the extracted centerlines with the ground truth
coordinates and determining the average displacement between the true centerline and
the extracted centerline.
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Phantom type
SP-Lat SP-Ax GP-Lat GP-Ax TP
Max Dev. 0.042 0.022 0.073 0.023 0.187
Mean Dev. 0.013 0.008 0.033 0.003 0.038
Max Dev. 0.012 0.017 0.015 0.024 0.019
Mean Dev. 0.004 0.004 0.004 0.005 0.005
Table 4.1: Summary of segmentation consistency results. Deviation (‘Dev’) is assessed
the distance from the true location of the vessel centerline. Note: and correspond to
inter-image and intra-image segmentation tests, respectively. Units are in mm.
4.2.2 Results
Vessel segmentations
All types of vessel phantoms were successfully segmented using our algorithm without
the need to implement any post processing filtering strategies. Examples of these
segmentations can be seen in Figure 4.7, which correspond to the analogous ultrasound
data seen in Figure 4.6.
1) Segmentation consistency
The inter-image segmentation and intra-image segmentation repeatability were both
tested. A summary of these values can be found in Table 4.1, wherein deviations are
reported as the displacement from the centerline. With the inter-image segmentation
comparisons, there was a difference between the axial and lateral orientations of the SPs
and GPs tested in this study, with both the mean and max centerline deviations being
larger in the lateral cases for both. Additionally, there was a significant difference
between all phantoms and the TPs. The maximum deviation was 187 µm, which
represents an approximately 4 voxel error, though the mean deviation of 38 µm was
much lower than this, and below the imaging system’s voxel resolution. The inter-image
and intra-image consistencies were within 20 µm and 5 µm when averaged across all
respective phantom types.
The two tortuosity metrics examined in this study, the distance metric and the sum
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of angles metric, had inter-image variability of 0.29% and 4.27% respectively, while
their intra-image variability was 0.09% and 3.68%. Thus, the small intra-voxel devia-
tions had more effect on the sum of angles metric than the distance metric, though both
were within 5% error for all cases tested. The intra-image segmentations demonstrated
a much higher degree of consistency, on average 4 times more consistent across all
phantom types. This was expected, as the only variable introduced in these cases was
the random seed point. It is unclear whether the principle variable introduced in the
inter-image segmentation causing the increased variability relative to the intra-image
segmentations was the 3D phantom generation technique, or the irregular characteris-
tics of the acoustic response from the tube.
Figure 4.8: A plot demonstrating the effect of sinusoidal vessel amplitude on the result-
ing segmentation errors. While the mean segmentation error increases with increasing
sinusoidal amplitude between 0.05 and 0.4 mm, the error when normalized to the fea-
ture size decreases.
2) Measuring sensitivity to morphology abnormalities
To test the sensitivity of our imaging-segmentation pipeline to tortuosity abnormalities,
we generated multiple SPs and modulated the amplitude from 0.05 mm up to 0.4 mm.
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The results of this test are displayed in Figure 4.8. Error was calculated by comparing
the location of the segmentation with the ground truth location of the phantom at 200
discrete locations throughout the segmentation. The displacement between the true
value and the measured segmentation was averaged for all segmentations. While the
absolute deviations between the extracted centerlines and the true coordinates of the
phantom were larger with greater sinusoidal amplitudes (darker curve), the magnitude
of the deviations relative to the sinusoidal amplitudes increases as the sinusoidal am-
plitude approaches the size of the voxels in our images (lighter curve). While we did
not examine curves with amplitudes below the 0.05 mm, we can say that our segmen-
tations are accurate to within a single voxel (50 µm x 50 µm x 50 µm)for all curves
tested between 0.05 mm and 0.4 mm.
4.2.3 Conclusions and proposed future work
Our preliminary in vitro work presented in this manuscript demonstrates the possibility
of implementing a blood vessel segmentation algorithm, originally written for the ex-
traction of tubular objects from clinical MR angiogram images, in our ultra-broadband
3D contrast ultrasound images. We tested three different phantom morphologies at
various spatial orientations and observed a high degree of repeatability in both intra-
image and inter-image segmentations. Each of the consistency analyses was performed
on five unique phantoms and tested five times per phantom. For these tests, the aver-
age deviations from the mean centerline were less than 50 µm, which was the voxel size
of our images. When the sensitivity was tested by comparing the accuracy of segmen-
tations as a function of sinusoidal amplitude, we found that we maintained sub-voxel
resolution for sinusoidal vessels with amplitudes between 0.05 and 0.4 mm.
Future work should focus on a more rigorous segmentation quality analysis. Monte
Carlo simulations should also be performed, in which reported vessel morphology (via
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the two tortuosity metrics) are set as the dependent variables, and noise, vessel struc-
ture, and initialization location randomized to more rigorously study the limits of the
technique’s sensitivity. Because these experiments were conducted in a noise-free water
bath, special attention will be paid during the next stages of the in vitro work to ensur-
ing that our methods will translate effectively in vivo by adding tissue-simulating noise
after the phantom images are acquired. Additionally, the effects of frequency dependent
attenuation (and thus loss of resolution) should be simulated. The eventual goal of our
work is to implement our segmentation algorithm on 3D acoustic angiography images
of diseased vasculature in order to improve sensitivity and accuracy of the ultrasonic
assessment of response to therapy.
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CHAPTER 5
DETECTING AND ASSESSING CANCER WITH ACOUSTIC
ANGIOGRAPHY
For both studies, vascular features were extracted from acoustic angiography images
acquired of in vivo cancerous lesions. The first study uses direct observations of vessel
morphologies to detect the presence of a tumor (Chapter 5.1), and the second uses
more global and indirect assessments of tumor perfusion to assess therapeutic response
to radiation therapy (Chapter 5.2).
5.1 Detecting aberrant vessel morphologies with acoustic angiography
Demonstrated herein is a combination of an algorithm for vessel segmentation, met-
rics for vessel morphologic analysis [52], and a high-spatial-resolution high-contrast
imaging approach, which together form a system for vascular mapping. Similar vessel
segmentation and analysis methods have been previously implemented for tissue dis-
ease and tumor response assessment in magnetic resonance (MR) angiographic data
[111; 48; 110; 44]. The physics of dual-frequency contrast-enhanced imaging, which
enables the acoustic angiographic approach essential to microvessel segmentation, have
Note: This chapter has two sections, one of which draw from previous published material. Previ-
ously published material was reprinted with permission from the publishers.
Chapter 5.1: Ryan C. Gessner, Stephen Aylward, Paul A. Dayton, Mapping Microvasculature
with Acoustic Angiography Yields Quantifiable Differences between Healthy and Tumor-bearing Tissue
Volumes in a Rodent Model, Radiology, 264(3), 733-740, Sept 2012
Chapter 5.2: Unpublished pilot study.
been previously described by Kruse and Ferrara [66], and the design of the prototype
imaging transducer has been previously presented in [102]. The purpose of this analysis
was to test our hypothesis that the morphologies of microvessels could be extracted from
US images and used as a quantitative basis for distinguishing healthy from diseased
tissue volumes in a rat model.
5.1.1 Materials and methods
Animal and contrast agent preparation
All animal protocols used in this prospective study were approved by our institutional
animal care and use committee. Animals used in this prospective study were female
Fischer 344 rats (approximately 250 g, Charles River Laboratories, Durham, NC).
A fibrosarcoma tumor model was established through the implantation of a 1 mm3
sample of tissue in the right flank region of the animals as previously described [54].
Animals were imaged after the tumor had grown larger than 0.5 cm in each of the three
principal axes. The right flanks of control (N = 7) and tumor-bearing (N = 10) animals
were imaged. Prior to imaging, the area around the right flank was shaved with an
electronic clipper. A depilating cream was also applied to remove the remaining hair
in the area. A 24-gauge catheter was placed in the tail vein for the administration of
contrast material.
Lipid-encapsulated microbubble contrast agents were prepared with the perfusion
agent formulation (Appendix A), resulting in a polydisperse size distribution of contrast
agents with a mean diameter of 0.9 µm and concentration of 1.3x1010 bubbles per
milliliter. Prior to intravenous administration, microbubbles were diluted in saline to a
concentration of 3.3x109 bubbles per milliliter. Contrast agent was continuously infused
through a syringe pump (Harvard Apparatus, Holliston, Mass) at a rate of 70 µL/min.
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Image acquisition
All images were acquired, processed, and analyzed by a PhD graduate student (R.C.G.,
with more than 3 years of experience working with high-spatial-resolution preclinical
US images). Volumetric US images were acquired with a prototype probe described in
Chapter 3.1. The difference between pulsing and receiving frequencies of this transducer
enables the suppression of tissue signal, because echoes from tissue contain substantially
less high-frequency harmonic content than those of microbubbles. The pulsing pressure
for all images was 1.23 MPa (mechanical index = 0.62), with a 15-MHz high-pass filter
used on the received lines of data to further suppress tissue signal.
Images were acquired with a frame rate of 3 Hz, with a five-frame averaging step
at each location to suppress spurious signal from contrast agent flowing in vessels
smaller than the spatial resolution of the system. Imaging began less than 1 minute
after the initiation of contrast material infusion, and each three dimensional acoustic
angiographic image required approximately 5 minutes to acquire. All three-dimensional
images were acquired with an inter image elevational step size of 0.2 mm by using the
linear motion stage of the US system. Control tissue volumes in this study were defined
as the three-dimensional images acquired in non-tumorbearing animals, against which
the images acquired in tumor-bearing animals were compared. The tissue imaged in the
control animals was the right flank, which was the same location imaged in the tumor-
bearing population. Both b-mode and acoustic angiographic images were acquired,
enabling retrospective vascular-tissue overlays and the delineation of tumor boundaries.
Oﬄine image analysis
All image data were exported from the US system as uncompressed audio video inter-
leave (AVI) files. The images were upsampled in the elevational direction by using a
custom trilinear interpolation script written in Matlab (MathWorks, Natick, Mass) to
104
yield isotropic voxels with a width, length, and height of 0.05 mm. This interpolation
helped expedite the vessel segmentation algorithm. Microvessels were extracted from
each animal’s image data by using the previously described vessel segmentation algo-
rithm based on multiscale extraction of centerlines [51]. Previously described vessel
morphologic metrics, the DM and SOAM [52], were then applied. Occasionally, a ves-
sel would exhibit an extremely high tortuosity value, several standard deviations away
from the mean for the animal from which it was extracted. These values may have
been true estimates or may have been artifacts from the imaging or analysis method.
To prevent these outliers from grossly skewing the distribution of vessel tortuosities,
we excluded from further analysis any vessel with either a DM or SOAM value greater
than 3 standard deviations from the mean for the animal from which it was extracted.
As a result of this step, between zero and two vessels were removed from each of the
17 animals in the study, with an average of 1.06±0.66 vessels (± standard deviation)
being removed per animal. This corresponds to an average of less than 4% (number of
vessels removed from an animal divided by total vessels originally extracted from that
animal) of the total vessels being removed as outliers from each animal (maximum of
two vessels, minimum of zero vessels). Additional information about the statistics of
vascular morphologies can be found in [112].
Statistical analyses
Four types of variability in vessel tortuosity were assessed: interpopulation, intrapop-
ulation, interanimal, and intraanimal. These types of vessel tortuosity variability are
defined as follows. Interpopulation variability is the differences in vessel tortuosity
occurring between group types (i.e., pooled tumor-bearing animals vs pooled control
animals). Intrapopulation variability is the differences in vessel tortuosities occurring
within a single population (a single tumor-bearing animal vs the pooled tumor-bearing
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population). This is computed by taking the standard deviation of the average tortuos-
ity values for each animal in the population. Interanimal variability is the differences in
vessel tortuosity occurring between a single animal and one or more other animals of a
different animal population (a control animal vs the pooled tumor population). Finally,
intraanimal variability is the range in tortuosity values reported within a single animal
(a large range suggests a more heterogeneous vascular network). The mean intraanimal
variability is the average intraanimal variability across all animals in the population.
The relative intraanimal variability is expressed as a percentage and is computed by
normalizing an animal’s original intraanimal variability (i.e. standard deviation) with
the mean tortuosity value, thereby enabling comparisons between the variability of two
different tortuosity metrics.
The statistical significance of the differences between the ensembles of microvessel
segmentations of the two animal populations was assessed by using a two-tailed Student
t test. Ensembles are defined as a collection of DM or SOAM values; they can consist
of these tortuosity metrics computed on either the vessels extracted from a single an-
imal or the pool of all vessels from the animals in a population. When animals were
compared with their own group, equal variances were assumed for the t test; although
when animals were compared with the opposite group, unequal variances were assumed.
Three statistical comparisons were made between individual animals and their respec-
tive populations, as well as between the two animal populations themselves. The first
comparison was used to test interpopulation variability in vessel tortuosity. All vessel
segmentations were pooled into two groups, and the reported tortuosity metrics were
compared to assess gross differences between the healthy and tumor-bearing popula-
tions. For this first comparison, a total of two tests were performed: the DM and
SOAM ensembles from the tumor-bearing group versus the control group. The second
comparison was implemented to test interanimal variability in vessel tortuosity. The
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ensemble of tortuosity values reported for the vessels extracted from each tumor-bearing
animal was compared against the pooled control population to allow us to retrospec-
tively simulate a “diagnosis” of these animals (i.e., an individual patient’s image data
compared with a healthy control population’s data set). Similarly, the ensemble of
tortuosity values reported for the vessels extracted from each control animal was also
compared against the vessels of the pooled tumor population. For this second com-
parison, a total of 34 tests were performed: the DM and SOAM ensembles for each
of the 17 animals compared against the opposite animal group’s pool. Finally, a third
statistical test was used to assess intrapopulation variability in vessel tortuosity. The
ensemble of tortuosity values reported for the vessels extracted from each animal in
the study was compared with the pooled aggregate of their respective population (with
their own data removed from the pool) to assess the consistency of the tortuosity of
vessels found within each of our two populations. For this third comparison, a total
of 34 tests were performed: the DM and SOAM ensembles for each of the 17 animals
compared against their own animal group’s pool. All three of these statistical tests
were performed by using Matlab. For the first assessment, which tested the differences
in vessel tortuosity between the vessels extracted from the two populations, statistical
significance difference was set at p less than 0.05. In the second and third statistical
assessments in which multiple comparisons were made, a Bonferroni correction was im-
plemented and statistical significance difference was set at p less than 0.00147 (original
significance level 0.05 divided by the 34 tests).
Estimating diagnostic utility of vessel maps
In addition to testing the statistical significance of the differences in vessel ensembles
(sick vs. healthy), an additional statistical test was conducted to evaluate how many
vessels needed to be extracted in order to achieve the an accurate estimation of disease
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state. This was performed by taking the complete vessel ensembles for all tumor-bearing
animals and sampling between 4 and 30 vessels from each animal. These smaller pools
extracted from the total ensembles were called ‘sub-samples,’ since they were a subset
of the original. The process itself was called ‘retrospective subsampling’ because it
was extracting these smaller pools from previously existing ensembles. The subsamples
were compared on an animal-by-animal basis with the pooled control population’s vessel
ensemble for both the DM and SOAM metrics. This process was repeated 1000 times
at each sub-sample size (between 4 and 30) and the resulting p values for the statistical
tests pooled. The rationale behind this experiment was to determine N, the number of
vessels required, which would result in the average p value for this iterative retrospective
test to fall below the 0.05 level. The statistical test performed was a two-tailed Students
t-test assuming unequal variance. All tests were performed in Matlab.
Receiver operator characteristic (ROC) curves were determined by using the pooled
ensembles for the two animal groups (tumor-bearing vs. healthy) and were parameter-
ized by the cutoff in tortuosity value which delineates the two populations. This value
was modulated between the minimum and maximum tortuosity values reported in the
study. The area under the curve was determined for both and used as a surrogate for
diagnostic classification utility.
5.1.2 Results
A total of 438 microvessels were extracted and analyzed from the acoustic angiography
image data (Figure 5.1). The average number of vessels extracted from the image data
of control flanks was 51.51% lower (15.86±2.41 vessels; range, 13-19 vessels) than that
of the tumor models (32.7±9.08 vessels; range, 20-50 vessels). The average size of the
10 tumors imaged in this study was 11.4±3.6 mm (range, 5.8-16.8 mm) for the longest
axis, corresponding to a volume of 0.452 cm3±0.331 (range, 0.070-1.076 cm3). Examples
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of segmented centerlines taken from acoustic angiographic image data can be seen in
Figure 5.2. The average DM for the tumor population was 23.76% higher (1.34±0.40)
than that for the control population (1.08±0.08) (p<0.0001) (Figure 5.3). The average
SOAM was 50.73% higher in the tumor population relative to the control population
(22.53±7.82 compared with 14.95±4.83) (p<0.0001). The intraanimal variation for the
DM was 0.07 and 0.33 (control vs tumor), which corresponds to a relative deviation of
6.60% and 24.90%, respectively. For the SOAM, the average intraanimal variation was
4.82 and 7.79 (control vs tumor), which corresponds to a relative deviation of 32.10%
and 34.53%, respectively (Table 5.1).
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Figure 5.2: Six extracted vessels show how different morphologic features influence the
quantitative tortuosity metrics. A slowly meandering vessel will have a higher DM, and
a vessel with high-frequency oscillations will have a higher SOAM.
The difference between the pooled DM ensemble for the tumor-bearing popula-
tion (1.34±0.40) and the control population (1.08±0.08) was significant (p<0.0001)
(Figure 5.3). Similarly, the difference between the pooled SOAM ensemble for the
tumor-bearing population (22.53±7.82) and the control population (14.95±4.83) was
significant (p<0.0001).
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The ensemble of tortuosity values computed from the vessels extracted from each
tumor-bearing animal was compared against the pooled control population. The p
value range for the 20 tests was 2.42x10−12 to 5.63x10−3. Of the 20 tumor animal
versus control group comparisons made, 18 had p values less than the Bonferroni-
corrected p value of 0.00147. Similarly, the ensemble of tortuosity values computed
from the vessels extracted from each control animal was compared against the pooled
tumor-bearing population. The p value range for the 14 control animal versus tumor
group tests was 1.11x10−16 to 2.09x10−3. Of the 14 tests, 13 had p values less than the
Bonferroni-corrected p value of 0.00147. A summary of the p values for these tests is
listed in Table 5.2.
Finally, tortuosity ensembles for each of the animals were compared against the
pooled vessel ensemble for their respective group to assess intragroup heterogeneity.
Thirty-four comparisons were made: one for each of the two tortuosity metrics in all
17 animals in the study. (These tests can be visualized by comparing the distributions
in Figure 5.3, A and C, with the animal’s own population pool in Figure 5.3, B and
D.) While some of these comparisons resulted in p values less than 0.05, none had p
values less than the Bonferroni-corrected p value of 0.00147. This suggests that while
marked differences between control and tumor-bearing animal groups were apparent
(as per the first and second statistical assessments), the groups were fairly consistent
relative to themselves. Despite their lack of significance below the Bonferroni-corrected
p value, there were two animals in the tumor animal versus tumor group comparisons
with p values less than 0.05 compared with only one animal in the control animal
versus control population comparisons with p values less than 0.05 (Table 5.2). This
trend could suggest that the degree of intragroup vessel morphologic heterogeneity was
slightly greater in the tissue volumes containing a highly angiogenic tumor.
An exponential model was fit to the means of the p value distributions at each
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Figure 5.3: Box plots show the ensembles of the reported DM and SOAM values for the
vessels extracted from the right flanks of the two different animal populations: healthy
(Controls) and tumor-bearing (Tumors) animals. A, C, The ensemble of each animal
in the study. B, D, The pooled ensemble for the control and tumor-bearing groups.
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Figure 5.4: Box plots showing the p values determined by both DM (A) and SOAM
(B) retrospective subsampling experiments. The 0.05 significance cutoff is shown in
dotted red lines for both.
subsample size to determine the intersection with the 0.05 cutoff. The intersections
were similar, with the DM and SOAM models intersecting the 0.05 cutoff at 9.45 and
9.17 vessels, respectively.
The results of the ROC analysis for the two pooled ensembles of vessels extracted
from the tumor-bearing and healthy imaging subjects are presented in (Figure 5.5).
Figure 5.5: ROC curves determined from the pooled control and tumor-bearing vessel
ensembles.
The area under the curve (AUC) for these two ROC curves were 0.84 and 0.80 for
the DM and SOAM, respectively.
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5.1.3 Discussion
In this study, we presented a high-spatial- resolution minimally invasive imaging ap-
proach and a quantitative analysis of microvessel structure extracted from these three-
dimensional acoustic angiographic images. All tumor-bearing animals had significant
increases in both of the reported tortuosity metrics (DM and SOAM) compared with
those of the vessels in the control population. The results from this study indicated we
can use microvessel centerlines extracted from high-spatial-resolution acoustic angio-
graphic images to provide a quantitative basis for distinguishing healthy from diseased
tissue volumes. The fact that animals within both control and tumor-bearing popu-
lations had significant differences from the aggregate pool of their respective groups
suggests that heterogeneity is present within the microvasculature of these rodents, al-
though our results also demonstrated there is a greater degree of vascular heterogeneity
in the presence of cancer.
There were several limitations of this study. First, the prototype acoustic angio-
graphic transducer enables excellent visualization of microvasculature but only within a
narrow depth of field (1 cm) centered around the acoustic focus (located approximately
1.3 cm into tissue). This means that vasculature beneath tumors is rarely captured on
our images unless the tumors are very small, nor are entire tumors visualized if their
diameters in the axial direction exceed 1 cm. Further developments in transducer and
US system technology would need to be achieved before acoustic angiography could
be implemented clinically with widespread utility. Performance of this technique is
currently in a similar realm of resolution and penetration depth as offered by photoa-
coustic imaging [113]. While photoacoustic imaging does not necessitate a contrast
agent to interrogate the microvasculature - an advantage over our acoustic angiography
approach - to our knowledge, there are not yet systems demonstrated in the literature
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with simultaneous resolution and depth of penetration as utilized here. Typically, pho-
toacoustic systems can achieve either similar spatial resolution at shallower depth of
penetration [107] or similar depth of penetration at a lower resolution [114]. Moreover,
these systems do not possess the portability offered by acoustic angiography, and they
necessitate computationally intensive reconstruction algorithms to achieve volumetric
imaging.
Another limitation of the study was tumor size heterogeneity. While the tumors
imaged in this study were all at least 0.5 cm in diameter, they were not all the same
size and thus not at the same point in the progression of the tumor model. Because
tumor volume was not standardized across the tumor-bearing animal population, the
degree to which the heterogeneity between subjects (tumor volumes, percentage of
necrosis, growth rates, etc) affected the interanimal deviations in the reported DM and
SOAM values is unknown. In addition, the relationship between tissue perfusion speed
and vessel tortuosity remains to be studied with our acoustic angiographic imaging
technique; however, this is of substantial interest because a previous human MR study
demonstrated that these two techniques (vessel morphologic analysis and perfusion
analysis) provide independently useful diagnostic information in the assessment of brain
tumors [44]. Finally, the syngeneic tumor grafts utilized here likely will have different
microvascular development characteristics than spontaneous tumors. Hence, although
we have demonstrated the utility of the imaging and analysis techniques described
here, the trends between tumor-bearing and healthy tissue may translate differently to
human conditions.
Future studies using this quantitative morphologic analysis of vessel structure will
test the relationship between vessel tortuosity and other ultrasonic methods for as-
sessing disease state in genetically engineered animal models to compare their relative
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sensitivities and uniqueness of diagnostic information. In addition, the temporal sensi-
tivity of the technique will also be evaluated, because vascular tortuosity abnormalities
have been observed when fewer than 100 cancer cells are present [35]; thus, techniques
capable of resolving microvasculature are exciting candidate strategies for early cancer
detection and rapid assessments of response to therapy. Practical applications: An
ideal bedside clinical imaging modality is one which can sensitively, accurately, safely,
and inexpensively predict therapeutic response, particularly in an era when medicine
is becoming increasingly personalized. Thus, the capability of advanced US imaging
and analysis techniques may have a substantial role in the future of cancer diagnostics
and assessment. We predict that the technique for detecting the presence of cancer
demonstrated in this article, with further development, could be used for rapid bedside
disease assessment in several clinical settings.
5.2 Assessing tumor therapeutic response with acoustic angiography
Over 20 years ago, the effects of single high doses of radiation on tumor vasculature
were reported in a very elegant study on human melanoma cells in mice.[115] These
effects were studied via the gold standard of histological analysis. Vascular effects were
observed by perfusing the vasculature with a radio-opaque medium, and then taking
x-ray images from subsequent histological tumor sections through the volume. This
provided a time-intensive but effective method of quantifying various features of tumor
vessel architecture, including vessel length, diameter, surface area, and volume per
unit tumor volume. These studies demonstrated several interesting findings. First:
a single dose of between 5 and 25 Gy could severely damage a large proportion of
vasculature within the irradiated tumors, and this decrease in the number of functional
vessels appeared between 3 and 10 days after irradiation. They observed a relationship
between dose and size of vessel affected; about 35-45% of the original vessels with
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diameters in the range 5-15 µm were nonfunctional 1 week after doses of 10 to 15
Gy, while vessels with larger diameters required higher doses to be affected in the same
amount of time. In their study they found that doses of 16, 21, and 20 Gy were required
to knock out greater than 50% of vessels in the following respective diameter ranges:
5-15, 15-25, and 25-35 µm. Finally: at their highest doses, they found that despite the
considerable loss of tumor vessels following irradiation, tumors exposed to 20-25 Gy
eventually became hypervascularized, and those tumors which eventually regrew could
even be more vascularized than control (non-irradiated) tumors.
Many research groups have been attempting to leverage the fundamental advan-
tages of ultrasound (cost, noninvasive nature, portability, realtime imaging) in cancer
treatment followup studies, whether treated by radiation or otherwise. Table 5.3 lists
several preclinical studies within the last 10 years which have implemented ultrasound
vascular imaging approaches in preclinical studies assessing response to radiation ther-
apy (either alone, or in conjunction with other anti-cancer agents). While clinically,
radiation therapy is rarely used as a stand-alone treatment regimine for tumors, the
subsequent effects of radiation on tumor vasculature can be visualized with several dif-
ferent ultrasound imaging approaches, and there is a wide array of existing literature,
including the gold standard of histology mentioned previously [115], to which we could
compare our own acoustic angiography imaging results. To this end, we designed an
imaging study in which we could evaluate the efficacy of acoustic angiography at as-
sessing the functional status of tumors during their response to radiotherapy. Tumors
were irradiated by varying levels of radiation (0, 5, and 20 Gy), and were subsequently
imaged over the following weeks. Naturally, because acoustic angiography is not yet
widely available, there exist no studies in the literature demonstrating its utility in
assessing tumor response to therapy.
Most of the preclinical studies performed to date implement power Doppler as their
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Treatment type
Year Animal Model Tumor type Radiation alone Combination Ref
2002 Rat Breast x [116]
2003 Mouse Lung/Brain x [117]
2003 Rat Breast x [118]
2003 Rat Breast x [119]
2005 Mouse Lung x [120]
2006 Mouse Lung x [121]
2007 Mouse Lung x [122]
2008 Mouse Prostate x [123]
2010 Mouse Lung x [124]
Table 5.3: Recent studies implementing ultrasound vascular imaging approaches to
assess various preclinical tumor models’ responses to radiotherapy
method of spatially mapping blood flow. Power Doppler, if used with microbubble con-
trast, is much more sensitive to slowly flowing blood flow (i.e. the microvasculature in
tumors) than the other widely implemented Doppler imaging approach, color Doppler.
The principle drawbacks of power Doppler are (1) like acoustic angiography, it provides
only a measure of the extent of blood flow (not a map of perfusion speeds), and (2)
unlike acoustic angiography, it is highly susceptible to respiratory motion artifacts. It
was our goal to evaluate tumor response to radiation therapy with acoustic angiogra-
phy, and compare the observed results against previously reported values obtained by
power Doppler.
5.2.1 Methods
5.2.2 Tumor model
All animal studies were conducted in accordance with approved protocols granted by
our institution’s IACUC. Fibrosarcoma tumor tissue samples, propagated from existing
tissue as previously described [101], were implanted in the lower flank area of 15 female
rats (126.8±7.4 g) (Charles River Laboratories - Durham, NC). The volume of the
tumor tissue was approximately 1-2 mm3 at the time of implant. After 14 days, the
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wound at the surgical site had healed and the tumors could be imaged with high
frequency b-mode to evaluate tumor size. The animals were then randomized into the
3 treatment groups: 0 Gy, 5 Gy, and 20 Gy. In an effort to limit the effect of tumor
size at time of therapy on resulting treatment efficacy, the distributions in tumor sizes
between the 3 groups were tested for statistical significance (2 tailed Student’s t-test
assuming equal variance). If any of the three groups were significantly different (p<0.05)
than another group, the groups were randomized again and re-tested for significance.
Tumor irradiation
14 days after tissue implantation, the animals were imaged, sorted into their groups,
and taken to the UNC Cancer Hospital for treatment. To avoid the possibility of
patient exposure to the animals, the irradiations were performed after normal hospital
operating hours as per the IACUC protocol. A clinical broad beam system was used
(Siemens PRIMUS linear accelerator) for all treatments. Animals were treated one by
one; prior to each treatment, animals were anesthetized in an induction chamber with
5%isoflourane-95% oxygen gas. They were then transferred to the computer controlled
patient stage beneath the treatment gantry, where anesthesia was maintained via mask
delivery at 2% isoflourane. (Figure 5.6A)
Each animal was palpated to identify the tumor location, and the center of the
tumor was indicated on the skin’s surface using a permanent marker. The animal was
then positioned appropriately such that the beam was centered at the tumor’s center.
A targeting light beam, coincident with the treatment beam, was used to position the
animal (Figure 5.6B). A beam size of 1.8x1.8 cm was used to ensure adequate coverage
of radiation dose, as this was larger than any tumor’s diameter at the time of treatment
(the largest tumor was 1.2 cm in diameter). A depth of 1.4 cm was used for treatment
targeting, and a 1 cm bolus was used to ensure maximum dose was delivered to the
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Figure 5.6: Labeled images of (A) the clinical irradiation system setup, (B) a top-down
view of an animal immediately prior to an irradiation procedure.
center of the tumor (0.4 cm into tissue) in the depth dimension. The doses delivered
to each animal were either 0 Gy (monitor unit = 0, control animals), 5 Gy (monitor
unit = 559) or 20 Gy (monitor unit = 2234) with 6 MV x-rays.
It is well known that radiation has an adverse affect when interacting with the
tissues within the gut. A previous study showed irradiating the exteriorized intestine
of rats at 15.5 Gy (i.e. radiation damage limited to gut alone) the mean survival time
was only 7.1 days. [125] Thus, because the tumors used in this study were placed on
the lower flank above the lower abdomen, it was our goal to understand the extent of
non-tumor tissues which could have been affected by the irradiation. We designed an
experiment to estimate which non-tumor tissues had interacted with the radiation beam
in which a synthetic beam was created and overlaid on a 3D micro CT image of a rodent
(data acquired from an open access institute). The open source image visualization
and analysis platform 3D Slicer (www.slicer.org) was used to manipulate the location
of the beam, and visualize the two datasets (beam and animal) concurrently. The
dataset was not for a rat, as was used in our studies, but because mice and rats have
“Digimouse Download” at http://neuroimage.usc.edu/neuro/
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proportionally similar anatomical structures it was assumed to be sufficiently accurate
for our purposes. The beam was a logical mask (assumed to be a step function in
radiation intensity), square in cross section, and extended through the entire height
of the image. To account for the slight variation in tumor locations within the lower
flank, the beam was made 50% larger than was experimentally applied (1.8 x 1.8 cm
in cross section) to account for inter-animal variability in dose.
Imaging studies
Each imaging study consisted of the acquisition of two types of images: b-mode for the
localization of tumor tissue relative to surrounding tissue types, and acoustic angiog-
raphy for the assessment of vascularization within the tumors. Animals were imaged
immediately prior to irradiation (Day 0) and then at Days 3, 6, 9, 12, and 18. A picto-
rial representation of this timeline is provided (Figure 5.7). Tumors were imaged until
they grew larger than 1.5 cm in the largest axis, or if they were predicted to surpass
this size by the following imaging study.
Figure 5.7: A timeline illustrating the tumor implantation, imaging, treatment sched-
ule. Relative distances between events are to scale.
Microbubble contrast dose and infusion, and ultrasound imaging parameters were
the same as previously described [101]. Animals were weighed after each imaging
study to monitor their health after radiation treatment. If any animals lost more than
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5% of their weight (relative to Day 0) flavored high protein dietary supplements were
provided to all animals in that treatment group, and daily subcutaneous injections of
sterile saline administered in 3 mL boluses to all animals in the treatment group. These
infusions and dietary supplements were provided to counteract the weight loss due to
treatment-induced nausea.
Image analysis
Three metrics were examined at each imaging timepoint for this study: animal weight,
tumor volume, and tumor perfusion ratio. The latter two were computed by first
defining a 3D region of interest (ROI) to the location of the tumor. This is normally
accomplished with frame-by-frame manually defined ROIs which then assemble into a
3D binary logical mask (1’s inside the tumor boundaries, 0’s outside) of the same size
as the original 3D image data. This can be a time consuming process, however, as a
1 cm tumor imaged with an inter-frame spacing of 150 µm has over 60 images which
require ROIs. With 15 animals and many timepoints per animal, it was estimated that
ROI definition alone would have necessitated over 13 hours (assuming 10 seconds per
ROI, and a range of tumor sizes between 0.5 and 2 cm in diameter). Instead, a more
efficient method was explored in this study, which exploited the elliptical shape of the
FSA tumor being imaged and would not tax the limits of human patience to the same
degree. A custom Matlab function was written which required the user to manually
define ROIs in 3 orthogonal planes through the center of the tumor (Figure 5.8). These
user-defined ROI perimeters represented a 3D cloud of points surrounding the tumor, to
which a volumetric ellipsoid could be fit. Preliminary studies revealed that the accuracy
of these semi-automated elliptical ROIs was comparable to the aforementioned frame-
by-frame ROIs (data not shown), and could be fully defined for each tumor in, at most,
40 seconds.
125
Figure 5.8: An illustration of how the regions of interest were defined in this study.
The left column (A,C,E) is identical to the middle column (B,D,F) notwithstanding
the overlaid user-defined boundaries of the tumor. G shows a rendering of the 3D
ellipsoid fit to the data defined by the curves shown in (B,D,F). The color of the frame
boundaries corresponds to the three orthogonal curves in (G). H: a cartoon schematic
illustrating the orientation of the 3 planes relative to physical space.
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Using these 3D ROIs, both tumor volume and perfusion ratio metrics could be
computed. The tumor volume was computed as the sum of all voxels in the ROI
multiplied by the voxel size (0.05 x 0.05 x 0.15 mm). This yielded a measure for volume
in units of mm3, or equivalently: µL. The second metric, the volumetric perfusion ratio,
was a unitless estimate between 0 and 1 of the proportion of the tumor’s volume which
was occupied by perfusing vessels. This was computed by determining the volume of
voxels within the 3D ROI which were above the noise floor, and dividing by the total
volume of the ROI. The noise floor was estimated by randomly sampling several images,
and determining the value of intensity of the image within non-perfused tissues. This
is a similar metric as the “power Doppler index,” as was used by many of the studies
listed in Table 5.3.
5.2.3 Results and discussion
After randomization prior to treatment (Day 0), the tumor size distribution for the
three treatment groups was as follows: 196.3±69.2 mm3 (0 Gy), 261.3±281.7 mm3
(5 Gy), and 175.4±87.4 mm3 (20 Gy) (Figure 5.9) These volumetric estimations of
volume correspond to average tumor diameters of (7.18±0.86 mm), (7.28±2.54 mm),
and (6.77±1.34 mm) for the same groups respectively.
Figure 5.9: The means and standard deviations of the tumor volumes in each of the
treatment groups prior to therapy. The 20 Gy treatment group is split into two subsets
(R: ‘responder’, NR: ‘non-responder’).
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The untreated tumors all surpassed the maximum allowable size by Day 6, and all
but 1 animal in the 5 Gy group was culled by day 9.(Figure 5.10) None of these animals
were significantly affected by the irradiation at 5 Gy. The animals irradiated by 20 Gy
were all below the critical size threshold until Day 18. It should be noted that although
three of the 20 Gy animals were sacrificed at the Day 18 timepoint, it was not because
the tumors had necessarily grown to a large size at this time. Rather, these 3 animals
(hereafter referred to as the “20 Gy non-responders”) experienced an inflection point
in their growth curves at this timepoint. As a result of scheduling logistics, it was
not possible to image any animals between the Day 18 and Day 28 timepoints, and
thus it was prudent to sacrifice them, thereby not allowing their then-growing tumors
to exceed the allowed size during that 10 day period. At Day 28, the two animals
remaining in the study (hereafter referred to as the “20 Gy responders”) did not have
tumors detectable by high frequency b-mode or manual palpation.
Figure 5.10: A survival curve illustrating the number of animals remaining at each
timepoint within the three different treatment groups. The two animals remaining at
Day 28 were the responders.
Radiation induced weight loss
By Day 5 it was evident that animals in the 20 Gy group were losing more weight than
their counterparts in the 0 and 5 Gy groups. The average percent change in weight on
Day 5 was -5.89±3.75% in the 20 Gy group compared to -1.22±1.30% and -1.39±1.49
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in the 0 and 5 Gy groups, respectively (p = 0.06 and p = 0.05 respectively). Thus,
because they had dropped below 95% of their original body weight, the animals in this
group were given daily saline injections and protein rich food supplements for two weeks.
Interestingly, there was a correlation between therapeutic outcome of irradiation and
degree of weight loss. The two animals whose tumors were effectively treated by the 20
Gy had lost less weight by Day 5 (mean normalized body weights were 0.93 compared
to 0.95 for the 5 vs. 20 Gy groups, respectively) and stopped losing weight three days
sooner (Day 6 vs. Day 9 for the responders vs. non-responders, respectively). (Figure
5.11). The non-responder subset eventually started regaining their body weights on
Day 9, and by Day 18, their mean weight was less than 1% different from their Day 0
body weight.
Figure 5.11: The animals weights for the different groups, normalized to each animal’s
Day 0 weight.
The irradiation simulation experiment in Slicer revealed a potential mechanism for
the weight loss observed in the 20 Gy group. Because the irradiations took place
without image guidance, it is impossible to know the true location of the beam for all
animals in the study, but based on the simulation data (Figure 5.12) it is likely that
the beam irradiated the bladder, small bowel, and lower bowel in all animals, though it
is unlikely that the kidneys were affected. Depending on the location of the tumors in
the anatomical axial axis (“A-Ax” in Figure 5.12A) the proportions of both small and
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lower bowel which were irradiated could have been modulated. This can be visualized
in (Figure 5.12C). Based on the doses used in this study and the the delivery location,
it is likely that the 20 Gy group’s post-treatment weight loss was due to radiation-
induced intestinal dysfunction (radiation enteritis). [126] This could be avoided in the
future by positioning the tumor above the quadricepts muscle on the thigh at the time
of implantation, as opposed to the flank area, as this would move the beam distally
along the anatomical axial axis, and nearly eliminate the its overlap with both large
and small bowels.
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Assessing response to therapy (tumor volumes)
Irrespective of the treatment group, all tumors in the study continued to grow after
treatment day, though there was a correlation between the irradiation dose and the
degree to which tumors continued to grow after treatment. Tumors grew 2.63, 1.60,
and 0.63 fold during the 3 days following irradiation for the 0 Gy, 5 Gy, and 20 Gy
groups, respectively. There was not a significant difference between any of the 3 groups
on Day 3 when comparing the distribution of tumor volumes, but when examining the
distribution of tumor growth normalized to their Day 0 volumes, the 20 Gy group was
significantly different than both the 0 Gy group (p = 0.004) and the 5 Gy group (p
= 0.002). This difference in significance between the normalized and non-normalized
data can be attributed to the heterogeneous size distributions of tumors at the Day 0
timepoint (Figure 5.9). The tumor volumes of the 20 Gy group remained well below
those of the 5 Gy group for all subsequent timepoints. (Figure 5.13)
Figure 5.13: Plots showing the raw and normalized volumes of the tumor tissue vs. time
(mean ± standard deviation). Data are averaged over the group at each timepoint.
The tumor growth curve data for the 20 Gy group is difficult to visualize when
plotted on the same scale as the rapidly growing 0 and 5 Gy treatment groups, thus
they are plotted separately in (Figure 5.14).
On Day 18, the average responder subset normalized tumor volume was 0.032±0.006
(black) compared to tumor volumes of 0.885±0.559 in the non-responder subset (gray)
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Figure 5.14: Plots showing the normalized volumes of tumor tissue vs. time for indi-
vidual animals within the 20 Gy treatment group. The non-responders and responders
are colored differently.
(Figure 5.14). After Day 18 there were no measureable tumors in the responder subset
of the 20 Gy treatment group.
Assessing response to therapy (tumor perfusion)
Immediately following radiation therapy, there did not appear to be any dramatic
differences between the treatment groups when examining the interior perfusion of
the tumors. This can be evaluated qualitatively (Figure 5.15) or via the quantitative
analysis presented in (Figure 5.16). All groups experienced between a 1.20 and 3.02 fold
increase in the volumetric perfusion ratio between days 0 and 3. While the responder
subset had a 47.6% smaller perfusion ratio at the Day 3 timepoint than the non-
responder subset (0.24±0.11 vs. 0.46±0.14), this is unlikely evidence of this metric
providing an early indication of eventual therapeutic response; on Day 6 and Day 9 that
the two subsets of the 20 Gy group essentially have identical perfusion ratios (percent
difference between them: 8.06%, and 8.75%; average percent standard deviation at
these timepoints >15%), and thus the difference between them on Day 3 is likely just
a coincidence.
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Figure 5.15: Representative samples of the image data analyzed in this study. These are
maximum intensity projections through the elevational imaging axis (out of plane step
direction of the transducer). Prior to the projections, the 3D image volume was first
masked by the animal’s 3D binary ROI at that timepoint. Thus, any vessel visualized
in this image is contained within the boundaries of the tumor margins.
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On Day 9, however, there is an inflection point in the perfusion ratio between
the responder and non-responder subsets of the 20 Gy treatment group. After this
timepoint, the responder subset’s perfusion ratio falls linearly to zero, while the non-
responder subset steadily increases back to over 50%. This is an interesting result,
since there was a 0.7 fold difference between the volumes of these two subsets while
the magnitude of the difference between the perfusion ratios was 1.1 fold. The total
number of animals within the responder and non-responder subsets was small (N = 2
and N = 3, respectively) so statistical comparisons between them do not carry much
weight, but a trend is clearly evident in this metric, providing motivation for additional
studies in the future to investigate the reliability of this quantity at predicting tumor
response.
Figure 5.16: Plots showing the perfused volume ratio vs. time for the different groups
(mean ± standard deviation).
These results are remarkably similar to a previous study [119] most similar to our
own, in which, following radiotherapy, power Doppler is implemented to estimate the
ratio of perfusion within a single 2D slice through the treated tumors. As in this
study, their tumor models were also located in the abdomen area, though were NMU
induced breast tumors and thus were not the same model implemented in our study.
This difference notwithstanding, they observed the same diverging treatment response
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curves for animals treated by a high dose of radiation (18 Gy) after an initial decrease
in tumor size. They also observed this difference in treatment response correlated
with their index for blood perfusion. Their metric for blood perfusion could predict
eventual tumor response at day 12 predicted eventual response. This is the same
timepoint at which the perfused volume ratio also demonstrated a marked difference
between the populations. Because we did not acquire power Doppler measurements
in our own study, and because the sample sizes in the responder and non-responder
subsets were so small, it is impossible to know which imaging method and corresponding
metric for perfusion is more sensitive. This result does, however, provide motivation
for additional studies to investigate the relationship and relative sensitivities between
these modalities, especially since the VisualSonics system used for acoustic angiography
has the capability to acquire power Doppler measurements.
A note for future studies
After the two subsets in the 20 Gy group diverged in their treatment responses on
Day 9, it became difficult to estimate the statistical significance of the trend. Because
repeating the study with additional animals was beyond the scope of this initial pilot
study, additional studies will likely be performed in order to evaluate the diagnostic
utitily of acoustic angiography when used in this post-treatment tumor evaluation con-
text. A standard power analysis using a 2-sided z -test with 0.05 significance level was
performed and should be referenced in this case (Figure 5.17). It was based on the
the means and standard deviations for the perfused volume ratio metric at the Day 12
timepoint (the first timepoint when the groups were qualitatively, if not measureably,
distinct. The results of the power analysis indicate that at least 8 animals will be
required in each group (non-responders and responders) to achieve 95% confidence at
the α = 0.05 level.
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Figure 5.17: An analysis to estimate the number of animals required in each group to
achieve the desired statistical power for deliniating responders from non-responders at
the Day 12 timepoint.
Limitations of the perfused volume ratio metric
There was a counterintuitive inflection point in perfusion volume ratio for the 5 Gy
group after the Day 6 timepoint (Figure 5.16). As evidenced by their growth curves
in Figure 5.13, these tumors are not undergoing any decrease or loss of malignancy.
Rather, this is an unfortunate and unavoidable effect inherent to the computation of the
perfused volume ratio metric when using our imaging equipment to image large tumors.
The perfusion ratio relies on summing the number of pixels above the noise floor within
the tumor boundary to quantify blood flow. This metric thus relies of signal intensities
being stable throughout the imaging field in order to consistently and reliably account
for the presence of blood vessels. Because the only transducer capable of imaging in
acoustic angiography mode is a fixed-focus piston transducer, the sensitivity to vessels
is non-uniform throughout the depth of field(Figure 4.5). This is not problematic
for imaging vessels close to the acoustic focus in the axial dimension, but can result
in underestimating perfusion in large tumors whose margins extend beyond the axial
depth of field. In other words, our imaging approach will make a large tumor appear
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as though it is not perfused with contrast in both the proximal and distal axial faces,
whether or not there are blood vessels present at these locations. The reader is referred
to the MIP of the Day 9 timepoint for the 5 Gy tumor in Figure 5.15 to illustrate this
effect.
This is an inherent drawback for imaging large tumors with fixed focus piston trans-
ducers - a limitation which extends to power Doppler imaging on these preclinical
systems as well - though a dynamically focused array transducer would be able to
compensate for this effect by creating a more uniform sensitivity profile in the axial
dimension. This notwithstanding, however, future users of the perfused volume metric
extracted from any ultrasound image, 3D or otherwise, must take care to ensure con-
sistent time-gain-compensation curves; users need to ensure consistent amplification of
noise and signal levels originating from different regions in tissue, or across multiple
timepoints, for this type of metric to have diagnostic meaning and value.
5.2.4 Concluding remarks
This study represents the first use of acoustic angiography to assess the inter-tumoral
blood perfusion of post-irradiated tumors. The results demonstrated that the ratio of
perfused volume to total tumor volume was correlated with tumor growth, and in fact
was sooner to change within a subset of animals who were treated effectively by a 20
Gy radiation dose and those who were not treated effectively by this dose (i.e. their
tumors reimmerged after shrinking). While it was beyond the scope of this study to
elucidate the underlying biological mechanisms for why a subset treated at 20 Gy did
not respond to the dose, it was likely a result of either their larger tumor sizes at the
time of irradiation (statistically speaking, a greater number of radio-insensitive cells
are present in a larger tumor), or the amount of healthy intestinal tissue which was
irradiated (evidenced by subsequent weight loss in the non-responsive tumor bearing
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animals) causing a heightened immune response within the gut.
Currently, the effects of radiation on tumor microvasculature is of interest to many.
This imaging approach could provide a method to assess longitudinal perfusion in a
high resolution way, though provided tumors fall within the size regime amenable to the
current imaging probe’s axial depth of field (tumor sizes from 1 mm to 1 cm), or until
array technology is developed. The imaging studies prerformed herein were limited to
structural information - tissue morphology from b-mode, vessel network architecture
from acoustic angiography - though it is possible that additional functional information
gleaned from other ultrasound imaging modes would improve diagnostic assessments
of tumors responding to therapy; blood flow rates can be parametrically mapped via
flash replenishment, and molecular signatures for disease can be detected via targeted
contrast agents. While flow is likely related to vessel architecture, in the past it has
been demonstrated that they provide independently useful information.
Previous acoustic angiography studies have used vessel morphological metrics to
detect the presence of cancer. These differences between tissue types (healthy vs.
malignant-tumor bearing) were immediately clear when looking at projections of the
acoustic angiography data. While in this study, tumor vessel density was markedly dif-
ferent between the responder subset and the other groups, from a qualitative perspec-
tive, there did not appear to be the same morphological differences in vessel structure
between any of the groups (0, 5, or 20 Gy). There have been several human mag-
netic resonance angiography tumor imaging studies published using the same vessel
extraction and morphological analysis, which showed quantitative differences in vessel
network architecture after successful tumor therapy, so it is possible that acoustic an-
giography could be used to extract diagnostic information (other than tumor size and
perfusion ratio) from tumor-bearing tissue volumes in the future, though the current
study parameters did not yield a promising model for testing this.
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Finally, in this study all quantitative values extracted from the image data was
limited to the boundaries of the tumor. The surrounding tissue was not assessed due
to the limited field of view offered by the imaging technology currently available. As
tumors get above 1 cm in diameter, they begin to dominate the field of view, occupying
well over half the available imaging voxels, thus the ratio of tumor tissue to non-tumor
tissue gets skewed as the lesions grow in size. This problem could be circumvented by
a widefield imaging approach. Currently, our group is collaborating with an industry
partner (Kitware, Carrboro NC) to enable the expansion of preclinical imaging into a
wider field of view, and software is already available in their open source Slicer platform
to enable to registration of multiple sub-volumes.
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CHAPTER 6
RADIATION FORCE ENHANCED MOLECULAR IMAGING
Both of the studies presented in this chapter implemented acoustic radiation force
as a method to increase the number of contrast agents retained by diseased tissues in
molecular imaging studies. For the first study, radiation force was implemented on
the dual-frequency transducer (Chapter 6.1) Despite some initially promising results
from this study, there were some unfortunate tradeoffs to using the dual-frequency
probe in this type of molecular imaging study (discussed in Chapter 6.1.4), so our
group pivoted to a widely available clinical ultrasound system as a method to both
administer radiation force and image targeted contrast agents (Chapter 6.2).
Since early observations of acoustic radiation force (ARF) on microbubble contrast
agents, researchers have speculated about the utility of this force to push populations
of microbubbles in a direction normal to their flow in a patient’s vasculature, thereby
guiding them out of circulation and against the wall of a vessel [61]. It has been
hypothesized that increasing ligand-receptor proximity and reducing the velocity of
Note: This chapter has two sections, both of which draw from previous published material. Pre-
viously published material was reprinted with permission from the publishers.
Chapter 6.1: Ryan Gessner, Marc Lukacs, Mike Lee, James Tsuruta, F.Stuart Fos-
ter, Paul A. Dayton. Radiation force-enhanced targeted imaging and near real-time molec-
ular imaging using a dual-frequency high-resolution transducer: in vitro and in-vivo results.
IEEE International Ultrasonics Symposium Proceedings. 2009
Chapter 6.2: Ryan C. Gessner, Jason Streeter, Roshni Kothadia, Steven Feingold, Paul A. Day-
ton. An In Vivo Validation of the Application of Acoustic Radiation Force to Enhance the Diagnostic
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flowing microbubbles would greatly increase the amount of targeted microbubble ad-
hesion in molecular imaging studies [62; 127; 70; 69; 128]. In vitro studies of ARF
on microbubbles have demonstrated the ability to increase the quantity of microbubble
adhesion more than 100-fold compared with molecular targeting without ARF [127]. In
vivo observations performed by intravital microscopy have also demonstrated between
four and 20-fold increases (depending on the vascular environment) in the amount of
targeted microbubbles retained in microvasculature after ARF pulses [70]. Similarly,
with the development of acoustically active drug delivery vehicles, it has been hypoth-
esized that ARF could be a mechanism to increase vehicle and drug concentration at
the desired target site via ultrasound. Researchers have shown the utility of ARF to
mediate the concentration of several types of potential therapeutic delivery vehicles
[67; 68; 129].
It has also been proposed that ARF might play a role in pulse sequences designed to
enhance the detection of targeted contrast agents in molecular imaging. Many current
molecular imaging studies involve the use of a waiting period, typically 5-20 minutes,
for free (unbound) microbubbles to clear the circulation before imaging of adherent
targeted agents can be performed [59]. This limitation makes molecular imaging with
ultrasound a slow process and likely results in loss of detected signal, because bound
microbubbles can detach or degrade over the waiting period. It has been shown that
rapid increase in adhesion of targeted microbubbles using ARF can be used to help
delineate signal from free and bound contrast agents [130; 131].
However, to date, literature demonstrating the application of ARF in vivo to im-
prove microbubble targeting has been scarce. This is likely caused by a disparity be-
tween the types of acoustic pulses used for imaging by clinical and preclinical imaging
systems, and the acoustic regime over which ARF-induced microbubble displacement
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is most efficient. Microbubble translation is maximized near the bubble’s resonant fre-
quency. For most efficient translation, a large duty cycle is required, and the mechanical
index must be low enough to avoid microbubble destruction [62]. A long duty cycle
and low mechanical index are typically not parameters beneficial for ultrasound imag-
ing, and thus it is likely that the paucity of in vivo ARF-enhanced molecular imaging
data is a result of these pulse sequences not being intuitively available on commercial
ultrasound equipment.
6.1 Molecular imaging with the dual-frequency prototype
6.1.1 Methods
In vitro experiments
To test the dual-frequency probe’s proficiency at facilitating microbubble targeting via
radiation force, two in vitro setups were implemented. Microbubble-target binding was
achieved in vitro via the avidin-biotin binding complex, using the in vitro targeted
agent formulation (Appendix A). Two flow phantoms were used: an optical phantom
and an acoustic phantom. The optical phantom was a 200 µm cellulose tube used to
optically verify the production of radiation force and radiation force enhanced target-
ing. The acoustic phantom was a wall-less agarose gel phantom in which radiation
force enhanced targeting was verified acoustically. A syringe pump was used at sev-
eral different constant volumetric flow rates to pump microbubbles (diluted to ∼5x106
bubbles/mL) through the phantoms. The waveforms used for administering radiation
force were 200-cycle 4 MHz sinusoids with a PRF of 15 kHz and peak negative pres-
sures of approximately 100 kPa. Even though this frequency was outside of the optimal
bandwidth of the low frequency element, it was chosen to reduce bubble destruction.
1) Optical phantom setup
The cellulose tube filled with avidin for 1 hour and then flushed with deionized
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water after this time had passed. The tube was oriented horizontally at the focus of
both the dual-frequency probe and a Photron high-speed camera (Model APX-RS -
San Diego, CA) equipped with a 60x water immersion lens (Olympus LUMPlanFI/w -
Melville, NY). The axes of the transducer and the camera were aligned perpendicularly
with the tube at the same location. A needle hydrophone was positioned in the optical
focus and the pulsing transducer was aligned to maximize the measured signal from
the hydrophone. Radiation force pulses were applied to the microbubble solution as
it was pumped through the tube at different flow rates. The efficacy of the radiation
force pulses to divert the flow of contrast agents and enhance targeting was observed
in real time as well as recorded for oﬄine confirmation.
Figure 6.1: An image displaying adherent bubbles successfully targeted to the wall of
the 200 µm cellulose tube by a single sweep of the dual-frequency transducer despite
the constant sheer stress induced by the volumetric injection rate of 5 mL/h.
2) Acoustic phantom setup
The biotinylated wall-less flow phantom was prepared as described by Needles et
al. using agarose at a concentration of 10 mg/mL [132]. The bore was created by
suspending a polyethylene tube (outside diameter: 1.09 mm) between the inlet and
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outlet needles and then removed after the gel had cooled. The bore was avidinated
the same way as the cellulose tube. The syringe pump was used to flow microbubbles
through the bore at a constant volumetric flow rate of 1 mL/h at a horizontal orienta-
tion. The dual-frequency transducer was vertically aligned with the tube and coupled
with the phantom surface using ultrasound gel. Radiation force pulses were applied and
then bound and free bubbles were imaged. Bound bubbles were delineated from freely
circulating bubbles in the video data using interframe averaging filtering [131; 132].
In vivo experiments
A fibrosarcoma tumor model was imaged to examine the effects of radiation force on
targeted bubbles circulating in vivo. The tumor was implanted on the right hind leg
as previously described [133] and allowed to grow to a diameter of ∼1 cm. Targeted
microbubbles were administered in 200 µL bolus injections via a 24 gauge tail vein
catheter. During the radiation force-enhanced studies, the transducer would sweep at
1 Hz over the center of the tumor as the microbubbles were administered both during
the injection and for 30 s following the injection. During passive targeting studies,
radiation force pulses were not administered. After waiting 25 min to allow for freely
circulating bubbles to clear from the animal, a 3D scan was acquired across the volume
of the tumor at step sizes of 200 µm.
6.1.2 Results
In vitro experiments
Biotinylated microbubbles were successfully targeted to avidinated phantom walls and
verified both optically and acoustically in the two different setups. In the optical
phantom, radiation force pulses were administered to microbubbles flowing at linear
flow velocities between 0.3 and 200 mm/s. The pulses were able to push bubbles to
the bottom wall of the tube, against buoyancy, at all linear flow velocities less than
145
50 mm/s. At flow rates faster than this the direction of the microbubble stream was
perturbed, though did not significantly divert within the viewing window of 500 µm. At
flow rates faster than 25 mm/s, bubbles could successfully be pushed to the wall, though
the shear stress tended to dislodge targeted bubbles in the phantom tube model rapidly.
In the gel phantom, microbubbles were successfully targeted to the wall of the phantom.
Because the tissue signal in dualfrequency imaging was suppressed, it was possible to
delineate bound bubbles from freely flowing bubbles using interframe filtering. Movie
files were exported to Matlab and a 10 frame moving average filter was applied prior
to a thresholding operation. The resulting signal was overlaid on top of dual-frequency
b-mode data and color coded in green. An example of this can be seen in Figure 6.2C.
Figure 6.2: A: A schematic cartoon showing the position of the transducer in relation
to the wall-less flow phantom. Incident RF pulses forced freely flowing bubbles (two
colors) against their buoyancy to become bound (black colored). B: A dual-frequency
b-mode image free and bound contrast agents within the phantom. Overlaid on top
of this image in green is the signal of adherent microbubbles delineated from moving
bubbles using interframe filtering. C: Only the signal returned by the filtering process
showing bound microbubbles delineated from freely flowing ones.
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In vivo experiments
Microbubbles targeted to angiogenic vasculature were used to compare radiation force
enhanced targeting with conventional passive targeting. Four injections of targeted
contrast agents were administered to an animal with the same 2D planes within the 3D
datasets examined between the different data collections throughout the study. Radia-
tion force targeted and control studies were alternated. The two studies implementing
radiation force pulses during the administration of the microbubbles showed improved
microbubble retention in every 2D image slice of data collected when compared to the
passive targeting studies, as evidenced by Figure 6.3.
Figure 6.3: Comparison of molecular targeted bubble signal as a function of distance
through the tumor.
The average improvement in mean pixel intensity within the same image slices of
the tumor between passive and radiation force-enhanced datasets was 13.3 dB (N = 12).
The maximum improvement in targeting intensity as a result of using radiation force
was 35.1 dB, while the minimum was 2.1 dB. The average mean pixel intensity increase
over baseline was 2.5±2.4% and 8.4±4.4% for passive and radiation-force enhanced
studies respectively (error is standard deviation). There was no significant decrease in
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targeting performance between the first and second trials of either the passive or radia-
tion force-enhanced studies, indicating that there was very little reduction in available
targeting sites due to previous studies’ adherent bubbles.
Figure 6.4: Two images comparing the targeted contrast agent intensity in multiple 2D
slices between passive targeting (A) and radiation force-enhanced targeting (B) studies.
Scale bars = 1 cm.
6.1.3 Discussion
In vitro experiments
In vitro experiments demonstrated the effectiveness of a dual-frequency probe in the
ability to enhance adhesion of targeted microbubbles using the low-frequency element.
Application of 4 MHz ultrasound at ∼100 kPa and a 75% duty cycle, swept at 1 Hz
across the sample volume, significantly increased the retention of targeted microbubbles
along the distal wall of a tube phantom. Contrast-specific imaging, achieved by exciting
microbubbles at 2.5 MHz and receiving broadband harmonic energy above 10 MHz,
was shown to suppress tissue signal and allow imaging of only bound and free contrast
agents. Successive slow-time filtering, performed by averaging video frames, enabled
filtering of free-floating microbubble signal and detection of bound targeted agents.
Signal from bound agents was color-coded in green and could be overlaid on either
tissue or contrast data in order to perform near real-time targeted imaging without the
requirement of a waiting period for signal from unbound contrast to clear.
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In vivo experiments
In vivo application of radiation force during targeted imaging studies was demonstrated
to significantly increase the amount of targeted contrast agent retained in the vascu-
lature. An average of 13 dB in signal enhancement was achieved compared to non-
radiation force enhanced targeting. This demonstrates the utility of radiation force to
enhance targeted microbubble retention in vivo, as is desired in molecular imaging or
microbubble-based therapeutic strategies.
6.1.4 Concluding remarks
In this preliminary study, the effects of acoustic radiation force produced by the gen-
eration 1 dual-frequency probe’s low frequency element were observed in two in vitro
phantom models and an in vivo tumor model. As was determined in a different study,
acoustic angiography cannot be performed without clearing microbubbles from the
imaging plane (Chapter 3.1). This represents a critical barrier for acoustic angiogra-
phy’s implementation in molecular imaging studies. Non-destructive contrast imaging
is important, as the amount of time required for freely flowing non-targeted contrast
agents to clear from the blood stream can vary, and being able to assess the degree
to which bubbles have cleared the system is an important first step prior to acquiring
image data; if freely flowing bubbles are present, then the user can wait long for them
to clear prior to acquiring data, but if a microbubble-clearing imaging approach is used
then this preliminary step is impossible.
While the dual-frequency probe’s design made it very flexible with respect to the
pulsing schemes used to administer radiation force, the fact that it could not non-
destructively image contrast agents forced us to implement a different imaging system
to test the hypothesis that radiation force was a method to enhance molecular imaging
studies. This followup study is presented in the following section.
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6.2 Volumetric molecular imaging with a clinical system
In this chapter, we describe the implementation of a widely used clinical ultrasound sys-
tem, the imaging parameters of which we have adjusted to produce ARF of a magnitude
substantial enough to cause nondestructive bubble translation. After the ARF pulses
used to enhance contrast targeting, we use contrast-specific imaging pulse sequences for
molecular imaging. This study uses a fibrosarcoma tumor model to illustrate the effect
of ARF-enhanced molecular imaging compared with conventional passive molecular
imaging. In addition, we investigate the effect on nonspecific adhesion caused by the
intentional push of microbubbles away from the center of the lumen toward the distal
walls within tumor vasculature. Results from preliminary in vitro studies are also pre-
sented that suggest that the pressure of the ARF pulse sequence is a significant factor in
promoting lasting bond kinetics between molecularly targeted microbubbles and their
target integrins, and that one must balance detrimental over-pushing with ineffective
under-pushing to achieve the optimal ARF-enhanced molecular imaging protocol.
6.2.1 Materials and methods
Imaging
All microbubbles imaged in our studies were formulated in-house as previously de-
scribed [54]. The two lipid formulations used were the in vivo targeted formulation and
the perfusion agent formulation (Appendix A). Both targeted and nontargeted bubbles
were of a diameter size distribution centered at 1.6 µm. This was achieved through a
differential centrifugation technique [134]. Imaging was performed on a Siemens clin-
ical ultrasound system (Acuson Sequoia 512; Siemens Medical Solutions, Mountain
View, CA, USA) using a linear array transducer (model 15L8). The transducer was
precisely positioned using a three-axis translational motion stage setup, as previously
described[135], and the same probe was used for both imaging and the application
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of ARF. For volumetric radiation force administration and imaging, the transducer
was swept in the elevational direction by a computer-controlled motion stage (Model
UTS150PP; Newport, Irvine, CA, USA) interfaced through LabView (National In-
struments, Austin, TX, USA) to a desktop computer. This motion stage allowed 3D
images to be captured and ARF pulses to be delivered uniformly across the volume.
ARF pulses were optimized in the pulsed wave (PW) Doppler mode at a frequency of
7 MHz. Adjusting the gate size (18 mm), location of the gate within the field (65 mm),
and blood velocity scale (1 m/sec) enabled us to achieve a 25% duty cycle pulse with a
PRF of 25 kHz (70 cycles). The amplitude of the ARF pulses was modulated by using
the power output dial of the ultrasound system (range -7 dB to 0 dB).
Calibration
Acoustic pressure measurements were determined by a calibrated needle hydrophone
(model HNA-0400; Onda, Sunnyvale, CA, USA) in a water tank. The acoustic pres-
sures produced by the linear array transducer in PW Doppler mode at the previously
mentioned parameters were measured at 100 µm increments in a 2.2x0.4-cm area in
front of, and parallel to, the aperture using the needle hydrophone. This region of
the acoustic pressure field was mapped at 0.5-, 1-, 1.5-, and 2-cm distances from the
aperture, for seven different power output settings. The peak negative pressure was
measured at each spatial location and power output setting. These pressures were
between 8 and 28 kPa for the system output setting studied, and the pressure field
deviated by <10% at the locations between 0.5 and 2 cm from the aperture face (in
the water tank).
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In vitro studies: effect of ARF pressure
To assess the relationship between output pressure and microbubble translation ef-
ficiency, an optical-acoustical system was constructed to enable visualization of mi-
crobubble translation during pulsing. A Photron high-speed camera (Model APX-RS;
San Diego, CA, USA) was fitted with a 60x water immersion objective lens (LUM-
PlanFI/w; Olympus, Melville, NY, USA) through a single-tube microscope (Edmund
Optics, Barrington, NJ, USA). The objective was inserted through a latex seal into the
water tank and aligned confocally with and at 90 degrees to the linear array transducer
(Figure 6.5A). A 200 µm acoustically and optically transparent cellulose tube (Spec-
trum Labs, Rancho Dominguez, CA, USA) was placed at the mutual focus, and a fiber
optic illuminator was used as a light source for the camera. A dilute concentration of
contrast agents (2x107 bubbles/mL; approximately 1:1000 from the initial concentra-
tion) was pumped through the tube and ARF pulses were applied perpendicularly to
both the flow direction and microbubble buoyancy. Videos were acquired of the con-
trast agents as they were pushed by the ARF pulses across the diameter of the tube.
Data were analyzed oﬄine and the spatial locations of the contrast agents were mapped
throughout their translation using a custom-designed program in Matlab (The Math-
Works, Natick, MA, USA). Bubble motion was tracked at each of the pressure outputs,
yielding a relationship between ARF-induced translational bubble velocity and acoustic
pressure amplitude.
A second study was performed in which the axial dimension of the transducer was
aligned with the optical axis, and ARF pulses were used to push contrast agents toward
the wall of the tube closest to the lens (Figure 6.5B). The purpose of this study was
to visualize the behavior of microbubbles at the tube wall after initial ARF pulses had
successfully pushed them to the boundary and thereby quantify conditions in which
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Figure 6.5: Experimental diagrams for the in vitro characterization of the effects of
radiation force on microbubbles. (A) System used to determine the relationship be-
tween microbubble translational velocity and output pressure from the transducer. (B)
System used to examine the effects of secondary radiation force on contrast agents after
making contact with the tube wall. In (A) the optical axis is along the x direction,
the acoustic axis is along the z direction and the microbubble flow axis is along the
y direction. Similarly, in (B), the optical axis and the acoustic axis are along the z
direction and the microbubble flow axis is along the y direction.
“over-pushing” occurred. We define over-pushing as any ARF setting that caused mi-
crobubble destruction, or lateral microbubble translation along the tube wall. At higher
acoustic pressures, lateral motion caused by both secondary radiation forces and force
vectors along the curved tube surface in response to primary radiation force would likely
cause adherent microbubbles in vivo to be knocked free. Thus, too much radiation force
could be detrimental to molecular imaging studies. Videos of the bubbles were acquired
for several seconds as they were pushed into the wall by ARF pulses, and analyzed later
oﬄine. Data were processed with a pixelwise standard deviation projection through
the time axis, thereby enabling the visualization of any lateral movement of bubbles
after they initially reached the tube wall.
In vitro studies: Estimating optimal in vivo study parameters
It is known that the amount of ARF experienced by a defined population of microbub-
bles is a function of the acoustic pressure and the exposure time in the acoustic field.
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Before in vivo studies, we estimated optimal experimental parameters for administering
ARF to a volume of tissue in which targeted contrast agents were circulating. We chose
to use a fixed translational speed of 1 mm s−1 for the mechanically scanned transducer,
as well as a fixed duty cycle for all ARF administration. The optimal pressure, Po, was
necessarily a balance between efficient bubble translation and bubble-wall interactions.
Our goal was to design an experimental protocol in which ARF was applied uniformly
across a volume of tissue. Because of the effects of tissue attenuation, Po was not
constant through the entire depth of tissue. This necessitated a compromise between
over-pushing in shallower regions of tissue and under-pushing at deeper regions of tissue.
The optimal initial ARF pressure to maximize targeting efficiency through a specific
tumor size was estimated by taking the minimum value of a cumulative error-function
(CEF) defined as
CEF =
∫ D
0
| Po − P (z) | dz (6.1)
where P(z) was the pressure of the radiation force beam derated for attenuation at
depth z into the tumor with an axial diameter D. Compensation for tissue attenuation
is achieved via the formula
P (z) = Pie
−αz (6.2)
where α is is the attenuation coefficient for the tissue [136]. A constant tissue
attenuation of 0.6 Np
cm
was assumed for the tumors used in the in vivo portion of the
study, because this falls within the range of attenuation values previously measured
[137; 138]. The units of this CEF are measured in kPa, although the true values
returned by the equation are less important than the relative values between different
power output settings. We computed the CEF for each of the output settings on the
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ultrasound system as a method for estimating the optimal ARF pressure amplitude for
a given tumor diameter. Similarly, we could estimate the axial distance travelled by
microbubbles, Da, within a volume of tissue as a result of the ARF pulses by computing
Da(z) = (velocity) · (time) = (m · P (z)) · (wb
vT
) (6.3)
where m is the slope of the curve for velocity of microbubbles as a function of
pressure (determined by the in vitro experiments with the schematic seen in Figure
6.5A, with units m(s kPa)−1), P(z) is the pressure of the ARF beam at depth z, wb is
the elevational width of the ARF beam (3 mm) and vT is the elevational sweep velocity
of the transducer during the application of ARF. Thus, the first term in parentheses will
yield the average velocity of the microbubbles exposed to ARF, and the second term
will yield the amount of time they are travelling. This calculation assumed an infinite
potential path length (i.e., no tube wall to prevent the bubble from being steadily
translated).
In vivo experiments
Fischer 344 rats (Charles River Laboratories, Durham, NC, USA) were used for studies
of ARF-enhanced and conventional molecular imaging (hereafter called passive target-
ing studies, i.e., those not using ARF). All animal studies were conducted in accordance
with protocols approved by the University of North Carolina School of Medicine’s In-
stitutional Animal Care and Use Committee.
Fibrosarcoma tumor models (N = 8) were established from propagated tumor tis-
sue courtesy of the Dewhirst Lab at Duke University. Before implantation, rats were
anesthetized using isoflurane and their left flank was shaved and disinfected. A 2-mm
incision was made above the quadriceps muscle and a ∼1 mm3 piece of tumor tissue
was placed subcutaneously. Imaging was performed on tumors after their longest axis
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had grown to approximately 1 cm.
During the molecular imaging studies, animals were anesthetized with 2.5% inhaled
isoflurane anesthesia mixed with oxygen, and their body temperature was maintained
at 37C through the use of a temperature-controlled heating pad. The area to be imaged
was shaved, further depilated using a chemical hair remover, and then coupled to the
ultrasound transducer using gel as previously described [135].
Microbubbles were administered in bolus injections via a 24-gauge tail-vein catheter.
The concentrations of stock solutions for both the targeted and control bubbles were
measured before each imaging study using a particle sizer as previously described [54].
The appropriate volume of stock solution was added to the catheter via a micropipette
tip and flushed with 100 µL of sterile saline such that a contrast dose of 2x108 bubbles
was administered consistently. Because of the dose limitations with the injected volume
of saline and contrast into the animals, two different types of studies were performed
over several days to examine (a) the effect of ARF pulse amplitude on microbubble
targeting efficiency relative to passive targeting, and (b) the effect of ARF at promoting
nonspecific adhesion in control bubbles relative to targeted bubbles also exposed to
ARF.
For study type (a), each animal underwent four distinct injection and ARF proto-
cols in the following order: (i) Passive targeting (no application of ARF) using targeted
microbubbles; (ii) application of ARF with a pressure of 4 kPa using targeted microbub-
bles; (iii) application of ARF using a pressure of 13 kPa with targeted microbubbles;
and (iv) application of ARF with a pressure of 21 kPa using targeted microbubbles.
After each of these four imaging protocols, there was a minimum wait time of 10 min
to ensure that there were no circulating microbubbles remaining. Similarly for study
type (b), each animal underwent distinct injection and ARF protocols in the following
order: (i) Passive targeting with control microbubbles, (ii) application of ARF with
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a pressure of 13 kPa with control microbubbles, (iii) passive targeting with targeted
microbubbles and (iv) application of ARF with a pressure of 13 kPa with targeted
microbubbles. Between each type (b) experiment, there was a minimum wait time of
10 min to ensure that there were no circulating microbubbles remaining in the tumor
vasculature. Because of injection volume limitations, study types (a) and (b) were not
performed in the same animal on the same day. To compare type (a) and type (b)
experiments, data were normalized to the mean image intensity within the volumetric
passive targeting image data (using targeted microbubbles without application of ARF)
in each animal because this imaging protocol occurred in both type (a) and type (b)
studies.
During all ARF-enhanced targeting studies, radiation force pulses were applied over
the entire volume of the tumor using the mechanically scanned transducer at pressures
of 4, 13 or 21 kPa (number of animals imaged at each setting: 4 kPa, N = 5; 13 kPa,
N = 7; 21 kPa, N = 5). The transducer was swept at a constant speed of 1 mm/s
across the tumor volume after contrast agents were administered to the animal, for a
total of 10 passes after the injection. During passive targeting studies, ARF pulses were
not administered (N = 4). After waiting approximately 10 min for freely-circulating
bubbles to clear from the animal’s system, a 3D imaging scan was acquired across
the tumor with interplane step sizes of 400 µm in the ultrasound system’s Cadence
contrast imaging mode (CPS). The bound microbubbles were then destroyed using a
high mechanical index b-mode 3D scan, and then the tumor reimaged in CPS mode at
the same slice locations for a baseline measurement of no targeted agents.
Our interimage step-size was below the -6 dB elevational beam width determined
in a previous study [31] to be ∼800 µm. Thus the volumetric data were down-sampled
oﬄine at 800 µm intervals to yield independent imaging frames for analysis as pre-
viously described [54]. The mean pixel intensities within the background-subtracted
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images were computed, producing a mean targeted bubble intensity for every 2D image
plane within the 3D image acquisition. As previously mentioned, the mean targeted
microbubble intensity values were normalized to the mean of the passive targeting
microbubble injection. This allowed us to reduce the impact of interanimal tumor
heterogeneity when making comparisons between animals. The brightness of adherent
microbubble contrast agents was assumed to be correlated with the degree of biomarker
expression. Thus, throughout the remainder of this manuscript, mean pixel intensity
will refer to the quantity defined by the difference between the average image’s intensity
before the destruction pulse and the average intensity of the image for the same region
of interest after the destruction pulse. This mean pixel intensity metric is a way to ap-
proximate the quantity of adherent microbubbles at a single 2D image slice’s location.
The statistical significance of our comparisons between the mean microbubble targeting
measured by the different imaging study settings was assessed using Matlab to imple-
ment a two-sided Student’s t-test assuming equal variances. Significance between two
different distributions was considered at a value of p < 0.05.
6.2.2 Results
In vitro studies: effect of ARF pressure
The positions of multiple bubbles (4<N<10) were tracked through space and time and
a linear relationship (R2 = 0.953) between velocity and radiation force amplitude was
observed, with a slope of 5.018 m·[s kPa]−1 (Figure 6.6A). For this linear curve fit, the
y-intercept was set to 0 (corresponding with a velocity of zero for microbubbles not
exposed to ARF).
At each acoustic pressure setting tested between 8 and 28 kPa, the ARF pulses were
able to force the microbubbles out of the center of the cellulose tube and against the
wall. As the pressure was increased, the aggressiveness of the lateral bubble movement
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Figure 6.6: Results from optical observations of in vitro radiation force on microbub-
bles. (A) The translational velocity of contrast agents as a function of radiation force
pressure amplitude. (B) Images of standard deviation projections of microbubble lat-
eral translation along the tube wall during radiation force pulsing at high (19 kPa) and
low (8 kPa) pressures. As the pressure is increased, lateral motion along the wall caused
by secondary radiation force can be clearly visualized as nonspherical trails. Note the
displayed images are negatives of the actual projections; large values appear dark in
these images.
and aggregation caused by secondary radiation force increased (Figure 6.6B). On the
basis of qualitative observations from pixel-wise time-axis standard deviation projec-
tions (Figure 6.6B), it was hypothesized that the secondary radiation force at pressures
>10 kPa would not facilitate lasting ligand-integrin bond kinetics, because ARF pres-
sures above this threshold caused bubbles to laterally translate along the cellulose tube
wall. Thus, Po was estimated to be 10 kPa because this setting would provide the best
compromise between efficient bubble translation (50 µm/s) and minimization of lateral
movement after contact with the vessel wall.
In vitro studies: estimating optimal in vivo study parameters
The CEF computations demonstrated that there was no single pressure appropriate for
all tumor sizes. A 2D surface plot of the CEF values illustrates that for varying tumor
sizes, there exist different acoustic pressures that will optimize radiation-force-enhanced
targeting over the entire tumor depth (Figure 6.7A). The CEF predicted that the 13-
kPa pressure setting would be the most effective in vivo protocol for a 1 cm tumor. A
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4-kPa and a 21-kPa setting were also tested in vivo to compare the relative targeting
efficiencies with the 13-kPa setting predicted by the CEF model.
Figure 6.7: (A) The CEF plotted as a function of initial ARF push pressure and
tumor diameter. Minimizing the CEF at a given tumor diameter provides the basis
for estimating the optimal push protocol for an in vivo study (white dashed line). The
Xs illustrate the three output settings that were tested and compared in the in vivo
validation studies. (B) Simulations predicting the distance a microbubble would be
pushed by ARF pulses for the three different initial pressure amplitudes as a function
of depth into tissue.
The calculations of Da, the expected distance microbubbles would translate in vivo
along the ARF beam’s propagation axis, revealed that both the initial push pressure
and the depth into tissue determined whether a contrast agent would be sufficiently
pushed out of circulation to the luminal wall (Figure 6.7B). In a previous histological
analysis of vessels within xenografted tumors, 100 µm was the upper bound on the range
of vessel diameters [22]. It was predicted that the three pressure settings tested in vivo
would provide sufficient microbubble translation (Da≥ 50 µm) at tissue depths <3.1
cm, 2.4 cm and 0.5 cm for the 21-kPa, 13-kPa and 4-kPa ARF amplitudes, respectively.
In vivo results
Microbubbles targeted to angiogenic vasculature were used to compare ARF-enhanced
targeting with conventional passive targeting (Figure 6.8). Of the tested ARF puls-
ing schemes, the maximum increase in microbubble targeting, as measured by mean
160
pixel intensities, was achieved using ARF pulses with a 13-kPa amplitude and a cRGD
targeted bubble (nomenclature “RF-13/cRGD+”). In all of the animals tested, the vol-
umetric targeted intensity was greater using RF-13/cRGD+ than with passive targeting
(nomenclature “RF-0/cRGD+”). Notably, there was improved microbubble retention
in 91% of all 2D image slices of RF-13/cRGD+ data collected when compared with the
RF-0/cRGD+ studies (Table 6.1). In the remaining 9% of 2D image slices (in which
the passive targeting images were brighter than the RF-13/cRGD+ images), there was
a <1 dB difference between the mean pixel intensity of RF-13/cRGD+ data compared
with the RF-0/cRGD+ case. Also of note, of the 9% of 2D image slices in which RF-
13/cRGD+ was not as bright as the passive targeting run, 80% of these were within
the same animal. This was likely an indication of a less angiogenic and more necrotic
tumor in this one animal, and thus there was very little adhesion of targeted agents,
either with or without ARF.
Figure 6.8: (A) A box-and-whiskers plot displaying the distribution of intensities within
targeted bubble images. Data are normalized to 0 kPa/cRGD+ dataset. Asterisks
indicate (p < 0.05) over ∗ the RF-0/cRGD+ data, ∗∗ the RF-0/cRGD- data. (B) A
comparison of the histograms of pixel intensities for cases listed. These histograms
show a larger proportion of bright pixel values when targeted bubbles are used, and
even more when radiation force is used with targeted bubbles.
The increase in mean pixel intensity across all animals was 77.8% higher with the
RF-13/cRGD+ over the RF-0/cRGD+ case: 11.4±7.0 compared with 6.4±4.8, re-
spectively. The values represent baseline-subtracted pixel intensities, and thus the
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RF-4/cRGD+ RF-13/cRGD+ RF-21/cRGD+
% of Animals Exposed to
ARF with Volumetric
Targeting > Volumetric
Passive Targeting
80% 100% 60%
% of Slices Exposed to
ARF with Mean Targeting
> Passive Targeting
65% 91% 51%
Table 6.1: A summary of the percentage of animals (top) and percentage of 2D image
slices (bottom) that exhibited a greater degree of microbubble targeting in the ARF-
enhanced targeting studies relative to the passive targeting studies.
units are measured in dB. The error in these values is the standard deviation of the
baseline-subtracted pixel intensities. Similarly, both the RF-4 (8.8±7.9) and RF-21
(8.8±7.0) settings produced a statistically significant increase in targeting of cRGD+
bubbles relative to the RF-0/cRGD+ case. Of note, the RF-13/cRGD- case suggested
a slight increase in mean pixel intensity for nonspecific microbubble adhesion relative
to the RF-0/cRGD+ case; however, differences were not significant (p = 0.15). The
histograms created from the amalgamation of all un-normalized data show that, in
general, the mean pixel intensity was higher for both ARF-enhanced and passive tar-
geting studies (Figure 6.8B) compared with nontargeted controls. Furthermore, these
histograms show that the RF-13/cRGD+ studies produced the greatest number of en-
hanced pixels. Figure 6.9 illustrates an example of ARF-enhanced targeted imaging
and conventional passive targeting. In this image, the tumor volume is presented with
a conically-stratified hinged cutaway, wherein elliptical regions of interest were drawn
such that they did not follow the tumor border but instead cut into the interior of the
tumor. This allows for microbubble targeting from within the tumor margins to be
visualized on the rendered 3D surface, which we found to be useful in visualizing 3D
molecular imaging data.
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6.2.3 Discussion
Optimizing radiation force: in vitro predictions and in vivo results
Using ARF to facilitate molecular targeting of microbubbles to integrins expressed
on diseased endothelium is an intuitive approach to improving the sensitivity of this
diagnostic imaging methodology, but its application is nontrivial. Our in vitro studies
allowed us to observe the behavior of microbubbles exposed to ARF pulses both during
their translation and after making contact with the wall of a vessel-mimicking phantom.
These analyses allowed us to tune parameters to predict the optimal settings for in vivo
studies.
The calculation of the CEF demonstrated that because of the effects of tissue at-
tenuation, there is no single setting for ARF amplitude that is universally appropriate
to increase molecular imaging sensitivity at all tissue depths. Our CEF model pre-
dicted that ARF pulses with 13-kPa pressure amplitude to be the most effective of the
three amplitudes studied. The model suggestions were supported by the in vivo study,
because the 13-kPa pulses had the highest microbubble targeting efficiency. The CEF
predictions for the two other pressure amplitudes tested (4 and 21 kPa) were very sim-
ilar (Figure 6.7), which was also reflected in the in vivo data, because these pressures
resulted in similar increases in microbubble targeting and were both less effective than
the 13-kPa ARF pulses. This CEF model assumed a constant attenuation of 0.6 Np
cm−1 throughout the depth of the tumor, which did not take into account the atten-
uation provided by the scatter of microbubbles in the tissue. Moreover, our method
of tuning ARF pressure via the CEF assumes that a uniform density of integrin (or
other biomarker) expression exists throughout the entire tumor volume. Although this
is likely not true in the highly heterogeneous microenvironment of tumors, unless the
heterogeneity is known a priori, the best strategy for improving molecular targeting
is one that maximizes the probability of microbubble bond formation at all locations
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within the tumor.
Our in vivo studies demonstrated an average increase in microbubble targeting of
nearly 80% relative to traditional passive targeting studies, as measured by average
pixel intensities within the baseline-subtracted images. It is important to emphasize
that 91% of all the 2D image slices within the ARF-enhanced datasets exhibited greater
microbubble targeting than the corresponding image frames taken from the passive
targeting data. Of the remaining slices that exhibited greater microbubble adhesion
in the passive targeting case, most were outliers found in a single animal that showed
poor microbubble targeting in all experiments. This, along with the rest of the data
summarized in Table 6.1, makes a compelling argument that ARF can improve the
diagnostic use of ultrasonic molecular imaging studies.
When comparing the control microbubbles (nontargeted) with the cyclic RGD mi-
crobubbles (targeted) in the absence of ARF, it was apparent that nonspecific targeting
was observed for the microbubble concentrations and tumor models used in this study.
However, the application of ARF significantly increased the mean pixel intensity from
the targeted agents, without significantly increasing the mean pixel intensity from the
control agents - thereby providing a means to increase signal to noise in situations
where there is a high nonspecific targeting background.
A persistent question surrounding the usefulness and applicability of ARF to in
vivo molecular imaging studies is whether pushing populations of bubbles away from
the proximal walls of vessels could actually be detrimental to maximizing the number of
microbubble-integrin bonds. Although microbubble targeting on proximal vessel walls
is likely negligible during the application of ARF pulses, after the pulses stop, these
binding sites are free to be populated by the passive targeting of bubbles circulating
through the vasculature. Regardless, based on our in vitro observations, the amount of
increased bubble adhesion caused by ARF substantially outweighs any loss of targeting
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on the proximal vessel walls. Another concern is whether acoustically forcing bubbles
into vessel walls will cause an increase in nonspecific adhesion and thereby increase
the rate of false-positive diagnoses. In this study, there was no significant difference in
targeting efficiency between the control bubble with ARF application compared with
the control bubble with no ARF (Figure 6.8). However, we suggest that this would
need to be re-evaluated for different adhesion ligands and tumor types.
Comparison with previous work
Previous in vitro work studying the increase in targeting efficiency of ARF-enhanced
studies relative to passive targeted bubbles adhesion has demonstrated a large depen-
dence on microbubble concentration. There was approximately 3 times more adhesion
in passive targeting experiments without an appreciable difference in ARF efficiency
when the bubble concentration was increased from 2.5x106 to 25x106 bubbles/mL [127].
This suggests that a larger difference in microbubble targeting effectiveness will be ap-
parent if a lower concentration of microbubbles is used, though these studies have yet
to be performed in vivo. In addition, because the magnitude of radiation force is high-
est at the resonant frequency of a microbubble [62], the frequency of our radiation
force pulses could have been a source of reduction in expected targeting effectiveness.
We were pulsing at 7 MHz, which was slightly higher than the resonance frequency
of our bubbles (∼6 MHz, as calculated using the method described in [139]). Finally,
secondary radiation force is known to create aggregates of multiple microbubbles af-
ter contacting vessel walls [61; 127; 140] (Figure 6.6B). If these aggregates form lasting
bonds with integrin targets, they will contribute to the image signal intensity differently
than would a single bubble. This could have contributed to the variability observed in
our in vivo studies.
In prior in vivo molecular imaging studies implementing ARF, Rychak et al. [70]
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optically observed a >20-fold increase in microbubble adhesion in vivo using intravital
microscopy in both the femoral artery and vein of a mouse model for inflammation,
although this study relied on optically counting microbubbles through invasive intrav-
ital microscopy to quantify retention rather than using ultrasound imaging. Thus, a
direct correlation between Rychak’s data and the data presented herein is not possible.
In Chapter 6.1 of this dissertation, we demonstrated the administration of ARF and
acoustic detection of the targeted bubbles using a prototype high-resolution probe and
custom pulse sequences, with an average microbubble targeting improvement of 13 dB
across all image slices when ARF was used compared with passive targeting. There
were many differences between that study and this one, including the ARF param-
eters and the imaging techniques’ contrast sensitivities, which could account for the
differences between the reported increase in sensitivity facilitated by radiation force in
that paper (13 dB, or ∼4.5-fold increase in detected contrast signal) relative to data
presented here.
Limitations and future directions
It was beyond the scope of the in vitro study of observations of contrast agents in-
teracting with the tube wall to quantify the motion and trajectories of the bubbles
after contacting the tube wall. This was because the aggregates of multiple contrast
agents continually formed clusters of bubbles in an erratic fashion because of secondary
radiation forces and thus made tracking individual contrast agents very difficult. The
lack of this analysis notwithstanding, the standard deviation projections seen in Fig-
ure 6.6b demonstrate this effect and suggested that higher pressures would reduce the
likelihood of lasting ligand-integrin bond formations. A more thorough analysis of this
lateral motion would help define Po more accurately than our coarse ability to adjust
the amplitude of the ARF pulses permitted.
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As mentioned previously, the best strategy for improving targeting is one that max-
imizes the probability of microbubble adhesion throughout the tumor. Because of
attenuation effects, it was not possible in our in vivo studies to apply ARF uniformly
at all axial depths. One potential strategy to apply a more homogeneous ARF profile
to multiple depths within tissue (not examined in these studies) would be to sweep
through multiple pressures at each spatial location. If at first a high pressure is used,
it facilitates microbubble targeting deeper into tissue (as a result of attenuation) while
simultaneously over-pushing at shallow depths. If the pressure is reduced steadily, mi-
crobubbles at shallower depths will be pushed at a more appropriate pressure without
negatively affecting the targeted bubbles deeper in the tissue, because the pressure
at these depths will have been reduced and thus the secondary radiation force effects
minimized. Of note, over-pushing targeted contrast agents would likely be detrimental
only to molecular imaging studies in which the lasting integrity of the microbubble’s
bond is critical. This limitation would probably not be a concern in ARF-mediated
drug delivery, in which the ultimate goal is rapid and efficient localization and release
of a microbubble’s payload. In many ultrasound-mediated therapies, the microbubbles
are disrupted immediately after pushing toward the endothelium, and long-term adhe-
sion is not required [67; 68; 129]. Another method to provide a more uniform pushing
region within the tissue could be to increase the F-number (z/D) of the transducer,
which would increase the depth of field of the transducer and thus offer a more uniform
beam profile in depth. Normally this would carry with it a detrimental trade-off in
spatial resolution, but would not negatively affect a radiation force enhanced molecular
imaging study since no images are acquired during the push phase.
The time window over which radiation force is applied may also affect the increase
in microbubble adhesion; if radiation force is administered continuously over several
minutes as microbubbles circulate through the animal, more bubbles will be pushed
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against the endothelium, although this increased microbubble traffic at the vessel wall
could be counterproductive if it causes previously adherent agents to become dislodged.
The experiments performed in this chapter were done on a widely used clinical
scanner without any additional customization of the software or pulse sequences, al-
though we suggest that improved results would be obtained if dedicated optimized
pulse sequencing and beam focusing/defocusing were available. Our approach did rely
on mechanical scanning of the transducer to uniformly apply ARF pulses from the 1D
linear array across the volume of tumor tissue, although this would be unnecessary if
a 2D matrix array probe were available for high-resolution contrast imaging.
6.2.4 Conclusion
The studies presented herein provide validation of ARF applied with a clinical ultra-
sound system as a mechanism to enhance molecular imaging. In all in vivo studies, the
average targeted microbubble signal throughout the 3D tumor volume was greater when
using ARF (at 13 kPa) when compared with passive targeting studies. Our 3D imag-
ing results demonstrate an improvement in signal intensity of 77.8% to our molecular
target over conventional passive molecular imaging without an increase in nonspecific
targeting. Furthermore, experiments suggest that for volumetric administration of ra-
diation force, there exists an optimal pressure for ARF-enhanced targeting, which is
a compromise between efficient bubble translation and adhesion-disruptive secondary
radiation force and lateral translation effects.
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CHAPTER 7
CLOSING REMARKS
Within this dissertation are the first studies implementing a transmit-low receive-high
contrast ultrasound imaging approach enabled by a prototype dual-frequency trans-
ducer form factor. Our acoustic angiography imaging method produces high contrast
and high resolution depictions of microvasculature. We have tested this transducer in
an in vitro context by first examining resolution and contrast to tissue ratios (Chap-
ter 3.1), and then using a novel microvessel phantom generation technique to generate
ground-truth coordinates for vascular networks to be defined and imaged (Chapter 4).
We then then extended our studies to both in vivo and ex vivo imaging applications.
The in vivo studies were designed first to detect the presence of a tumor within a tissue
volume (Chapter 5.1), and then later to assess the same tumor model’s response to
radiation therapy (Chapter 5.2). The acoustic angiography imaging approach was used
in an ex vivo imaging context to assess the vasculature within a liver biomatrix scaffold
model, a platform for creating of artificial organs (Chapter 3.2). A vessel mapping al-
gorithm, originally developed for human magnetic resonance angiography images, was
implemented in both of these in vivo and ex vivo contexts. Finally, the ultrasound
pulsing technique, radiation force, was used as a method to improve the diagnostic sen-
sitivity of ultrasound to malignant tumors (Chapter 6). Together, the results of these
studies suggest that the acoustic angiography imaging approach, enabled by our new
dual-frequency ultrasound transducer, could eventually be used to detect and monitor
tumors in a clinical imaging context.
7.1 The future acoustic angiography
The scope of the acoustic angiography work to date is limited to the work presented
in this dissertation. As such, the technology is in its infancy, but has shown initially
promising results as a clinically translatable acquisition strategy for contrast imaging.
Unfortunately, there are only two transducers in the world capable of acquiring acoustic
angiography images, both of which are at UNC. Additionally, even if these probes were
mass produced, there are several drawbacks which hinder their utility and thus will
limit their widespread implementation as currently designed. First, their mechanically-
scanned piston form factor is obsolete; manufacturers have stopped creating these de-
signs and have instead switched to linear and matrix array transducers. Thus, the
number of ultrasound systems capable of operating our transducers will steadily de-
cline over the coming years. Second, implementing a transmit-low receive-high acoustic
angiography approach on an array transducer is very important as a means to improve
image quality. The axial beamfield maps of the transducers (Chapter 3.1) revealed a
very shallow depth of field for these transducers (< 1 cm). This problem manifested
itself in a underestimation of the perfusion of larger tumors which were unresponsive
to radiation therapy (Chapter 5.2). From a diagnostic standpoint, this systematic bias
is unacceptable, though unavoidable in focused piston transducers. Though not yet
available, an array transducers specifically designed to operate in acoustic angiography
mode, would be capable of dynamic focusing, which would circumvent this issue. With
collaborators, the Dayton lab at UNC is currently building two different form factors
for transducers capable of operating in acoustic angiography mode (a catheter design
for intravascular ultrasound, and a transrectal design for prostate assessment), so these
avenues are being explored. Finally, image segmentation and classification techniques
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to characterize vessel morphologies will require further development and training to
achieve the level of automation, sensitivity and specificity required for a clinical tool.
Assuming the depth of field issues are resolved through better transducer designs,
the future of acoustic angiography based vascular assessments appear bright. In the
clinic, it could enable a bedside tool for rapid image acquisition, resulting in use-
ful quantitative metrics to assist clinicians in fine-tuning patient-specific treatment
plans. Owing to the high frequencies used to create high-resolution images with the
acoustic angiography approach, only superficial cancers could be imaged, such as thy-
roid, melanoma, breast, and prostate lesions. Neovascularization within atherosclerotic
plaques might also be an imaging application. Preclinical researchers are not faced
with the same depth restrictions, as their mouse and rat models are comparatively
small, and thus acoustic angiography-based microvascular mapping would enable can-
didate cancer therapeutics to be efficiently and noninvasively assessed in a wider array
of tumor types.
Given the success of previous work related to quantifying vascular morphology for
cancer assessment, the promising imaging quality achieved and the quantitative results
demonstrated to date, we believe that acoustic angiography and microvascular mapping
could have a large impact in preclinical and clinical cancer diagnostics.
7.2 The future molecular imaging with ultrasound
Molecular imaging with ultrasound is an exciting field because it adds a new dimension
of diagnostic capability to this already ubiquitous modality. It is certain that the future
role of ultrasound in medicine will continue to increase due to its safety and convenience.
Already some manufacturers are producing diagnostic systems no larger than a cellular
phone that are intended to be as widely available as stethoscopes. With advancing
understanding in molecular changes involved in disease progression, it is likely that
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molecular imaging will enable detection of pathology and observation of response to
treatment before phenotypic changes occur. Technology already exists to significantly
increase the sensitivity of ultrasound to targeted contrast agents, such as presented in
this dissertation with the addition of radiation force as the bolus of contrast agents
circulates through volume of tissue suspected of containing a tumor. The addition of
radiation force is not without limitations, however. While it has demonstrated the
ability to increase the signal intensity from within tumors during molecular imaging
studies, there is an additional variable in longitudinal studies of the consistency with
which the radiation force is applied from timepoint to timepoint. In other words, to
maximize the utility of this technique, it is paramount that identical pulsing sequences
be applied in the same manner.
There are several other limitations of molecular imaging beyond simply field of view
and contrast retention issues (addressed in Chapter 6). One active area of research is
the effort to improve the monodispersity of the contrast agent populations injected. Re-
solving this issue will remove a substantial variable limiting the ability of ultrasound to
perform quantifiable contrast measurements (i.e. to correlate image intensity to num-
ber of targeted contrast agents). Until that time, measurements can only be relative.
Additionally, contrast agents have been engineered with modified lipid shell structures
and ligand architectures to provide targeted contrast agents with better retention char-
acteristics, and reduced immunogenicity. Transducers and signal processing are being
developed to detect targeted contrast agents non-destructively, with high contrast-to-
tissue ratios, and in real-time despite background signal from freely circulating contrast.
Finally, the development of phase change and sub-micron contrast agents will enable
ultrasound contrast to reach beyond the limits of the endothelium, especially important
when trying to leverage the leakiness of tumor vessels for diagnostic purposes.
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APPENDIX A
MICROBUBBLE CONTRAST AGENT FORMULATION
Three different microbubble formulations were used for these studies. Perfusion agents
(used to depict blood flow), in vitro targeted agents (biotinylated microbubbles used to
simulate a molecular imaging study via the biotin-avidin binding complex), and finally
in vivo targeting agents (used to image regions of upregulated αvβ3 expression). The
details of their formulations are as follows.
A.1 Perfusion agents
These were created using a 9:1 molar ratio of DSPC and DSPE-PEG2000 (Avanti Polar
Lipids, Alabaster, AL).
A.2 In vitro targeted agents
These were created using 9:0.5:0.5 molar ratio of DSPC, DSPE-PEG2000 and DSPE-
PEG2000-Biotin (Avanti Polar Lipids, Alabaster, AL).
A.3 In vivo targeted agents
These were created with a 9:0.5:0.5 molar ratio of DSPC, DSPE-PEG2000 (Avanti
Polar Lipids), and DSPE-PEG2000 cross-linked to a cyclic RGD peptide (Cyclo-Arg-
Ala-Asp-D-Tyr-Cys) (Peptides International, Louisville, KY).
These lipid solutions were mixed into 1 mg/mL buffer solutions made of a 0.8:0.15:0.05
ratio of phosphate buffered saline, propylene glycol, and glycerol, respectively. Aliquots
of 1.5 mL of were transferred to 3 mL vials, capped, and decafluorobutane was ex-
changed with the air in the vial headspace using a custom vacuum apparatus. The
vials were then stored at 5◦C until immediately prior to injection. Prior to injection,
the vial was shaken vigorously for 45 seconds using a mixer (Vialmix, Bristol-Myers
Squibb Medical Imaging, North Billerica, MA) to produce the microbubble contrast
agents.
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APPENDIX B
IEEE DECEMBER 2010 COVER IMAGE
High-Resolution, High-Contrast Ultrasound Imaging Using a Prototype Dual-
Frequency Transducer
Caption: These images illustrate high-resolution contrast-enhanced imaging of the
microvasculature, made possible with a prototype dual-frequency transducer designed
to excite microbubbles near resonance and detect scattered echo content at frequencies
greater than 15 MHz. On the left are 3-D images of a rat kidney, where the top is
a maximum-intensity projection, and the bottom illustrates planar slices through the
data. On the right are maximum intensity projections and planar slices from a subcu-
taneous fibrosarcoma tumor in a rat model. For further reading, see the accompanying
article: R. Gessner, M. Lukacs, M. Lee, E. Cherin, F. S. Foster, and P. A. Dayton,
“High-resolution, high-contrast ultrasound imaging using a prototype dual-frequency
transducer: In vitro and in vivo studies,” IEEE Trans. Ultrason. Ferroelectr. Freq.
Control, vol. 57, no. 8, pp. 17721781, Aug. 2010. Images courtesy of Ryan Gessner,
Marc Lukacs, Mike Lee, Emmanuel Cherin, F. Stuart Foster, and Paul A. Dayton. R.
Gessner and P. A. Dayton are with the University of North Carolina and North Car-
olina State University Joint Department of Biomedical Engineering, Chapel Hill, NC.
M. Lukacs, M. Lee, E. Cherin, and F. S. Foster are associated with the University of
Toronto and the Sunnybrook Health Science Centre, Sunnybrook Imaging Research,
Toronto, ON, Canada.
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APPENDIX C
EX VIVO LIVER SCAFFOLD PREPARATION
Note: This appendex describes the experimental preparation required for the imaging
studies performed in Section 3.2. This work was performed in collaboration with the
Reid Lab. The graduate students who performed the decellularizations were Ariel Han-
son and Brient Wu.
Decellularization of liver tissue
Wistar rats (weights 250-300 g) were obtained from Charles River Laboratories, Wilm-
ington, MA. They were housed in the animal facilities handled by the UNC Division of
Laboratory Animal Management and were fed ad libitum until used for experiments.
All experimental work for this study was approved by and performed in accordance
with the UNC Institutional Animal Use and Care Committee guidelines.
All media were sterile-filtered (0.22-µm filter) and kept in the dark at 4oC before
use. To keep collagens stable in the biomatrix scaffolds, the pH of the perfusion media
for biomatrix scaffold preparation was kept at 7.5-8.0. DME/F12 (Gibco/Invitrogen,
Carlsbad, CA) and was used as the basal medium for preparation of biomatrix scaffolds.
All reagents except those noted were obtained from Sigma (St. Louis, MO).
The protocol for decellularizing rat livers to produce biomatrix scaffolds has been
Figure C.1: Decellularization process: (Top)Flushing liver with a serum-free basal
medium (e.g. DME/F12) to remove blood; (Middle) Delipidating with phospholipase
A2 (PLA2) and then with PLA2 combined with deoxycholate; rinsing with serum-
free DME/F12; Perfusing with 3.4 M high salt buffer (salt concentration dictated by
collagen types in the tissue), with soybean trypsin inhibitor, and all kept at a pH of
7.5-8.0; rinsing to remove salt; (Bottom) Treating with nucleases to remove residual
nucleic acids and then rinsing with serum-free basal medium and stored at 4 C.
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described in prior publications 3. Briefly, male rats were anesthetized with Ketamine-
Xylazine, and their abdominal cavity opened. The portal vein was cannulated with a 20-
gauge catheter to provide a perfusion inlet to the vasculature of the liver, and the vena
cava transected to provide an outlet for perfusion. The liver was then removed from
the abdominal cavity and placed in a perfusion bioreactor. The blood was removed by
flushing the liver with 300 mLs of DMEM/F12 (Gibco, Grand Island, NY). Delipidation
(36 U/L of phospholipase A2 in 1% sodium deoxycholate; Fisher, Pittsburgh, PA) was
used to remove plasma and nuclear membranes; this delipidation buffer was perfused
through the liver for 1 hour or until the tissue became transparent. This was followed
by perfusion for 90 minutes with a high salt buffer. Solubility constants for the known
collagens in the liver are such that 3.4 M NaCL is adequate to keep all of the liver’s
collagens in an insoluble state. The liver was rinsed for 15 minutes with serum-free
DMEM/F12 to eliminate the delipidation buffer and then followed by perfusion with
100 mls of DNase (1 mg per 100 mL; Fisher, Pittsburgh, PA) and RNase (5 mg per
100 mL; Sigma Aldrich, St. Louis, MO) to remove any residual contaminants of nucleic
acids from the scaffold. The final step was to rinse the scaffolds with DMEM/F12 for
1 hour to eliminate any residual salt.
The decellularized liver was stored overnight at 4 C (FigureC.2) and perfused with
media at 3 mL min−1 via a peristaltic pump (Masterflex, Cole-Parmer - Vernon Hills,
IL) before the imaging study was performed. Prior to an imaging study, the biomatrix
scaffold was transferred from the perfusion bioreactor into the sample imaging chamber.
When in the sample imaging chamber, perfusion was maintained at 4 mL min−1 through
the portal vein via the same peristaltic pump.
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Figure C.2: Photograph of the decellularization bioreactor. The reagents flow through
the inlet tubing (via a mechanical pump) and into the liver through the portal vein
(right side). The liver is placed on a porous platform allowing waste to be collected in
the bottom of the container and actively pumped out through an outlet on the left.
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